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Abstract 
This thesis explores physiological changes occurring after acute brain injury. 
The first two chapters focus on traumatic brain injury (TBI), a significant cause 
of disability and death worldwide. I discuss the evidence behind current 
management of secondary brain injury with emphasis on partial brain oxygen 
tension (PbtO2) and intracranial pressure (ICP). The second chapter describes 
a subgroup analysis of the effect of hypothermia on ICP and PbtO2 in 17 
patients enrolled to the Eurotherm3235 trial. There was a mean decrease in 
ICP of 4.1 mmHg (n=9, p<0.02) and a mean decrease in PbtO2 (7.8 ± 3.1 
mmHg (p < 0.05) in the hypothermia group that was not present in controls. 
The findings support previous studies in demonstrating a decrease in ICP with 
hypothermia. Decreased PbtO2 could partially explain worse outcomes seen in 
the hypothermia group in the Eurotherm3235 trial. Further analysis of PbtO2 
and ICP guided treatment is needed.   
The third chapter focuses on delayed cerebral ischaemia (DCI) after 
aneurysmal subarachnoid haemorrhage (aSAH), another form of acute brain 
injury that causes significant morbidity and mortality. I include a background of 
alpha-calcitonin gene-related peptide (αCGRP), a potential treatment of DCI, 
along with results from a systematic review and meta-analysis of nine 
experimental models investigating αCGRP. The meta-analysis demonstrates 
a 40.8 ± 8.2% increase in cerebral vessel diameter in those animals treated 
with αCGRP compared with controls (p < 0.0005, 95% CI 23.7 to 57.9). 
Neurobehavioural scores were reported in four publications and showed a 
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standardised mean difference of 1.31 in favour of αCGRP (CI -0.49 to 3.12). I 
conclude that αCGRP reduces cerebral vessel narrowing seen after SAH in 
animal studies but note that there is insufficient evidence to determine its effect 
on functional outcomes. A review of previous trials of αCGRP administration 
in humans is included, in addition to an original retrospective analysis of CSF 
concentrations of αCGRP in humans. Enzyme-linked immunosorbent assay of 
CSF (n = 22) was unable to detect αCGRP in any sample, which contrasts with 
previous studies and was likely secondary to study methodology. Finally, I 
summarise by discussing a protocol I designed for a dose-toxicity study 
involving the intraventricular administration of αCGRP to patients with aSAH 
and provide some recommendations for future research. This protocol was 
based upon the systematic review and was submitted to the Medical Research 













This thesis explores the physiological changes that occur after acute brain 
injury. The first two chapters focus on traumatic brain injury (TBI), a significant 
cause of disability and death worldwide. TBI involves primary and secondary 
brain injuries. Primary brain injury is the initial trauma to the brain and is best 
managed with prevention strategies. Secondary brain injury is that which 
occurs in the minutes to days following the initial trauma and is due to several 
injury processes, with a final common pathway of brain ischaemia. Secondary 
brain injury can be attenuated by maintaining basic physiological variables 
within an equilibrium. Two such variables are intracranial pressure (ICP, the 
pressure within the skull) and partial brain oxygen tension (PbtO2, a measure 
of brain oxygenation). Increased ICP and decreased PbtO2 are associated with 
worse outcomes in patients with TBI. Therapeutic hypothermia (TH), the 
controlled reduction in core body temperature below 36°C, has been trialled 
as a treatment for TBI and does not appear to be beneficial. The second 
chapter of this dissertation documents the effect of TH on ICP and PbtO2 in 17 
patients enrolled to the Eurotherm3235 trial (a trial of hypothermia as a 
treatment for patients with raised ICP after TBI). The analysis demonstrated a 
decrease in ICP and PbtO2 in patients randomised to hypothermia. These 
findings support other studies by indicating a reduction in ICP with cooling. 
Decreased PbtO2 could partially explain worse outcomes seen in the 
hypothermia group in the Eurotherm3235 trial. However, I conclude by stating 
the importance of further analysis of PbtO2 data.  
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Whilst researching changes in brain blood flow and PbtO2 in TBI I became 
interested in other pathologies that can alter brain tissue perfusion and 
conducted a review of delayed cerebral ischaemia (DCI) after subarachnoid 
haemorrhage (SAH, a type of stroke). The third chapter of this thesis concerns 
DCI, a life-threatening complication of SAH that may respond to early 
treatment because its onset is delayed. There is a strong association between 
brain vessel narrowing and DCI. Alpha calcitonin gene-related peptide 
(αCGRP) is a potent vessel dilator that may be effective at reducing brain 
vessel narrowing after SAH. I report analysis of data from nine animal SAH 
models in which αCGRP was administered. There was a 40% increase in brain 
vessel diameter in those animals treated with αCGRP compared with controls. 
There was evidence to suggest that the treated animals had a better functional 
outcome (less neurological disability). I conclude that αCGRP reduces brain 
vessel narrowing after SAH in animal studies but note that there is insufficient 
evidence to determine its effect on functional outcomes. The results of 
previous studies examining the concentration of αCGRP in cerebrospinal fluid 
(CSF, fluid around the brain and spinal cord) in humans with SAH is 
summarised. I describe my study of αCGRP concentrations within the CSF of 
patients with and without SAH. In contrast to previous studies, I did not detect 
any αCGRP in 22 CSF samples. I argue that this was due to methodological 
problems. Finally, I summarise by discussing a protocol for a study involving 
the administration of αCGRP into the CSF of patients with aSAH and provide 
recommendations for future research. 
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Chapter 1: Traumatic Brain Injury 
The first two chapters of this thesis concern traumatic brain injury (TBI). Here 
I explain the epidemiology of TBI and the evidence base for current 
management with a focus on intracranial pressure (ICP) and partial brain 
oxygen tension (PbtO2). I go on to provide a brief outline of therapeutic 
hypothermia (TH). I conclude the chapter by summarising the difficulties with 
TBI research and suggest recommendations for future research.  
Traumatic Brain Injury 
Traumatic brain injury, defined as a blunt or penetrating trauma to the brain, 
can be broadly divided into mild, moderate or severe, depending upon the 
patient’s Glasgow Coma Scale (GCS) following the injury (1). The Glasgow 
Coma Scale is a basic clinical indicator of neurological function. The three 
parameters that make up the GCS are based on best responses from the 
patient’s eye, voice and motor function (E, V, M, Table 1). A GCS of 3-8 
following the injury represents a severe TBI and usually indicates a need for 
neuro-intensive care (2). The GCS was never intended to be used as a sum 
score and the greater importance of its three individual components was 
highlighted by Teasdale and Jennett as early as 1983 (3). A common criticism 
of the GCS is that it is not linear for outcome prediction (4). Indeed, a GCS of 
four predicts a mortality rate of both 48% and 19% depending on the 
components that make up the score (E1 V1 M2 and E2 V1 M1 respectively) 
(5). GCS is also poorly reproducible. In a study of emergency physicians 
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independently assessing GCS, scores were the same in only 38% and were 
two or more points apart in 38% (6). In another study involving a written clinical 
scenario, the GCS was correctly identified by less than half of all physicians 
and only 56% of neurosurgeons (4). Despite these limitations, and evidence 
suggesting that simpler scales perform just as well, the GCS is still ubiquitous 
in clinical practice and is referenced in National Institute for Health and Clinical 
Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and 
Brain Trauma Foundation (BTF) guidelines (4, 7).     
 
Table 1: Glasgow Coma Scale 
      
 
Behaviour Response Score 





To speech 3 
To pain 2 





Orientated to time, place and person 5 
Confused 4 
Inappropriate words 3 
Incomprehensible sounds 2 





Obeys commands 6 
Localises painful stimulus 5 
Withdraws from painful stimulus 4 
Abnormal flexion 3 
Abnormal extension 2 
No response 1 
 
Total Score 
Mild brain injury ≥13 
Moderate brain injury 9 - 12 
Severe brain injury <9 
Table 1: Glasgow Coma Scale 
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Epidemiology 
Traumatic brain injury is a significant cause of disability and death and a huge 
economic burden on society. In the UK, TBI is the commonest cause of death 
and disability in those aged 1-40 (8). Annually, there are approximately 
200,000 hospital admissions attributable to head injuries, of which 11,000 are 
severe and require treatment in an intensive care unit (ICU). Most of these 
admissions are young adult males (8, 9) but there is a trimodal distribution with 
peaks in young children, young adults and the elderly. Most head trauma is 
secondary to falls, assaults and road traffic collisions (RTC), with RTCs 
accounting for the greatest proportion of severe TBI and death.  In the US, 
approximately 50,000 people die following TBI each year and of those who 
survive to discharge, approximately 43% have an ongoing disability at one 
year after the initial injury (10). 
In addition to the morbidity and mortality associated with TBI there is a 
significant economic burden. In Europe the annual monetary cost exceeds €33 
billion (11, 12). In the US, it was estimated to be $60 billion in the year 2000 
(13). 
It is difficult to provide an accurate estimate of the effect of TBI in third-world 
countries due to incomplete records, but it is thought to be at least as 
significant due to the larger incidence of RTCs. An estimated ten million people 
suffer severe TBI worldwide each year (14). Because of the enormous 
incidence of TBI occurring in third-world countries, any intervention for TBI 
should be affordable and practical to low income areas.  
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Primary and Secondary Brain Injuries 
Primary injury after TBI reflects the initial trauma to the head causing direct 
physical damage to the brain parenchyma, tissue damage, shearing or 
vascular damage in addition to destabilising cell membranes. Public health 
measures to prevent TBI may be the best management strategy for these 
injuries.  
Much of the morbidity associated with TBI can be attributed to secondary 
insults. Secondary brain injury occurs hours to days after the initial event and 
can have an intracranial or systemic aetiology. Intracranial causes include 
haematomas, cerebral oedema, hydrocephalus, raised ICP, excitotoxicity, 
infection and imbalances in free radicals, and oxygen and substrate delivery. 
Systemic brain insults are often related to brain tissue hypoxia and are 
ischaemic in nature (15-17). It is these secondary injuries that we aim to 
influence and which this thesis focuses on. Surrogate indicators of brain 
perfusion and oxygenation measured on the ICU in an aim to reduce 
secondary brain injury include intracranial pressure (ICP), cerebral perfusion 
pressure (CPP), and partial brain oxygen tension (PbtO2)(18).   
In severe TBI, additional changes occur to accommodate fluctuations in 
cerebral blood flow (CBF) and ICP. A basic understanding of these changes is 
necessary for the management of TBI. Cerebral blood flow must be maintained 
to ensure adequate delivery of oxygen and glucose to the brain to prevent 
secondary brain injury. Maintaining this blood flow is dependent upon the 
mean arterial pressure (MAP) of blood entering the brain, and the ICP exerted 
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on vessels within the skull. When the MAP decreases, there are physiological 
changes which take place to maintain CBF. Similarly, if the MAP increases, 
putting the brain at risk of cerebral oedema and increased ICP, there are 
changes which take place to reduce the MAP. This is pressure autoregulation 
and is key to understanding the correct management of patients with severe 
TBI (19, 20).  
Intracranial Pressure 
The skull can be thought of as a fixed box, containing three compartments of 
approximately 80% nearly incompressible brain parenchyma, 12% blood and 
8% cerebrospinal fluid (CSF). The total volume within this box is approximately 
1600mls. If the volume of any one of these compartments increases, the ICP 
will increase unless the volume of another compartment is reduced to 
compensate. There is limited volumetric compensation from CSF and blood 
before increased ICP causes cerebral herniation. When intracranial volume 
increases after TBI, secondary to oedema, hydrocephalus or increased blood 
volume, several changes occur. Firstly, CSF leaves the skull into the spinal 
canal, then venous blood and more CSF is forced out of the skull. Eventually, 
this compensatory mechanism is fatigued as the venous sinuses are emptied 
and there is minimal CSF remaining that can be displaced. This describes the 
Monro-Kellie hypothesis, stating that the cranium is incompressible with a fixed 
volume that exists in a state of equilibrium (21-23). Figure 1 demonstrates a 
CSF-pressure-volume curve indicating that small increases in volume lead to 
minimal changes in ICP until a further small change in volume leads to a 
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dramatic increase in ICP. Areas 3-4 on the curve reflect the rapid 
decompensation that occurs when the brain has exhausted its ability to 
compensate for increases in volume. An increase in volume greater than 100-
120mls is sufficient to cause a dramatic increase in ICP (20).  
 
Figure 1: Intracranial Pressure-Volume Curve 
A normal ICP value in a supine adult has been reported as between 7-15 
mmHg, although it varies by 1-2 mmHg as we change position, cough or 
sneeze (24). The standard reference for ICP is derived from ventricular-sited 
ICP monitors. Less accurate sites include the subarachnoid, epidural and 
subdural spaces, but intraparenchymal monitors are now standard of care 
(Table 3).  
In healthy adults ICP is maintained through changes in CSF volume and 
venous blood volume. Patients admitted to the ICU with severe TBI may have 
an intracranial bolt inserted into the skull with a probe placed in the brain 
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parenchyma, ventricles, epidural or subarachnoid spaces, providing a 
continuous measure of ICP (Fig.2).  
 
Figure 2: Potential Sites of ICP Monitoring. 1, Intraventricular drain; 2, 
Intraparenchymal probe; 3, Extradural probe; 4, Subarachnoid probe.  
 
Despite trials of non-invasive methods of measuring ICP, an intraventricular 
drain placed in one of the lateral ventricles or brain parenchyma connected to 
an external pressure transducer remains the gold standard (25, 26). 
Intraventricular drains are the preferred choice in the presence of 
hydrocephalus because of their ability to drain CSF (27). This route also offers 
the ability to administer thrombolytics in patients with intraventricular 
haemorrhage and antibiotics in patients with ventriculitis (28, 29). In patients 
with intracranial hypertension and small ventricles, intraventricular monitors 
can be technically difficult to site. The risk of infection from intraventricular 
monitoring is also higher than alternative methods and is estimated to be 
between 5-11% (30-32). Intraparenchymal pressure monitors have a lower 
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rate of infection (approximately 1%) but give a localised estimated of ICP in 
certain cases (33). If there is a disturbance in CSF circulation, as may occur 
after TBI, the measured intraparenchymal pressure may reflect a 
compartmentalised pressure and not the true ventricular ICP. In addition to 
this, intraparenchymal monitors can suffer from a small drift from their baseline 
measurement and recalibration cannot be performed once the sensor is in 
place (26). Due to fluctuations in ICP a mean value should be taken over at 
least 30 minutes (31). The transducer should be zeroed at the external auditory 
meatus and may require repeat zeroing if possible. Traditionally, the monitor 
was placed on the right because this is the non-dominant side in approximately 
80% of the population, but may also be placed on the pathological side (34-
36). Note that patients who have PbtO2 measured will have an 
intraparenchymal probe measuring ICP, PbtO2 and brain temperature. It is 
unclear whether probes should be placed at the site of injured tissue to better 
reflect the PbtO2 and ICP in the affected areas or in healthy tissue.  
Advantages and Disadvantages of ICP Monitoring Sites 
Location of Sensor Advantages Disadvantages 
Intraventricular  
Is the current gold standard and 
allows drainage of CSF to 
decrease ICP 
Highly invasive with associated 
infection rate. Requires more technical 
ability from physician. 
Intraparenchymal 
Low infection rate, easier to place 
than intraventricular 
Measure focal pressures rather than 
CNS pressure 
Subarachnoid 
Low infection rate, no brain tissue 
damage 
High failure rate and limited accuracy 
Extradural 
Low infection rate, no brain tissue 
damage and simplest to place 
Not as accurate as those above 
Table 2: Intracranial Pressure Probe Sites: advantages and disadvantages. CSF, 
cerebrospinal fluid; ICP, intracranial pressure; CNS, central nervous system  
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Cerebral Perfusion Pressure 
Cerebral perfusion pressure in the healthy adult is the pressure gradient 
between arterial and venous blood. It is the difference between MAP and 
central venous pressure (CVP), both calibrated at the level of the right atrium. 
It is commonly estimated as the difference between the MAP and the ICP due 
to the increase in pressure surrounding the cerebral vessels. The MAP is the 
mean average arterial pressure of a single cardiac cycle and can be calculated 
as the cardiac output (heart rate x stroke volume) x the systemic vascular 
resistance (the resistance to blood flow throughout the circulation). The MAP 
can be estimated by adding the diastolic pressure to one third of the pulse 
pressure (systolic minus diastolic pressure). It is preferred to the systolic 
pressure because it reflects the perfusion pressure at which organs, such as 
the brain and kidneys, receive their blood supply (20).  
 
Figure 3: Mean Arterial Pressure 
I have stated that the MAP and CVP are calibrated at the level of the right 
atrium in healthy subjects, but in TBI patients managed with head elevation 
the level of calibration may be different. Some authors advocate that MAP and 
ICP should be set at the level of the foramen of Monro/the tragus of the ear to 
avoid CPP over-estimation (37, 38). Rao et al. highlight the importance of 
standardised measurement points. Measuring blood pressure (BP) at the level 
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of the heart in a patient with 30 degree head elevation results in a CPP 11 
mmHg higher than that measured at the tragus of the ear (37, 38). Kirkman et 
al. cite two papers referenced by the BTF that describe worse outcomes in 
patients with a CPP below 60 mmHg (37). However, these two studies used 
the level of the heart to zero their BP measurements and as such represented 
a ‘true’ CPP below 50 mmHg (39, 40). Rao et al. found that of 58 European 
centres, 62% calibrated MAP at the heart, while 36% calibrated at the head 
(the remaining centre calibrated at the heart unless ICP was above 20 mmHg, 
when they would then recalibrate at the head) (38).  
 
 
Figure 4: Cerebral Perfusion Pressure 
 
In a healthy adult, with a MAP of 80-100 mmHg and an ICP of 5-10 mmHg, 
CPP is maintained at about 70-85 mmHg. If a patient’s MAP is low and their 
ICP is high, the effect can be a catastrophic decrease in CPP leading to brain 
tissue ischaemia (41). Figure 5 shows the traditional Lassen curve 
demonstrating a rapid increase and decrease in cerebral blood flow when the 
body decompensates for changes in cerebral perfusion pressure (42).  
There is no class I evidence (defined as good-quality randomised controlled 
trials (RCT)) that CPP-guided therapy improves outcomes, and some evidence 
suggests it makes no difference, whilst others suggest it may worsen 
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outcomes. In the early nineties the lower threshold for CPP was 70 mmHg 
based on prospective data demonstrating improved outcomes associated with 
higher CPP (43, 44). The benefit of a higher CPP may come from the higher 
MAP and avoidance of the adverse effects of hypotension. Decreased CPP 
below 50 mmHg has been associated with brain tissue hypoxia and ischaemia 
from surrogate markers (one RCT n=189, and two small cohort studies)  (45-
47). However, a CPP above 70 mmHg has been shown to increase the risk of 
acute respiratory distress syndrome (ARDS) and is not associated with 
improved outcomes (46, 48, 49). The Selfotel trial (a multi-centre RCT of 427 
patients) found no correlation between CPP and neurological outcomes as a 
secondary measure as long as CPP was ≥60 mmHg. The authors concluded 
that a CPP >60 mmHg has little influence on the outcomes of patients with TBI 
(50). The Lund concept introduced still different targets of CPP based on a 
‘volume-targeted’ approach over 20 years ago. Despite not being adopted and 
remaining controversial, it is still described and reviewed in contemporary 
literature. The Lund concept is based on blood-brain barrier (BBB) and 
autoregulation impairment and advocated a CPP of 50 mmHg to minimise 
intra-capillary hydrostatic pressure and water content and avoid rises in ICP 
(51). A 2013 Cochrane review noted that there was no evidence that the Lund 
concept is a preferable treatment option (no studies met the inclusion criteria). 
Another review highlights that there is evidence against the use of some 
individual components of this strategy (52, 53).  
It is still unclear what the optimal target CPP is but the current 2016 BTF 
guidelines state the following:  
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• There is insufficient evidence to support a level I or II A recommendation 
for CPP targets.  
• Aim for a target CPP of 60 to 70 mmHg.  
• It is unclear whether 60 or 70 mmHg is the minimum optimal threshold.  
• Aggressive attempts to maintain CPP above 70 mmHg should be 
considered due to the risk of ARDS (54).  
The BTF also recommend using guideline-based CPP monitoring to reduce 
two-week mortality. This is based upon one retrospective cohort study of 2,300 
patients that demonstrated a decrease in two-week mortality from 22 to 13% 
(OR 0.52, 95% CI 0.39-0.70; p < 0.0001) which appears to be associated with 
an increased adherence to guidelines. However, it should be noted that both 
ICP and CPP monitoring guideline adherence increased in this study, not 
solely adherence to CPP guidance (55).  
 
Figure 5: Cerebral Blood Flow Change with Cerebral Perfusion Pressure 
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Cerebral Blood Flow 
There is roughly 150mls of blood in the skull, 100mls of which is in the venous 
system, but CBF is relatively high. Cerebral blood flow is the blood supply to 
the brain and is typically 45-50ml 100g-1 min-1, ranging from 20ml 100g-1 min-1 
in white matter to 80ml 100g-1 min-1 in grey matter. This equates to 
approximately 15% of the cardiac output, or 700ml.min-1 (56). The 
electrochemical function of cells in the brain begin to fail when CBF falls below 
20ml 100g-1 min-1. In addition to this, changes in CBF lead to changes in the 
cerebral arterial blood volume and can subsequently lead to increases and 
decreases in ICP as the artery dilates or constricts to accommodate the 
different blood volumes. The blood flow is equal to cerebral perfusion pressure 
(MAP - ICP) divided by the cerebrovascular resistance. One of the limitations 
of these figures is that they are derived from data based on the Kety and 
Schmidt technique (a method of assessing blood flow based on the change in 
a substance delivered by the arterial system and returned to the vascular 
system) which can be limited to global, rather than regional data. They may 
also be more applicable to healthy tissue than pathological tissue (57, 58).  
 
Figure 6: Cerebral Blood Flow 
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CBF is broadly dependent on factors which can modulate cerebrovascular 
resistance (the radius of the cerebral blood vessel): 
• CPP; 
• Cerebral metabolic rate for oxygen (CMRO2); 
• Arterial partial pressure of carbon dioxide (PaCO2); 
• Arterial oxygen content (CaO2). 
More specifically, CBF can also be altered by hypoxia, hypercapnia, metabolic 
demand, pain, low CPP and raised MAP as well as drugs which induce arterial 
dilatation, such as high-dose volatile agents (all except nitrous oxide) (59).  
Because neurons produce adenosine triphosphate (ATP) almost entirely by 
the oxidative metabolism of glucose and ketones and have a very limited 
capacity for anaerobic metabolism, they can only survive extremely short 
periods of ischaemia compared with other tissues. This is typically three to 
eight minutes (41). 
Increased metabolic demand, as occurs during TBI, is directly proportional to 
CBF (and therefore oxygen and glucose delivery) and is often referred to as 
flow-metabolism coupling. It is thought that vasoactive substances such as 
nitric oxide, adenosine, carbon dioxide, potassium and hydrogen ions control 
this response (41).  
In healthy individuals, CBF is said to be maintained with a CPP of 50-150 
mmHg (26, 60). In patients following TBI or with ischaemic brain tissue, CBF 
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is more reliant on BP. When MAP is increased, CBF increases, as does 
cerebral volume and hence ICP. When CPP decreases, CBF decreases, 
reducing the ICP, but perhaps reducing CBF to an insufficient level. Normal 
autoregulation has been shown to be present in up to approximately 70% of 
patients with TBI (61). When CPP is lower than 60 mmHg, there may be 
insufficient cerebral perfusion leading to cerebral vasodilation in an attempt to 
provide more oxygen and glucose, which actually increases the cerebral blood 
volume and further increases ICP. The rise in ICP further decreases the CPP 
and a vicious cycle is born (Fig.7). The solution may be to increase MAP, 
thereby increasing CPP, causing vasoconstriction and decreased cerebral 
volume, lowering ICP. As discussed above, this is an oversimplification of a 
complex disease and increased CPP >70 mmHg is not associated with 
improved outcomes (46, 50). 
 
Figure 7: The ROSNER Cascade 
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Optimal Cerebral Perfusion Pressure (CPPopt) 
I have discussed cerebral autoregulation and acknowledged that there is 
interpatient variability in autoregulatory function after TBI (61, 62). Therefore, 
targeting non-individualised CPP may be an oversimplified management of a 
complex physiological process (63). Autoregulation relies, in part, upon 
cerebrovascular pressure reactivity, the contraction and relaxation of cerebral 
arterial walls in response to increases and decreases in transmural pressure 
respectively (64, 65). With this response intact, increases in MAP are said to 
cause cerebral vasoconstriction within 5-15 seconds, with associated 
decreases in cerebral volume and ICP. The opposite, with a decrease in MAP, 
is also said to be true (66, 67). It has been proposed that individual patients 
have different pressure reactivity thresholds (63). Patients with chronic 
hypertension may have a rightward shift of the Lassen curve (i.e. a higher MAP 
requirement, Fig.5) (68). Research has been concentrated on identifying an 
individualised optimal CPP (CPPopt), based upon cerebrovascular pressure 
reactivity (63, 69-71). Ventilated patients with severe TBI demonstrate slow 
arterial blood pressure (ABP) variations of 20 seconds to three minutes which 
are transmitted to ICP (67, 72). This transmission between ABP variations and 
ICP has been used by Czosnyka et al. to determine a cerebrovascular 
pressure reactivity index (PRx) (67, 72). The PRx can be defined as the moving 
correlation coefficient between mean intracranial pressure and mean arterial 
pressure (73). It is calculated by 40 consecutive five second averages of MAP 
and ICP being captured at 60 Hz. The value generated is between -1 and +1, 
with normal reactivity seen with a coefficient of -1 and abolished reactivity seen 
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at +1 (i.e. passive behaviour of a non-reactive vascular bed). The relationship 
between CPP and PRx appears U-shaped when plotted on a graph (Fig. 8) 
(63, 67, 69-71, 74, 75). Steiner et al., demonstrated from a retrospective 
analysis of 114 consecutive TBI patients, that PRx can be used as a means of 
identifying CPPopt for individual patients using long-term ICP and MAP 
monitoring (75). Aries et al., have gone on to use a similar algorithm to find 
that CPPopt can be calculated for 55% of patients’ monitoring period. The 
same authors have shown that CPP too high in comparison to CPPopt is 
associated with increased incidence of severe disability, and CPP too low in 
comparison to CPPopt is associated with increased incidence of mortality (70, 
76). Interestingly, the CPPopt graphs published by Aries et al., show a mean 
CPPopt of approximately 75 mmHg, with certain patients’ CPPopt as high as 
107.5 mmHg, much higher than the BTF recommended 60-70 mmHg  (54, 70). 
PRx calculation requires high frequency data sampling (>60Hz), which 
requires additional software to extract and process the waveform data. This is 
not commonplace in many ICUs (77, 78). Because of this limitation, Depreitere 
et al., have developed a low-resolution autoregulatory index (LAx), a moving 
index using minute-by-minute data sampling of ICP/MAP correlation 
coefficients over 3-120 minutes (78). Different LAx values and time windows 
can be combined and weighted to provide CPPopt recommendations which 
appear to be more easily obtainable than PRx (79). Depreitere et al. applied 
the LAx method to a data set obtained from 21 patients and demonstrated that 
the median CPPopt over the first 48 hours was not significantly different 
between the PRx and LAx methods. Furthermore, the LAx method was able to 
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produce a CPPopt recommendation in 97% of the monitoring time versus 44% 
with the PRx method (78). The same paper reports a correlation between the 
time patients’ CPP was in the LAx-based CPPopt range and survival (median 
(IQR) 9.1% in non-survivors versus 22.0% in survivors (p=0.006). It seems, 
based on this, that a method of analysing autoregulation using lower resolution 
data can produce comparable outputs to the PRx method and give CPPopt 
recommendations in a higher proportion of monitoring time. Santos et al. have 
also demonstrated that minute-by-minute ICP and MAP data can be used to 
generate a pressure reactivity index (called L-PRx) in intracerebral 
haemorrhage patients. Their method appears to compare well with the original 
PRx over a 20-minute period and is able to provide CPPopt recommendations 
in the same range (80). Therefore, high-frequency data sampling and 
processing may not be a limitation to the use of CPPopt to guide treatment. 
Sánchez-Porras et al. studied long pressure reactivity index (L-PRx), another 
method of low frequency (minute-by-minute) analysis of ICP and MAP using 
20-minute averages. An initial study of 29 patients suffering from TBI found 
that L-PRx correlated strongly with 6-month outcome (81). Lang et al. went on 
to investigate outcome prediction using CPPopt in 307 patients after severe 
TBI using PRx and L-PRx. PRx was found to be a significant mortality predictor 
whilst L-PRx was not. The study suggested that mean CPP above and below 
CPPopt were associated with severe disability and mortality respectively. 
These findings were not statistically significant for L-PRx and the authors 
concluded that PRx and L-PRx cannot be used interchangeably (76).    
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CPPopt has been investigated in patients with TBI, SAH and intracerebral 
haemorrhage. However, most studies have been retrospective or prospective 
observational studies (69, 71, 75, 82, 83). I have found no published RCT data 
demonstrating improved outcomes in any of these groups where CPPopt has 
been utilised. There are a few difficulties with CPPopt. Firstly, continuous 
monitoring of CPPopt is difficult in the clinical setting. Data becomes missing 
due to patient transfers for CT; delays in having monitoring boxes attached; 
delays due to staff not appreciating the importance of certain monitoring 
(possibly due to lack of teaching); and technical faults due to broken monitoring 
leads which happens not infrequently. Whilst a tertiary referral centre with a 
team that has specific research interests in CPPopt may have good results 
without data loss, I suspect its application may be more difficult elsewhere (69, 
70). These are obstacles to be overcome but should not limit its 
implementation. Secondly, it appears that the mean CPPopt (to achieve 
optimal reactivity) is slightly higher than the CPP currently recommended. It 
may be that a higher CPP does correspond to better autoregulation, but it may 
also be that better autoregulation comes at the cost of increased incidence of 
acute respiratory distress syndrome. Thirdly, Aries et al., identify that PRx is a 
global index and represents the mean of all intracranial vascular territories. 
The authors go on to acknowledge that certain areas (e.g. sites of injury) may 
require perfusion pressures that are different to the global index (70). LAx and 
CPPopt appear very promising but need to be applied to a larger group. If RCT 
evidence of improved outcomes existed one could imagine software 
developed to produce real-time imaging of individualised CPPopt with 
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automatic intervention recommendations being implemented. CPPopt Guided 
Therapy: Assessment of Target Effectiveness (COGITATE, Clinical Trials: 
NCT02982122) is a multicentre study due to start in 2017. The team aims to 
allocate TBI patients to either BTF management with CPPopt targets, or BTF 
management with CPP targeted between 60-70 mmHg. It will be interesting to 
read the results of this study, and any subsequent studies including patients 
with SAH.  
 
Figure 8: Optimal Cerebral Perfusion Pressure : example graph of PRx 
against CPP showing U-shaped relationship with CPPopt being 
approximately 80 mmHg. 
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Arterial Tension of Carbon Dioxide and Oxygen 
Hyper- and hypocapnia cause cerebral vasodilation and vasoconstriction 
respectively (84). The mechanism appears to be regulated by changes in CSF 
pH rather than arterial pH, although there may be some direct arterial 
involvement (84-89). Hyperventilation causes arterial hypocapnia leading to 
cerebral vasoconstriction and decreased cerebral blood volume which is 
reflected by a decrease in ICP (90). Hyperventilation is said to be able to 
reduce ICP by a mean of 50% within two-to-30 minutes (20). The relationship 
between PaCO2 and ICP does not appear to be linear and the greatest effect 
is between a PaCO2 of 30-50 mmHg (4-6.5 kPa) (91). The vasoconstriction is 
also associated with a reduction in CBF. Hyperventilation has been reported 
to reduce CBF by over 30% in healthy volunteers (92). The increase in CBF 
appears to plateau above 10.6 kPa and there is no further reduction in CBF 
below 2.7kPa (Fig.8) (20, 41, 93). Brain extracellular pH decreases with an 
increase in brain PaCO2. This results in mediators such as nitric oxide, 
prostanoids and cyclic nucleotides becoming active and intracellular calcium 
concentration decreasing leading to increased CBF (89). If patients are 
intentionally hyperventilated to induce hypocapnia, the vasoconstriction is said 
to only last approximately five hours before a gradual increase in CBF occurs 
(20, 94). Muizelaar et al., emphasise that any vasoconstrictive effect of 
hypocapnoea will be time-limited due to perivascular spaces normalising pH 
within 24 hours (95). Prolonged hyperventilation to reduce PaCO2 causes 
cerebral vasoconstriction and decreased CBF, which not only reduces ICP but 
also causes ischaemia (96, 97). Considering this, hyperventilation to induce 
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marked hypocapnia is only advocated in the short-term during neurosurgery 
or acute neurological deterioration (54). If a patient has poor arteriolar tone 
due to severe hypotension, this relationship between PaCO2 and CBF may be 
almost completely abolished (98). 
 
Figure 9: Cerebral Blood Flow Variation: Changes in Cerebral Blood Flow 
with Arterial Partial Pressures of Carbon Dioxide (PaCO2)  
 
Hypoxia appears to be an independent predictor of poor outcome after severe 
TBI (99). Over a range of partial pressure of oxygen (PaO2) of 7.0 to 13.3 kPa, 
there is little change in CBF. This is thought to be because CBF responds to 
the arterial content of oxygen (CaO2) rather than PaO2 (100). CaO2 is relatively 
constant with a PaO2 between 7.0 to 13.3 kPa (101). Acute hypoxia 
significantly increases CBF: A decrease in PaO2 of from 6.7 to 3.3 kPa (50 to 
25 mmHg) causes enough cerebral vasodilation to double CBF (102). The 
response to hyperoxia (PaO2 >15 kPa) is less clear but there is reported to be 
a variable decrease in CBF of 9-27% (101).  
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Partial Brain Oxygen Tension 
Partial brain oxygen tension reflects the partial pressure of oxygen in the extra-
cellular fluid of the brain and the amount of oxygen available for anaerobic 
respiration and ATP production. It acts as a marker for the balance between 
oxygen delivery and consumption, in a similar way that jugular venous bulb 
saturation is lower with increased oxygen consumption. The difference is that 
while jugular bulb venous oxygen saturations measure global cerebral 
oxygenation, PbtO2 can reflect venous partial pressure of oxygen from a focal 
area of brain tissue (103-105). The most commonly used sensors have been 
the Licox Integra system (GMS, Kiel-Mielkendorf, Germany), the Neurotrend 
sensor (Codman, Johnson & Johnson, Raynham, MA, USA, no longer 
commercially available) and the Neurovent sensor (Raumedic AG, 
Helmbrechts, Germany). The Licox system is comprised of three optical 
sensors in a microporous polyethylene tube with a diffusible membrane and 
can provide data on brain temperature, PbtO2 and ICP (Fig.9). After diffusing 
across brain tissue and a semi-permeable membrane, oxygen is reduced by a 
gold polarographic cathode creating an electrical current directly proportional 
to the oxygen concentration (106). The sensors are inserted under direct vision 
during surgery or via a craniotomy on the ICU using a triple-lumen cranial 
access device allowing monitoring and microdialysis (107). Readings are 
available immediately, although a reported period of 30 minutes to two hours 
is required for values to become consistent (103, 104). Most PbtO2 reading 
errors occur within the first four hours of placement (104). PbtO2 monitoring is 
reportedly safe, causing an iatrogenic haematoma in less than 2% of patients, 
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similar to parenchymal ICP monitoring, and safer than external ventricular 
drains (EVD) (108).  
The 0.8 mm diameter probes are usually positioned in the sub-cortical white 
matter and can measure PbtO2 in an area of approximately 15-20 mm2 from the 
probe (104). Following insertion, patients should undergo a repeat x-ray 
computed tomography (CT) head scan to confirm correct placement of the 
probe. The PbtO2 value relies on oxygen diffusing from the vasculature into 
brain tissue so correct location of the probe is essential for interpretation of 
PbtO2 values (109, 110). Values measured from healthy-appearing frontal sub-
cortical white matter, where most probes are placed, may not reflect what is 
happening around focal injuries. Because of this, probes are sometimes sited 
adjacent to the focal injury, such as haematomas or haemorrhagic contusions, 
in patients following severe TBI. This is important when using PbtO2 to guide 
treatment. If the probe is sited in healthy tissue and reads 25 mmHg, then one 
might be falsely reassured and not alter management (see below for treatment 
thresholds). However, if that same probe had been sited in damaged tissue in 
the same patient it may read 15 mmHg and thus change management 
according to a predefined treatment algorithm. Furthermore, any research to 
assess a treatment threshold or association with functional outcomes may not 
demonstrate consistent results if different sites for PbtO2 monitoring are used. 
This leads to the following questions: Where is the best place to insert the 
PbtO2 probe? Is it in healthy tissue, adjacent to damaged tissue or directly 
inside the damaged tissue? Does PbtO2 guided management have an effect of 
functional outcomes? To my knowledge, after a non-systematic Medline 
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search, there are no RCTs assessing the impact of probe placement on PbtO2 
readings and functional outcomes. There have been a small number of human 
studies assessing probe location but these have used different locations in 
different patients and thus inference is limited (36, 108, 111, 112). Perhaps the 
best of these is a single centre database review of prospectively collected data 
(n = 405) between 1995 and 2009. The PbtO2 sensor was placed in normal 
brain in 159 patients and abnormal brain in 246 patients. Mean PbtO2 readings 
in abnormal brain were 25.6 ± 14.8 mmHg compared with 30.8 ± 18 mmHg in 
normal brain. Patients with a favourable outcome had higher PbtO2 (32.2 ± 16.3 
compared with 25.1 ± 13.5, P < 0.001) and patients with an unfavourable 
outcome were more likely to have a probe sited in abnormal brain tissue. 
However, patients were not randomised to probe placement and the authors 
note that the position of probe placement was significantly influenced by the 
type of injuries the patient had. 71.1% of patients with diffuse injuries had 
probes placed in normal appearing tissue compared with 11.5% of patients 
with mass lesions on CT (36). A subsequent porcine model assessing four 
probe placements in 12 swine has demonstrated that PbtO2 readings are 
dependent on the distance of the probe from the site of focal injury. 
Physiological interventions (e.g. hyperoxia) appeared to have little effect on 
PbtO2 at the site of injury but increased PbtO2 in healthy tissue (113). 
It has been suggested that this ability of PbtO2 sensors to identify focal tissue 
hypoxia could be used to identify delayed cerebral ischaemia (DCI) after 
subarachnoid haemorrhage (SAH) (112). Due to the localised measurements 
I suggest this technique is likely to be limited and highly inaccurate.  
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Figure 10: Schematic Diagram of Integra Licox Machine (Ingera, France). 1, 
Polythene tube with diffusable membrane encasing electrodes; 2, silver 
polarographic anode; 3, gold polarographic cathode; 4, electrolyte chamber  
 
The significance of PbtO2 in TBI is not fully understood but it does correlate well 
with regional CBF and demonstrates the same autoregulation physiology 
discussed above. There is some evidence that PbtO2 can be increased by 
manipulation of the MAP and CPP, suggesting that PbtO2 could be a surrogate 
marker for CBF (114-116). PbtO2 may not be simply a marker of local cerebral 
ischaemia. Rosenthal et al., demonstrated a relationship between CBF and 
arterio-venous oxygen tension difference (110, 117). PbtO2 is not solely 
dependent on the CBF/CPP but also the amount of dissolved plasma oxygen 
passing through brain tissue. In this way, PbtO2 can be affected by other 
pathology, such as impaired lung function, which is not uncommon in trauma 
patients with severe TBI. This means that clinicians can improve PbtO2 by 
providing adequate oxygenation. PbtO2 is a promising tool and has been 
reported as being superior to jugular venous oxygen saturations, regional 
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transcranial oxygen saturations and near infrared spectroscopy in detecting 
cerebral ischaemia (103, 104, 118). Level I evidence of improved outcomes 
associated with PbtO2 monitoring or guided treatment is lacking. 
Brain Trauma Foundation Guidelines 
There are three physiological states that almost certainly worsen outcomes 
following TBI: hypoxia, hypotension and hyperventilation in actively ventilated 
patients. Due to the aetiology and clinical course of TBI, designing a 
prospective RCT to evaluate treatments for TBI is difficult. Few of the BTF 
recommendations are based on level I evidence (defined as that derived from 
good quality RCTs). Despite this, the authors note a significant reduction in 
severe TBI mortality from 50% to 25% since the 1980s following the 
implementation of evidence-based protocols (119). These protocols 
emphasise the importance of monitoring and adequate cerebral perfusion.  
Analgesia, Sedation and Paralysis 
The initial trauma and assessment, procedures undertaken by ICU and 
emergency department (ED) staff, surgical procedures, endotracheal 
intubation and mechanical ventilation and subsequent endotracheal suction 
can all be sources of pain. In addition to being unpleasant for the patient, pain 
can lead to increases in ICP. Morphine, fentanyl and remifentanil are all 
appropriate first-line therapies to provide analgesia, sedation and depression 
of airway reflexes in patients who are intubated. Reducing airway reflexes in 
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these patients is beneficial to prevent coughing and the associated increase in 
ICP (120).  
The benefits of sedation include their synergistic action with analgesia, limiting 
ICP elevations related to coughing and agitation and aiding mechanical 
ventilation (120). By reducing agitation and muscle use they reduce oxygen 
consumption while also reducing CMRO2 and CO2 production. Propofol 
appears to be the ideal sedative agent for patients with severe TBI (121). It 
offers a quick onset, is easily titratable and quickly reversible to enable a 
predictable effect and intermittent neurological assessment on demand. 
Unfortunately, Propofol can cause significant systemic vasodilation and is best 
avoided in patients with refractory hypotension, especially with raised ICP 
which may further reduce the patient’s CPP. In addition to this, long-term or 
high-dose administration of Propofol can also lead to rhabdomyolysis, 
metabolic acidosis, renal failure and bradycardia, a so-called ‘Propofol-related 
infusion syndrome’ (PRIS). Roberts et al., found that PRIS had an incidence 
of just over 1% in a study of 1,017 patients and that the mortality rates for these 
patients was 18% (122). Alternative sedative agents include benzodiazepines 
used as a continuous infusion or in intermittent boluses. Benzodiazepines can 
be beneficial in providing an anticonvulsant and amnesic effect. 
Neuromuscular blocking agents reduce ICP and can be considered for 
refractory intracranial hypertension, but are related to longer ICU inpatient 
stays and pneumonia. Their routine use is not recommended (18, 123). 
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Hypoxia 
There are a number of studies associating short-term hypoxia with poor 
outcomes following TBI although many are also associated with hypotension 
(17, 124-126). The primary evidence to support worse mortality from hypoxia 
is derived from the retrospectively analysed data of the Traumatic Coma Data 
Bank (TCDB) (99). Data from 1,030 patients were analysed and demonstrated 
a significant increase in morbidity and mortality in the 22.4% of patients with 
hypoxemia. Cooke et al. also found that 27% of 131 patients admitted to an 
ED with TBI in Northern Ireland were hypoxic (PaO2 <10 kPa or cyanosed) on 
arrival and this was associated with increased mortality. There was an 
association between severe TBI and increased rates of hypoxia and 
hypotension and increased mortality, but no causative relationship can be 
inferred from this study (125). Furthermore, Stocchetti et al., found that brief 
hypoxia (SaO2 <60%) increased mortality from 14.3% to 50% when compared 
with patients who had no hypoxia. Of the 50% with hypoxia who survived to 
discharge, all were severely disabled. This was a small study of 50 patients 
who had episodes of hypoxia (SaO2 <90%) whilst being transferred to hospital, 
and the results were not corrected for confounding factors (124).   
The 2016 BTF guidelines no longer have a separate section regarding hypoxia 
above their section on hypotension (present in 2007 guidelines), most likely 
due to the interrelation with hypotension and the limited body of evidence (54). 
The 2007 BTF guidelines offered the following level III recommendation:  
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• Oxygenation should be continuously monitored and hypoxia (defined as 
PaO2 <60 mmHg or O2 saturation <90%) avoided (123). 
Hypotension 
Hypotension, defined as a systolic blood pressure (SBP) <90 mmHg (although 
more recently some argue <110 mmHg in TBI (127, 128)) or MAP <65 mmHg, 
following severe TBI is associated with increased morbidity and mortality, both 
from pre-hospital and in-hospital data (99, 127-131). Hypotension is reported 
to occur in up to 73% of patients in ICU and an isolated episode of hypotension 
has been associated with increased morbidity and a doubling of mortality in 
patients with TBI (99). Hypotension has been documented as an independent 
risk factor for increased mortality in severe TBI as demonstrated by studies 
from the TCDB (99). This fits with physiological data showing that CPP, and 
hence CBF, decreases significantly with a decrease in MAP and must be 
aggressively managed in the hypotensive patient. It is unlikely that 
haemodynamic instability is caused by TBI in isolation. There are several 
factors that can lead to hypotension in TBI patients. Trauma to long-bones, 
chest, abdomen, pelvis and blood vessels, as well as polyuria secondary to 
diabetes insipidus from brain injury are the most frequent causes of 
hypotension in this population. In addition to these causes, cardiogenic shock, 
spinal shock and anaesthetic agents can all cause hypotension (18, 132).  
The 2016 guidelines have updated their SBP threshold based on two studies. 
The first is a retrospective database (Los Angeles Trauma System database) 
review by Berry et al. This review investigated 15,733 adult TBI patients 
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(moderate to severe) admitted to 13 centres in Los Angeles between 1998 and 
2005 and allocated participants to three age categories (15-49, 50-69 and 
>70). Outcomes were in-hospital mortality and Glasgow Outcome Score at six 
months post-injury. Adjusted odds ratios (AOR) were used to determine 
increased odds in mortality for their defined optimal SBP. For ages 15-49 the 
optimal SBP threshold was 110 mmHg (AOR 1.98, CI 1.65-2.39, p<0.0001); 
for ages 50-69 it was 100 mmHg (AOR 2.20, CI 1.46-3.31, p=0.0002), and for 
patients ≥ 70 years it was 110 mmHg (AOR 1.92, CI 1.35-2.74, p=0.0003) 
(127). The second study is a small prospective (n=60) single-centre study of 
patients with severe TBI that assessed extended Glasgow Outcome Scale at 
six months. The investigators found that hypotension within the first 48 hours 
was predictive of mortality and functional outcomes at higher SBP thresholds 
than previously thought. The authors of the paper suggest that a SBP threshold 
of 120 mmHg may be more efficacious at minimising secondary insults after 
TBI (128). The BTF now recommend the thresholds from the Berry et al. study:  
• SBP should be maintained ≥100 mmHg for patients aged 50 to 69, and 
≥110 mmHg for patients aged 15-49 and >70 (54). 
Management of Hypotension 
The BTF guidelines do not give specific advice on how to maintain the 
recommended SBP thresholds. There have been a small number of reviews 
assessing fluid management in the pre-hospital treatment of hypotension after 
TBI (133-135). This includes assessment of nine RCTs and one cohort study 
of pre-hospital care which found no benefit from hypertonic or colloid solutions 
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versus isotonic saline (133). The aim of in-hospital management of crystalloid 
resuscitation is to achieve or maintain normovolaemia and colloid osmotic 
pressure. Excess fluid is associated with ARDS/acute lung injury and cerebral 
oedema (46, 48, 136-139) and insufficient fluid is associated with worsening 
hypotension and acute kidney injury (140, 141). Hypertonic saline solution 
(HSS) has been trialled as an alternative to typical cystalloids and does not 
appear to be beneficial for TBI or haemorrhagic shock. One RCT of 222 
patients with haemorrhagic shock reported a reduction in mortality when 
comparing 250mls of HSS with 250mls of isotonic saline (ARR 9%, p<0.03) 
(142). Subsequent RCTs have not supported this finding (143, 144). A 
relatively recent RCT recruited 1,087 patients with TBI and allocated them to 
either TSS or 0.9% sodium chloride. The study was terminated early due to an 
inability to demonstrate improved neurological status or mortality at six months 
after the TBI (143). Colloids have been assessed as a choice of fluid 
resuscitation in trauma, burns and post-surgical patients and were not found 
to be superior in a 2012 Cochrane review (RR 1.01, 95% CI 0.92 to 1.09). As 
such, they are not recommended in TBI (145-147). 
Patients not responding to fluid therapy, and those with congestive heart 
failure, may benefit from vasopressors. Noradrenaline is the recommended 
vasopressor and should be titrated through a central venous line (18). 
Noradrenaline is a catecholamine which acts as an alpha-receptor agonist 
causing increased vascular smooth muscle tone and increasing peripheral 
vascular resistance, thereby increasing SBP, MAP and CPP. In addition to its 
alpha-1 properties, noradrenaline exhibits alpha-2 properties and is not without 
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risk. Tschuor et al., reported that noradrenaline’s alpha-2a properties may lead 
to increased platelet activation and microthrombosis (148). In addition to this, 
both noradrenaline and dopamine can cause arrhythmias, peripheral 
ischaemia, hypertension, dyspnoea and urinary retention (149). Dopamine 
causes cerebral vasodilation and increased ICP, so is best avoided in TBI 
unless necessary via a peripheral venous line until a central line is available 
for noradrenaline (150). In patients who are tachycardic, it has been suggested 
that phenylephrine, a pure alpha-agonist, may be more beneficial than 
dopamine and noradrenaline. Indeed, Sookpkung et al., found that 
phenylephrine resulted in a higher MAP and CPP than dopamine and 
noradrenaline (151). Other experimental models have reported better brain 
oxygenation with the use of noradrenaline versus phenylephrine (152). Both 
inotropes are used.  
Intracranial Pressure 
The 2016 BTF guidance acknowledges its advice to monitor ICP is based on 
“a low-quality body of evidence” (54). The 2007 indications to monitor ICP from 
the BTF were: all salvageable patients with a severe TBI and abnormal CT 
scan or those with a normal CT scan who are over 40 years of age, have motor 
posturing, or systolic blood pressure <90 mmHg (123). This is no longer a level 
II or III recommendation because it is based on descriptive studies, or studies 
that do not meet BTF inclusion criteria. However, the committee have re-stated 
the 3rd edition recommendations to highlight patients at risk of intracranial 
hypertension (54). Raised ICP (>20 mmHg) is associated with poor outcomes 
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following TBI, and extremely elevated levels can be life-threatening, resulting 
in brainstem compression and decreased CBF (153).  
There are a number of studies indicating that ICP monitoring reduces mortality 
after TBI (154-159), yet some have shown no benefit and others have 
demonstrated worse outcomes (160-163). Shafi et al., analysed the US 
National Trauma Data Bank from 1994-2001 and included patients with severe 
TBI aged 20 to 50 with abnormal CT head scans and ICU stays of three or 
more days. Deaths within 48 hours of injury and patients with delayed 
admissions (over 24 hours from injury) were excluded. Patients who had ICP 
monitoring (n = 708) were compared with those who did not (n = 938). 
Interestingly, only 43% of patients meeting BTF criteria for monitoring received 
ICP monitoring (the databank was analysed pre-2006 guidelines). ICP 
monitoring was associated with a 45% reduction in survival (OR = 0.55; 95% 
CI, 0.39-0.76; p < 0.001) after adjusting for confounding factors such as 
admission GCS, age, BP and injury severity score (164). The BEST:TRIP trial 
was a multi-centre RCT in Bolivia and Ecuador which included 324 patients 
allocated to two groups. One group was allocated to ICP monitoring with an 
intraparenchymal monitor and had ICP maintained ≤20 mmHg using current 
BTF guidelines (n=157). The second group was managed according to 
imaging and clinical examination alone (n=167) (123, 160). The primary 
outcome was a composite of 21 components including survival time, duration 
of impaired consciousness and neuropsychological status at six months. There 
was no significant difference in the primary outcome between the two groups 
and the authors conclude that “care focused on maintaining monitored 
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intracranial pressure at 20 mmHg or less was not shown to be superior to care 
based on imaging and clinical examination”. The study did report significant 
treatment regimen differences, most notably an increase in the use of 
barbituates in the ICP-monitored group. The chief criticisms of this study are 
that it was undertaken in countries with limited pre-hospital care and where the 
use of ICP monitors is infrequent so the external validity is questionable. The 
authors are careful to acknowledge that the findings do not support the 
monitoring-based interventional guidelines used in the study, rather than not 
supporting ICP monitoring per-se (160). A Cochrane review from 2015 looking 
at this single RCT echoes its findings (165), and a review from 2014 of two 
RCTs and seven cohort studies (n = 11,038) found no benefit from ICP 
monitoring (OR, 1.16; 95% CI, 0.87–1.54), and that there was a tendency 
toward longer ICU and hospital stay in those patients with ICP monitoring (165, 
166). Both reviews note the importance of further large sample RCTs to 
confirm their findings. A number of authors have since argued that ICP 
monitoring is still beneficial in the management of patients with TBI and it is 
still recommended by the BTF 2016 guidance (54, 56, 167-169). The BTF 
describe “moderate-quality evidence” from four observational studies 
(n=13,164) that ICP-guided treatment leads to decreased in-hospital and two-
week post-injury mortality (55, 170-172). It appears to be these studies which 
lead the BTF to continue to recommend ICP monitoring and ICP-guided 
treatment.  
The current guidelines advocate treating ICP above 22 mmHg as a level IIb 
recommendation (previous threshold was 20 mmHg) (54, 123). Data for this 
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change comes from one cohort study from Cambridge which used a database 
of 459 patients with TBI (data collected from 1992 to 2009) and found a 
threshold of 22 mmHg was beneficial for both survival and favourable 
outcomes (173).      
Intracranial Pressure Dose Response 
 
As with CPP, it may be that the management of ICP is more complex than 
targeting a generalised ICP threshold. The effect of intracranial hypertension 
may not be based solely on its magnitude but could be based on duration and 
intensity. More simply, as an example, an ICP of 25 mmHg for ten minutes 
may be more predictive of poor outcome than an ICP of 20 mmHg for one hour. 
Furthermore, the amount that intracranial hypertension affects outcomes may 
be dependent upon whether cerebral autoregulation is intact and its 
relationship to CPP (174). The magnitude of intracranial hypertension times 
the duration, or the area under the curve of ICP versus time, has previously 
been termed “ICP dose” and appears to be related to mortality and 
neurological outcome (175). Güiza et al. assessed the impact of the duration 
and intensity of intracranial hypertension on six-month neurological outcomes 
in 261 adult and 99 paediatric TBI patients in a prospective multi-centre study 
(174). The team analysed minute-by-minute ICP and MAP data and 
demonstrated that higher ICP can be tolerated for shorter durations of time 
than lower ICP. In adults, ICP above 20 mmHg lasting longer than 37 minutes 
was associated with worse outcomes. In children this time was eight minutes. 
In addition to this, when the CPP was below 50 mmHg, all episodes of 
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intracranial hypertension, regardless of duration, were associated with worse 
outcomes. When graphed, intensity was measured from 10-40 mmHg on the 
X-axis and duration was measured from 5-360 minutes on the Y axis. The 
study also assessed 6-month mortality and neurological outcome as death, 
vegetative or severely disabled (Glasgow Outcome Score 1-3). A correlation 
coefficient, ranging from -1 to 1, was used indicating an ICP insult occurring 
more frequently with a lower or higher Glasgow Outcome Score respectively 
(i.e. -1 = correlated with worse outcomes, 1 = correlated with better outcomes, 
0 = no correlation, defined as the transition point between -1 and 1). The LAx 
method of assessing cerebral autoregulation was also utilised. In both the adult 
and paediatric populations there was an approximately exponential 
relationship at the transition point of correlation with better outcomes to worse 
outcomes in relation to ICP duration and intensity (Figure 11). In adults, ICP 
thresholds of 15, 20, 25 and 30 mmHg were associated with worse outcomes 
at 223, 37, 12 and 8 minutes respectively. In addition, the cumulative effect of 
intensity and duration (the ‘ICP dose’) per patient, or the percent of time the 
patient spent to the right of the curve in Figure 11, was independently 
associated with mortality at six months. The authors also found that when 
autoregulation was impaired the curve shifted to the left and when intact the 
curve shifted to the right. CPP was also associated with a change in response. 
When CPP fell below 50 mmHg outcome was uniformly poor. However, the 
curve progressively shifted to the right from 50 mmHg to ≥70 mmHg.  
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Figure 11: Intracranial hypertension duration and intensity with associated 
Glasgow Outcome Score (simplified from original). For original graph see 
Güiza et al.(174) The line represents an approximate exponential relationship 
between ICP dose and outcome. CPP, cerebral perfusion pressure; ICP, 
intracranial pressure. 
At a basic level one could argue that this is an intuitive finding: intracranial 
hypertension is associated with worse outcomes and the higher the magnitude 
and longer the duration the worse the outcome will be. However, when 
combined with a measure of cerebral autoregulation and a measurement of 
CPPopt it may be that we can individualise treatments to remain to the left of 
the curve in Figure 11. The authors write that perhaps their findings may 
explain why previous RCTs using static ICP thresholds were “destined to fail” 
(174). Indeed, other authors have suggested that individualised ICP thresholds 
based on autoregulatory status are more predictive of mortality than 
generalised thresholds of 20 and 25 mmHg (176). Perhaps in the future we will 
see interventions measured on individually targeted CPPopt and ICP based 
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on cerebral autoregulation. When there exists some uncertainty regarding the 
positive role of ICP monitoring in ICU the real test will be whether CPPopt and 
individual ICP targets can be used to alter patient outcomes.  
Osmotic Therapy: Mannitol and Hypertonic Saline 
In a survey from 1996, 100% of neurosurgical units in the UK used mannitol 
as a treatment for intracranial hypertension (177). The mechanism by which 
mannitol reduces ICP is two-fold. The short-term effect of mannitol is to expand 
the circulating volume and decrease blood viscosity causing increased CBF 
and oxygen delivery. The increase in circulating volume also increases cardiac 
output. Because of this, one might expect mannitol to cause a rise in ICP. 
However, where cerebral autoregulation is intact, compensatory 
vasoconstriction occurs, reducing cerebral blood volume and ICP. After this 
initial response, cardiac output and BP may decrease due to peripheral 
vasodilation. Due to the fall in cardiac output and the subsequent osmotic 
diuresis, it is advisable to compensate the effects of mannitol with adequate 
fluid replacement. The second action of mannitol is to establish an osmotic 
gradient between the plasma and brain cells which pulls water from the 
cerebral extracellular space into vessels and reduces cerebral oedema, 
thereby reducing ICP. These osmotic properties of mannitol require 15-30 
minutes to take effect (178). A prerequisite for this secondary slower action is 
an intact BBB. Cerebral oedema can be exacerbated by mannitol with a 
disrupted BBB (177). The long-term use of mannitol as a continuous infusion 
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may further exacerbate cerebral oedema as the mannitol molecules 
accumulate in the cerebral interstitial space (179).  
There has been one RCT comparing 41 patients with moderate/severe TBI 
who were randomised to receive blinded solutions of either 20% mannitol or 
0.9% sodium chloride. The study found a relative risk for death of 1.75 (95% 
CI 0.48 to 6.38) and an absolute increase in the risk of death of 11% (95% CI 
-14 to 35%) in the mannitol group (180, 181). This was an out-of-hospital study 
to determine the effect of mannitol on BP and was not an ICP-targeted study 
in ICU patients. 2007 BTF guidelines did not recommend the prophylactic use 
of mannitol, but did note that it is an effective method to reduce a raised ICP 
after severe TBI (123). The 2016 guidelines note that although hyperosmolar 
therapy may reduce ICP, there is insufficient evidence to support any level of 
recommendation. The committee acknowledge that HSS is increasingly used 
instead of mannitol and “is universal in its belief that hyperosmolar agents are 
useful in the care of patients with TBI” (54). 
Many ICUs use HSS as a treatment for intracranial hypertension, either 
individually or in combination with mannitol. HSS is reported to expand the 
intravascular volume and extract water from the intracellular space, both 
increasing cardiac output and CBF and reducing ICP. Furthermore, HSS 
achieves this without the deleterious effects associated with hyperosmolarity, 
such as pulmonary oedema, central pontine demyelination or renal failure 
(182, 183). It may be that HSS is more beneficial than mannitol in treating 
raised ICP as Kamel et al., showed in their meta-analysis from 2011 (mean 
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ICP reduction was 2.0 mmHg greater for HSS versus mannitol, 95% CI -1.6 to 
5.7) (184). HSS may be more effective at lowering ICP and ICU stay but does 
not appear to have a significant effect on mortality (185, 186). 
Despite mannitol being widely used in ICU’s, there appears to be poor 
consensus on the optimal dose to reduce ICP. In 2008, Sorani et al., published 
a retrospective analysis of mannitol use in 28 patients with TBI (187). The 
authors administered mannitol in doses of 50g or 100g with continuous ICP 
monitoring whilst aiming to maintain CPP > 60 mmHg. The mean ICP was 22.0 
± 10.6 mmHg prior to administering mannitol and decreased after mannitol was 
administered. The ICP continued to decrease for 30 minutes to 15.7 ± 8.1 
mmHg in all patients. After 30 minutes, ICP was equal in the 100g group (15.6 
± 10.9) and the 50g group (15.7 ± 6.3). However, at 100 minutes, ICP remained 
decreased in the 100g group but had almost returned to its initial value in the 
50g group (14.2 ± 6.7 versus 18.6 ± 7.6 mmHg; P = 0.001). Sorani et al., also 
published a meta-analysis of the ICP dose-response relationship of mannitol. 
The authors examined 18 studies and found a not statistically significant weak 
linear relationship between changes in ICP and dose (delta ICP = 6.6 x dose - 
1.1; p = 0.27). There was, however, a decrease in ICP when the initial ICP was 
higher than 30 mmHg and non-linear regression suggested that the greatest 
ICP decrease occurred shortly after mannitol was given (188).  
Neurosurgical Intervention 
Surgical intervention in the form of decompressive craniectomy is a 
controversial intervention for intracranial hypertension refractory to medical 
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therapy. The procedure involves removing part of the skull to allow volume 
expansion with the aim of maintaining a stable ICP. Although decompressive 
craniectomy is associated with a decrease in ICP, outcomes are not 
necessarily improved. The DECRA trial (Decompressive Craniectomy in 
Diffuse Traumatic Brain Injury) found a decrease in ICP and length of ICU stay 
in 155 adult patients with severe TBI enrolled to a randomised controlled trial 
(189, 190). Patients with intracranial hypertension (20 mmHg for > 15 minutes) 
refractory to first-tier interventions were allocated to either bifrontotemporal 
decompressive craniectomies or standard care. The craniectomy group 
showed a reduction in ICP with fewer medical interventions and a shorter stay 
in ICU. Despite this, they also had worse outcomes (70% versus 51%; OR 
2.21; 95% CI 1.14–4.26; p = 0.02) and rates of death at six months were similar 
between the groups (189, 190). RESCUEicp (Randomized Evaluation of 
Surgery with Craniectomy for Uncontrollable Elevation of Intracranial 
Pressure) was a prospective RCT running from 2004 to 2014 that allocated 
patients to surgical treatment (n = 202) or medical treatment (n = 196). The 
initial treatment was to maintain ICP ≤ 25 mmHg and CPP > 60 mmHg. 
Patients were managed with routine care, ventriculostomy, hyperosmolar 
therapy and TH (not < 34°C). Patients with refractory intracranial hypertension 
for one-to-12 hours despite these treatments were randomised to 
decompressive craniectomy and medical therapy or ongoing medical therapy 
without surgical intervention. In contrast to the DECRA trial, RESCUEicp 
demonstrated 22% less mortality in the surgical group at six months post-injury 
(191). However, those surviving in the surgical group were more likely to be in 
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a vegetative state or severely disabled. Cooper et al., argue that the use of the 
term “favourable outcome” is questionable in this paper. The proportion of 
patients with full independence at six months (moderate disability or better) is 
almost identical between the groups (26.6% medical, 27.4% surgical). They go 
on to state that all of the extra 22 patients who survived in the surgical group 
were in a vegetative state or severely disabled and none were independent. 
Furthermore, they point out that there was a high mortality amongst medical 
patients (48.9%) when compared with medical patients from the DECRA trial 
(18%) (192). 2016 BTF guidelines are yet to be updated to include evidence 
from the RESCUEicp trial.  
Partial Brain Oxygen Tension to Guide Treatment 
Normal values of PbtO2 have been reported as 23-35 mmHg from a study 
assessing awake patients undergoing functional stereotactic brain surgery for 
treatment of movement disorders (193) and is the value quoted by the 
Neurocritical Care Society (194). Both raised ICP and low PbtO2 have been 
shown to be independent predictors of poor prognosis in severe TBI, and 2007 
BTF guidelines advocated initiating therapy to increase PbtO2 if it decreases 
below 15 mmHg (195-199). However, contemporary articles suggest that a 
threshold of 20 mmHg may be more beneficial (194, 200). The 2016 BTF 
guidelines state that the previous recommendation has “been revised”, and 
there is now no recommended threshold due to insufficient evidence. Five 
studies (n = 222) are included in their analysis and comprise of cohort and 
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observational studies observing worse outcomes with various thresholds of 
PbtO2 ranging from 15 mmHg to 25 mmHg (35, 195, 201-203). 
Patient Condition PbtO2 Value (mmHg) 
Stable Neurosurgical Patients 23-35 
Moderate Brain Hypoxia 20 
Critical Brain Hypoxia 15* 
Severe Brain Hypoxia 10 
Table 3: Brain tissue Oxygen Tension Thresholds. * PbtO2 threshold to start 
treatment as per Brain Trauma Foundation Guidelines (2007), there is no 
longer a threshold in the 2016 guidelines  
 
Despite Pbto2 monitoring being generally advocated in the treatment of TBI, 
there is uncertainty about treatment thresholds and whether monitoring or 
treatment based on PbtO2 will improve outcomes. A single-centre retrospective 
analysis of 74 patients with severe TBI assessed patients with and without 
PbtO2 monitors (n = 37 in each group). There was no significant survival 
difference found between the two groups (64.9 vs. 54.1 %, p = 0.34) or 
difference in discharge GCS, or functional outcome. The PbtO2 group did have 
a significantly lower injury severity score and patients were placed on 
monitoring based upon the practices of the attending neurosurgeon rather than 
being randomised (204). There has been a prospective RCT from Taiwan that 
randomised patients with moderate to severe TBI to PbtO2-guided therapy and 
ICP monitoring (PbtO2 > 20 mmHg, n = 23) or ICP-guided therapy without PbtO2 
monitoring (ICP < 20 mmHg and CPP > 60 mmHg, n = 27). Probes were sited 
in the 2-3cm margin of necrotic brain tissue from preoperative CT scans. 
Patients in the PbtO2 group had standard ICP guided treatment as per usual 
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care, but the primary focus was on PbtO2 guided treatment (i.e. if ICP was >20 
mmHg and PbtO2 was <20 mmHg the priority was on treating PbtO2). The 
authors report significantly higher survival rates in the PbtO2 group (given as 
figures, no documented numbers) but acknowledge a generally low survival 
rate between both groups and a small sample size (205). The BOOST-2 trial 
(Brain Oxygen Optimization in Severe TBI Phase 2) was a ten-centre RCT of 
PbtO2 monitoring in severe TBI (ClinicalTrails.gov: NCT00974259). I can find 
no formal publication of this trial but the NETT (Neurological Emergencies 
Treatment Trials) website states that the trial enrolled 122 patients and 
demonstrated that a PbtO2-based treatment protocol reduced the mean 
hypoxia burden by 74% with a trend towards improved functional outcomes 
(206). The BOOST-3 trial aims to enrol patients with severe TBI and randomly 
allocate them to a treatment protocol based on ICP monitoring alone or ICP 
and PbtO2 monitoring. The primary outcome will be extended Glasgow 
Outcome Scale at six months post injury. There is a draft protocol for this study 
on the NETT website but it is not yet registered on ClinicalTrials.gov (207). 
A few studies have investigated the optimal CPP required to maintain 
adequate PbtO2 in TBI and SAH patients (196-198, 208). PbtO2 appears to be 
variable across patients and a CPP of 60-100 mmHg is required to achieve 
satisfactory brain tissue oxygenation (196). Perhaps this reflects the 
multifactorial nature of PbtO2 and the different metabolic requirements of these 
patients. As mentioned earlier, CPP = MAP – ICP, so the CPP is dependent, 
in part, upon ICP. A raised ICP lowers CPP and is associated with worse 
outcomes in patients with TBI. Furthermore, patients who have a raised ICP 
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and lower PbtO2 have worse outcomes than those with an elevated ICP but a 
normal PbtO2 (199).  
Geukins et al., have proposed three ways in which PbtO2 monitoring may 
improve patient outcomes and go on to suggest a treatment algorithm: 
1. Early recognition of brain tissue hypoxia leading to earlier aggressive 
intervention e.g. decompressive craniectomy; 
2. Directing osmotherapy (Oddo et al. found that hypertonic saline was 
superior to mannitol in reducing ICP whilst improving PbtO2 (209)); 
3. Targeting PaCO2 to avoid hyperventilation reducing PbtO2 and 
preventing further cerebral ischaemia (104). 
Nanguroori et al., in their systematic review of four studies (no RCTs, n = 491), 
found that PbtO2-centered care was associated with improved outcomes when 
compared with purely ICP/CPP-based therapy (OR = 2.1; 95% CI = 1.4-3.1) 
(210). Geukins et al., have advocated a step-wise approach to managing brain 
tissue hypoxia as follows: 
1. Increase FiO2 to 100% for two minutes to restore PbtO2 temporarily, 
check the probe and reduce elevated ICP if necessary; 
2. Increase MAP/CPP with vasopressors e.g. noradrenaline or 
phenylephrine and assess response; 
3. Increase FiO2 to 60%, aspirate pulmonary secretions and increase 
positive end-expiratory pressures by increments of 2-4 cmH2O if 
needed, whilst maintaining a normal ICP; 
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4. Reduce metabolic demand with good analgesia, sedation and maintain 
normothermia; 
5. Transfuse patients with a haemoglobin concentration below 9 g/dl. 
 
Given the evidence that PbtO2-directed therapy may improve outcomes, it 
seems appropriate to continue to monitor and correct low PbtO2 values as 
suggested by the Neurocritical Care Society’s 2014 consensus summary 
statement (194).  
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6.  
Figure 12: Proposed Management of Low Partial Brain Oxygen Tension. 
FiO2, fraction of inspired oxygen; ICP, intracranial pressure; MAP, mean 
arterial pressure; PbtO2, partial brain oxygen tension; CXR, chest x-ray; ALI, 
acute lung injury; ARDS, acute respiratory (104).  
 
Therapeutic Hypothermia 
Therapeutic hypothermia is defined here as the controlled reduction of core 
temperature below 36°C (211). The intentional cooling of patients is not a new 
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concept. Fay proposed cooling of patients after TBI in 1945 (212). In the 1950s 
TH was investigated in animal models of TBI (213, 214) and uncontrolled case 
series where it was thought to improve outcomes (212, 215-218). TH was also 
applied to patients following cardiac arrest (219). However, side effects such 
as pneumonia, cardiac arrhythmias and coagulopathy and difficulties in 
managing patients with hypothermia prevented its widespread use. Interest in 
TH resurged in the 1980s after experimental TBI models demonstrated 
decreased neuronal loss and improved outcomes in animals managed at 30-
33̊C (220-223). Further benefit was suggested from a small number of clinical 
trials in the 90s leading to renewed interest  (224-228). A 2003 systematic 
review stated that TH may reduce the risk of mortality and poor outcome after 
TBI but noted the many variables in treatment may influence results. These 
included the depth of hypothermia, rate of cooling, rate of rewarming and 
duration of hypothermia (229). TH is currently used as a treatment for hypoxic 
ischaemic encephalopathy (230), after cardiac arrest (231, 232) and remains 
a limited treatment option for severe TBI (54). In addition to TH for TBI, patients 
are often cooled to normothermia (therapeutic normothermia), which is the 
reduction and maintenance of an elevated core temperature to 36.0-37.5 °C 
(233). Targeted temperature management (TTM) refers to TH and therapeutic 
normothermia and the international critical care society recommends this term 
in preference to TH (234). For simplicity and because recent publications still 
use the term, I refer to TH throughout. The definitions of depths of hypothermia 
vary considerably in the literature so I have avoided terms such as mild, 
moderate and deep (211, 235).  
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Physiological Effects of Hypothermia 
Temperature sensitive processes that occur after TBI such as excitotoxicity, 
free radical generation, neuroinflammation and programmed cell death have 
been reviewed extensively (236-241). A brief description of some of the 
mechanisms by which hypothermia is thought to alter the pathophysiology of 
TBI is discussed below. 
Hypothermia has been associated with a reduction in CMRO2. It has been 
reported that a 1°C reduction in body temperature causes a 5-7% reduction in 
CMRO2 leading to reduced oxygen and glucose consumption (225, 242-244). 
When core temperature decreases to 32°C metabolic rate decreases to 
approximately 50% of normal with an associated decreased consumption of 
oxygen and production of carbon dioxide (245). This mechanism could enable 
adequate cerebral perfusion with a lower CBF. In 1954, Rosomoff and 
Holaday, in an animal study of ten dogs, found that deep hypothermia lowered 
CBF with a linear decrease in CMRO2 from 35°C to 26°C (213). In contrast, 
Kuluz et al. observed, in a study of adult rats with selective brain cooling from 
normothermia to 30.9 ± 0.5°C, that CBF increased to 215 ± 25% of control 
levels. CBF then decreased during rewarming. This apparent cerebral 
vasodilatory response was thought to explain any potential beneficial effect 
from TH (246). More recently, Kawamura et al., have used positron emission 
tomography to demonstrate a reduction in CBF and CMRO2 by 37+/-27% and 
52+/-16% respectively in patients were cooled to 33-34°C (247). However, the 
pathophysiology of TBI is extremely complex and other temperature sensitive 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 1: Traumatic Brain Injury 51 
processes that occur after TBI such as excitotoxicity, free radical generation, 
neuroinflammation and programmed cell death have also been reviewed 
extensively (236-241).  
Another consequence of TBI is altered BBB permeability, resulting in 
movement of water, electrolytes and neurotoxic substances across the 
vascular system into the brain parenchyma (205, 248, 249). Experimental 
models have shown that extravasation of proteins through the BBB is reduced 
with mild hypothermia (248). Furthermore, hypothermia appears to 
significantly reduce brain water content with cerebral ischaemia and may also 
attenuate cerebral oedema, perhaps contributing to the decrease in ICP seen 
with hypothermia (250-252). In experimental models, hypothermia appears to 
reduce BBB permeability in TBI models by changing matrix 
metalloproteinases, extracellular enzymes that can disrupt the BBB (253). 
Limiting the pathological disruption in BBB permeability may be important in 
reducing vasogenic oedema and infiltration of inflammatory cells which are 
linked to adverse outcomes (254, 255).   
In addition to attenuating BBB permeability, and therefore the circulating 
inflammatory response, there is experimental evidence that hypothermia can 
directly alter the inflammatory response of the central nervous system (CNS). 
Astrocytes and microglia appear to proliferate around the injury and release 
pro-inflammatory mediators as well as reactive oxygen species (256). 
Hypothermia has been seen to significantly reduce the activation of both 
astrocytes and microglia following TBI and attenuate increases in tissue 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 1: Traumatic Brain Injury 52 
superoxide and nitric oxide (257-262). Hypothermia appears to cause this is 
by increased action of superoxide dismutase and action of nictric oxide 
synthase (263, 264). Hypothermia also appears to modulate neuronal necrosis 
and apoptosis in CNS injury models (265). 
Patients suffering TBI, or cerebral ischaemia, can have changes to calcium-
dependent signalling pathways that are mediated by disrupted signalling of 
protein kinases (266-269). Calcium/calmodulin-dependent protein kinase II 
(CaMKII), an important protein kinase mediating synaptic activity, is inhibited 
by cerebral ischaemia and this inhibition may be reduced by hypothermia 
(267). Protein kinase C (PKC) is inhibited after cerebral ischaemia where it is 
translocated to the membrane and hypothermia has reduced the translocation 
of PKC and its inhibition in experimental models (270).  
The initial phase of TBI is associated with an efflux of excitatory amino acids 
and it has been suggested that hypothermia reduces this excitotoxicity (238, 
244, 271, 272). Hypothermia of ischaemic areas (30°C and 33°C) has been 
seen to attenuate the rise in extracellular levels of dopamine and glutamate 
after generalised cerebral ischaemia (257). A number of studies have 
replicated this suggesting that hypothermia reduces excitotoxicity after 
cerebral ischaemia (273, 274).  
Most of the evidence referred to above is from experimental models of TBI in 
animal studies. Pre-clinical studies have also demonstrated that hypothermia 
appears to not only improve histopathological outcomes but also reduce 
neurological deficits (223, 238, 275-278). As discussed below, most human 
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trials do not replicate these findings (279-281). Furthermore, clinical trials of 
interventions attempting to manage these sequelae, such as excitotoxicity, 
have generally failed (282). 
Complications of Hypothermia 
Intracellular shifts of electrolytes occur when patients undergo TH which can 
result in hypokalaemia, hypophosphataemia and/or hypomagnesaemia (283). 
Cold-induced diuresis is common and may be related to tubular dysfunction, 
hormonal changes and increased venous return due to the peripheral 
vasoconstriction associated with hypothermia (284, 285). This tubular 
dysfunction can further exacerbate the above electrolyte disturbances. 
Hypokalaemia can cause or exacerbate arrhythmias which are an independent 
effect of hypothermia (283). The increased metabolism of fat that occurs with 
hypothermia causes an increase in ketones and lactic acid which contribute to 
the mild acidosis commonly seen in patients with hypothermia. This is not 
usually significant and pH is rarely below 7.25 (286). Reduced insulin secretion 
and insulin resistance leading to hyperglycaemia have been associated with 
hypothermia (287-290).  
There is a strong association between TH and cardiac arrhythmias, particularly 
bradycardia, with maintenance of blood pressure and stroke volume, meaning 
an overall decrease in cardiac output (approximately 25%) and an increase in 
systemic vascular resistance (243, 291-294). It is thought that the decrease in 
metabolic rate associated with hypothermia more than compensates for this 
decrease in cardiac output (295). Furthermore, there is evidence from a 
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retrospective cohort study (n=111) that patients who developed bradycardia 
when treated with TH for out-of-hospital cardiac arrest had better neurological 
outcomes (296). Maintaining euvolaemia is important in both the induction and 
maintenance of hypothermia. Peripheral vasoconstriction and cold-diuresis 
secondary to TH are associated with increased plasma noradrenaline, 
activation of the sympathetic nervous system and atrial natriuretic peptide and 
decreased antidiuretic hormone function as well as renal antidiuretic hormone 
(243). All of this can contribute to hypovolaemia and potentially decrease CPP 
leading to worse CBF. It is worth noting that patients are more likely to become 
hypovolaemic when treated with diuretics, such as mannitol. As mentioned 
earlier, both therapeutic and pathological hypothermia are associated with 
significant arrhythmias. This is usually seen at temperatures <30°C. An 
additional complication associated with hypothermia is reduced and altered 
platelet function as well as altered clotting enzymes at temperatures below 
35°C and 33°C respectively (297, 298).  
Pneumonia is often reported as a common side-effect of TH.  A 2009 Cochrane 
review investigating the benefits of TH in TBI found that although there was a 
trend towards an increased risk of pneumonia, this trend was not significant 
and the level of evidence to support it was poor (299) . 
Two of the most predictable side-effects of hypothermia are vasoconstriction 
and shivering. Studies in healthy humans have demonstrated that shivering 
starts at around 35.5°C and that vasoconstriction starts at around 36.5°C (235, 
300). The effects of these two haemodynamic responses have been 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 1: Traumatic Brain Injury 55 
investigated in post-operative patients and shivering is associated with 
increased cardiac events, especially in elderly patients (301-303). The 
increased metabolism and oxygen consumption associated with shivering 
leads to increased respiratory rate and tachycardia, further increasing oxygen 
demands (303, 304). This response is slightly different in the sedated patient 
on ICU because of mechanical ventilation. It is important to control shivering 
to reduce oxygen consumption and patient discomfort. This can be performed 
in the following ways: 
• Drugs that lower shivering thresholds, such as paracetamol, non-
steroidal anti-inflammatory drugs and opiates (e.g. pethidine); 
• Paralysing agents and sedatives: A 2010 systematic review of sedation 
protocols from 68 ICUs found midazolam to be the most commonly 
used agent to suppress shivering, followed by Propofol (305) but 
muscle relaxants have also been used (306); 
• Skin counter-warming. 
Rewarming carries its own risks and is associated with rebound intracranial 
hypertension (229).  Rapid rewarming may also lead to hypoglycaemia and 
electrolyte disturbances as insulin sensitivity returns to baseline and 
intracellular potassium is released (307). It is not clear what the ideal rate of 
rewarming is, only that rapid rewarming is associated with poor outcomes after 
TH (307-309). Rates of rewarming have varied from 1°C per day (310, 311) to 
1°C per hour (312, 313), with many studies using 0.25°C per hour (308, 314). 
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Therapeutic Hypothermia in Traumatic Brain Injury: Clinical 
Evidence 
Despite many animal studies demonstrating that TH at 32-35°C offers 
neuroprotection and may improve outcomes after TBI, there is limited clinical 
data to support its use (233, 238, 315, 316). A Cochrane review from 2009 
examining 22 RCTs (n = 1,382) investigated TH as a treatment for TBI and 
demonstrated fewer deaths in patients treated with TH (OR 0.76, 95% CI 0.60 
to 0.97). The review also found that patients treated with TH were less likely to 
have an unfavourable outcome (OR 0.69, 95% CI 0.55 to 0.86). However, the 
authors concluded that TH may be beneficial in reducing morbidity and 
mortality from TBI but that the only trials showing significant benefit were of 
low quality, with a tendency to overestimate the treatment benefit. As such, TH 
was only recommended for use in patients taking part in RCTs (317). A review 
in 2014 assessed 18 studies that provided mortality data and concluded that 
TH was associated with a significant reduction in mortality and poor outcome 
after TBI (318). The 2009 and 2014 reviews concluded that the evidence 
supporting TH for TBI was of low quality and suggested that more RCTs were 
needed. Two subsequent multicentre RCTs, Eurotherm3235 and B-HYPO 
(Brain Hypothermia), both published in 2015, appear to add to the growing 
consensus that TH is not beneficial after TBI (279, 281).  
The B-HYPO trial rapidly cooled patients with TBI to 32-34°C within six hours 
of their injury or kept them normothermic (35.5-37°C). Patients were cooled for 
at least 72 hours and were rewarmed at a rate of <1°C per day. 150 of the 
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planned 300 patients were recruited and the trial was stopped due to low 
recruitment and likely futility. The trial found no differences in neurological 
outcomes or mortality between the groups. Criticisms of the trial include that it 
was relatively underpowered and that trials stopped early tend towards 
exaggerated treatment effects (281, 319, 320). Interestingly, fever control 
management (i.e. maintaining normothermia in patients with fever) was 
reported to significantly improve mortality. A 2015 systematic review of 16 
RCTs investigating TH in TBI found that most studies () reported that 
avoidance of fever was associated with improved outcomes including 
decreased length of ICU stay and mortality (321). 
Eurotherm3235 was a multi-centre RCT investigating TH (32-35°C) for ICP 
reduction after TBI. The trial enrolled patients with TBI who had ICP >20 mmHg 
for five minutes despite stage one treatments (Fig.11). Enrolment to the study 
was allowed up to 72 hours after TBI due to the greatest benefits of 
hypothermia appearing to be associated with early cooling. Patients were to 
remain cooled until their ICP was <20 mmHg and no longer temperature-
dependent (322). 387 patients were enrolled at which time recruitment was 
suspended due to safety concerns. The authors concluded that in patients with 
ICP >20 mmHg after TBI, TH plus standard care did not result in better 
outcomes than standard care alone. Stage three (Fig.11) treatments were 
required to control ICP in 54% of patients in the control group and in 44% of 
patients in the hypothermia group. The adjusted common odds ratio for the 
GOS-E score was 1.53 (95% confidence interval, 1.02 to 2.30; p = 0.04), 
indicating a worse outcome in the hypothermia group (279). Criticisms include 
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that only 10% of patients were treated within 12 hours of injury. These patients 
may have had brain oedema at randomisation and one-to-two litres of cold 
saline to induce hypothermia could have been detrimental (323). Looking at 
the 10% of patients who received TH before 12 hours, mortality was halved in 
the intervention group (HR 0.54 [0.07-4.03]), although there are very large 
confidence intervals. Cooper et al. argue that a treatment threshold of 20 
mmHg is too low and cite 25 mmHg as a more favourable threshold whilst still 
advocating TH in TBI (323). 
The authors of these comments are investigators for POLAR-RCT 
(Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury). This study 
aims to randomise 500 patients to at least 72 hours of TH (33°C) initiated within 
three hours of injury, or standard normothermic management (324). The trial 
is currently recruiting patients (ClinicalTrials.gov NCT00987688). Another 
ongoing trial is LTH-I (Long-term Mild Hypothermia for Severe Traumatic Brain 
Injury), a prospective RCT aiming to recruit 300 TBI patients randomised to 
five days of TH (34-35°C) or normothermia (36-37°C) (325).  
Recent reviews conclude that TH has not led to a decrease in mortality in 
clinical trials and that it might increase the risk of worse outcomes (320, 326). 
Given the positive results from animal studies of TH for TBI and the 
disappointing results from clinical trials, Hirst et al., are conducting a 
systematic review and meta-analysis of these animal studies to try to explain 
the disparity (327). I expect that there have been many small, heterogenous 
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pre-clinical studies which demonstrate risk of bias and experimental design 
flaws. 
Summary: Difficulties with Clinical Research 
In 1998 Roberts et al., in a systematic review, concluded that there was 
insufficient evidence to support or refute the existence of a real benefit from 
using hyperventilation, mannitol, CSF drainage, barbituates or corticosteroids 
in the management of TBI (180). In 2006,  Adamides et al., conducted a review 
of treatments for TBI and concluded that there was no Class I evidence to 
support the routine use of any of the therapies they examined 
(hyperventilation, osmotherapy, cerebrospinal fluid drainage, barbiturates, 
decompressive craniectomy, TH, normobaric hyperoxia, and hyperbaric 
oxygen therapy) (328).  In 2017, nearly 20 years on from the Roberts’ paper, 
there is probably sufficient evidence to refute the existence of a real benefit 
from corticosteroids (329). We may be moving towards being able to refute TH 
and decompressive craniectomy as beneficial treatments. However, we can 
now add ICP, PbtO2 and CPP monitoring and their guided treatments to our list 
of uncertainties. The 2016 BTF guidelines have a single recommendation 
based on level I evidence: the use of steroids is not recommended for 
improving outcome or reducing ICP after TBI (54). This may seem cynical, but 
negative results, if based on good-quality trials that change practice for the 
better by stopping ineffectual or harmful interventions, may be as equally 
important as positive results.  
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Stein, in his comprehensive 2015 review of why trials fail in TBI, explains that 
there has been a 100% failure rate in identifying drugs that work in the acute 
phase of TBI (330). However, as he points out, this problem is not limited to 
TBI research and there is a high failure rate for phase III trials in sepsis, stroke, 
cancer, cardiology and orthopaedic research. Many positive results from 
experimental models and early clinical trials that do not translate to phase III 
trials, leading many to ask the question: Why do phase III trials fail (331-335)? 
Perhaps unsurprisingly, answers for TBI research include poorly conducted 
animal studies informing clinical trials; commercial and financial pressures to 
progress to phase III trials and complete trials on time; using an over-simplified 
definition of a complex disease; multiple variables masking positive signals 
and poor trial set-up or running (330, 336, 337). The authors of these 
suggestions provide clear advice to future trial developers about how to avoid 
similar pitfalls.  
RCTs investigating TH <35°C suggest worse outcomes in TBI patients treated 
with TH (279). Unfortunately, due to the complex nature of TBI and TH, there 
remain questions about whether the timing of onset of TH, the rate and 
duration of cooling and rewarming, and the degree of hypothermia effect the 
results seen from trials of TH. Furthermore, one could question whether TH is 
beneficial in a subset of patients with TBI whilst harmful in others. 
Retrospective analysis of data from the Eurotherm3235 trial is ongoing. One 
area of interest is whether TH affected the PbtO2 of patients with TBI. This work 
makes up the first part of original research in my thesis and is discussed in the 
next chapter (338). 
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Chapter 2: Therapeutic Hypothermia Reduces 
Intracranial Pressure and Partial Brain Oxygen 
Tension 
Introduction 
This chapter describes the retrospective analysis of a subset of data from 17 
patients enrolled into the Eurotherm3235 trial. Patient data included in this 
study were taken from patients enrolled at the Edinburgh site, which recruited 
42 of 387 patients. As such, the enrolment and treatment methods are from 
Eurotherm3235. Professor Peter Andrews has kindly given permission for 
relevant parts of the methods to be reproduced here (339). Collection of PbtO2 
data and its analysis is original research and was not part of the 
Eurotherm3235 trial protocol. Work from this analysis was published prior to 
completion of the Eurotherm3235 trial (338). Due to the early stopping of this 
trial, the total number of subjects was limited to 17.  
As discussed in Chapter I, intracranial hypertension and decreased PbtO2 are 
targeted as potentially avoidable causes of morbidity after TBI. TH appears to 
reduce ICP but might adversely affect CBF. I report a retrospective analysis of 
prospectively collected data from 17 patients admitted to the Western General 
Hospital, Edinburgh. Patients with ICP >20 mmHg refractory to initial therapy 
were randomised to standard care (control) or standard care and TH 
(intervention, 32-35°C) to reduce ICP. ICP and PbtO2 were measured using the 
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Licox system, and core temperature was measured by rectal thermometer. 
Data were analysed at the hour before cooling, the first hour at target 
temperature, two consecutive hours at target temperature, and after six hours 
of hypothermia. There was a mean decrease in ICP of 4.3 ± 1.6 mmHg 
(p<0.04) from 15.7 to 11.4 mmHg, from precooling to the first epoch of 
hypothermia in the intervention group (n=9) that was not seen in the control 
group (n=8). All time periods demonstrated a decrease in ICP in the 
intervention group. There was a mean decrease in PbtO2 of 7.8 ± 3.1mmHg 
(p<0.05) from 30.2 to 22.4 mmHg, from precooling to stable hypothermia in the 
intervention group, which was not observed in controls. The findings support 
previous research in demonstrating that hypothermia decreased ICP, which 
might facilitate reduced hyperosmolar agent use. I go on to suggest that the 
decrease in PbtO2 is not below the 2007 BTF suggested treatment threshold of 
15 mmHg, but might indicate a decrease in CBF in certain patients. Finally, 
individual patients demonstrated a significant reduction in PbtO2. The reason 
for this was unclear and further research assessing PbtO2 data is 
recommended in normothermic patients. 
Materials and Methods 
Patients were randomised to receive either standard care without TH (control) 
or standard care with TH (intervention). Hypothermia was initiated with 20-30 
ml/kg refrigerated (4°C) 0.9% Sodium Chloride given intravenously and 
maintained using cooling blankets. The depth of hypothermia within the 32-
35°C range was guided by the patient’s ICP. Higher pressures resulted in a 
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colder target temperature. The aim was to lower the core temperature by the 
minimum required to achieve an ICP of ≤20 mmHg within the limits of 32-35°C. 
If target ICP was not achieved at 35°C, core body temperature was decreased 
by increments of 0.5°C until an ICP of ≤20 mmHg, or a core temperature of 
32°C, was reached. Unit guidelines for the detection and treatment of shivering 
were applied to all patients. Therapeutic hypothermia was maintained for at 
least 48 hours in the treatment group and continued until ICP was maintained 
below 20 mmHg. Figure 12 outlines the study plan.  
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Figure 13: Stages of Management of Traumatic Brain Injury. Information for figure taken from 
BTF guidelines (Brain Trauma Foundation et al. 2007). CPP, cerebral perfusion pressure; 
CSF, cerebrospinal fluid; ICU, intensive care unit; SOL, space occupying lesion   
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Figure 14: Study Flowchart . EEG, electroencephalogram; ICU, intensive 
care unit; ICP intracranial pressure. Adapted from Eurotherm3235 trial with 
permission (288). Stages are as per figure 11 
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Inclusion and Exclusion Criteria and Eligibility 
Inclusion Criteria: 
• Legal age for consent to take part; 
• Primary closed TBI; 
• Raised ICP > 20 mmHg for ≥ five minutes after first line treatments with 
no obvious reversible cause (e.g. patients position, coughing or 
inadequate sedation); 
• ≤ 72 hours from the initial injury; 
• Cooling device or technique available for > 48 hours; 
• Core temperature ≥ 36°C at the time of randomisation; 
• An abnormal CT head defined as one that shows haematoma, 
contusion, swelling, herniation or compressed basal cisterns. 
Exclusion Criteria 
• Patient already receiving TH; 
• Administration of barbiturate infusion prior to randomisation; 
• Patient unlikely to survive for the next 24 hours in the opinion of the ICU 
consultant or consultant neurosurgeon treating the patient; 
• Temperature ≤ 34°C on hospital admission; 
• Pregnancy. 
 
Eligible patients for the study had raised ICP despite stage 1 therapy (Fig.11) 
for the management of TBI.  
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Randomisation and Treatment Allocation 
Randomisation occurred after meeting inclusion criteria using a telephone 
randomisation service. Treatment allocation was minimised using the following 
baseline covariates: 
1. Trial Centre; 
2. Age < or ≥ 45 years; 
3. Post-resuscitation GCS motor component 1-2 or 3-6; 
4. Time from injury < or ≥ 12 hours; 
5. Pupils both reacting, or one, or neither reacting. 
Investigators were not blinded to treatment allocation because it was clinically 
obvious which patients were receiving TH.  
Management of Patients in PbtO2 Study 
PbtO2 has been recorded with the Integra Licox system in all patients admitted 
to the WGH ICU for ICP management since May 2010. At the time of analysis 
data were only available for 17 patients. Patients were managed as per the 
2007 BTF guidelines, intubated and ventilated to achieve a PaCO2 of 4.5 to 
5.0 kPa, sedated and nursed with 30° head elevation. CPP was maintained at 
≥60 mmHg by manipulating MAP with fluids and noradrenaline and limiting ICP 
≤20 mmHg. The Licox probe was inserted into the brain parenchyma via a 
dedicated triple-lumen bolt that was sited via a burr hole for measurement of 
ICP, PbtO2, and brain temperature. Monitors were inserted into frontal white 
matter in the non-dominant hemisphere for diffuse injuries or on the site of 
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maximal trauma in focal injuries. The probe was not sited in non-viable tissue. 
Hourly core body temperature was recorded via rectal thermometer. The ICU 
Pilot software (CMA, Stockholm, Sweden) integrated minute data from the 
monitors to a bedside computer. 
Refractory intracranial hypertension in either group led to escalation of 
therapy, including 125mls of 5% sodium chloride or 200mls of 20% mannitol 
as a bolus injection. Paralysis and further CT head scanning were also 
available. Neurosurgical intervention was available on site as required. 
Patients in the control group were cooled to normothermia (36.5-37.5°C) and 
pyrexia (>38°C) was managed with paracetamol and cooling blankets. All 
patients received seizure prophylaxis with a loading dose of Phenytoin 
(20mg/kg) and a maintenance dose (4-5mg/kg) for seven days post injury.  
Data and Statistical Analysis 
Cat Graham, a local Wellcome Trust Clinical Research Facility statistician, 
provided help with suggesting methods of statistical analysis. Data analysis 
was pre-specified and after determining the time to reaching target 
temperature was highly variable I decided not to perform an intention to treat 
analysis. Analysis was divided into four separate time periods coinciding with 
patient temperatures. The first two hours of PbtO2 data recorded were 
discarded from analysis to reduce artefact from the Licox monitor which has 
been previously documented and was present in this study (103, 104).  
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Data from 17 patients, nine intervention 
and eight control, were analysed. These 
were the first 17 patients enrolled to the 
Edinburgh site that had PbtO2 data 
recorded. The four time points used 
were: Time 0, the hour before 
randomisation (induction of cooling or 
control); Time 1, the first hour of 
hypothermia (<35°C); Time 2, the first 
episode of stable hypothermia (<35°C), defined as two consecutive hours of 
hypothermia; and Time 3, six hours of stable hypothermia. Values are given 
as the mean ± standard error of the mean unless otherwise stated. One-way 
repeated measures of variance (analysis of variance [ANOVA]) were 
performed to identify differences within each group and paired Student’s t-tests 
were performed to identify differences within the groups at the set time points. 
Independent Student’s t-tests were performed to identify differences between 
the groups. All statistical tests were performed using Statistical Package for 
Social Sciences 20.0 (SPSS version 20; IBM, Inc., Armonk, NY).  
Following on from my viva in September 2017 I have added a section to the 
conclusion chapter which discusses the reasons for the tests used in more 
detail. 
 
Figure 15: Times of Analysis 
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Figure 16: Flow Diagram of Data Analysis. PbtO2, partial brain oxygen 
tension; ICP, intracranial hypertension; SPSS, statistical package for social 
sciences  
Results 
Control Group Demographics 
All eight patients were male and the mean age was 34. Three patients suffered 
extradural haemorrhages (EDHs) as their primary injury, two subdural 
haemorrhages (SDHs), two traumatic subarachnoid haemorrhages, and one 
patient suffered a diffuse injury. Three patients had non-depressed skull 
fractures. The median GCS on admission to the ED was seven (range 3–14, 
Table 4). 
Intervention Group Demographics 
Two participants were female, seven were male, and the mean age was 41. 
Three patients suffered EDH as their primary injury, three had diffuse injuries, 
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one had contusions, and one had diffuse injuries and a SDH. Five patients had 
non-depressed skull fractures and one had a depressed skull fracture. The 
median GCS on admission to the ED was seven (range 3–14, Table 4). 
Missing Data 
The first two hours of PbtO2 data recorded were discarded from analysis to 
reduce artefact from the Licox monitor. This artefact has been previously 
documented (103, 104). Half of the control group were not included in the Time 
0 analysis of PbtO2 due to missing data (n=4/8, Appendix 1). In the remaining 
patients, PbtO2 recording was present over two hours before randomisation 
and the data was included from Time 0. ICP and PbtO2 data were also missing 
when monitors were detached to facilitate patient transfer. In addition, core 
temperature recordings were occasionally missing from patient charts. Due to 
the small sample size and relatively small amount of data missing, statistical 
models to analyse the effect of missing data were not performed. Raw data 
highlighting missing sections is included in Appendix 1 for ICP, PbtO2 and core 
temperature. I have added a section on management of missing data in the 
conclusion and reflective chapter. 
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Table 4: Clinical Characteristics of Patients. CT, computed tomography; 
EDH, extradural haemorrhage; F, female; GCS, Glasgow Coma Score; M, 
male; SAH, subarachnoid haemorrhage; SDH, subdural haemorrhage. 
Patients 1-8 were in the control group, patients 9-17 were in the intervention 
group.  
 
Time to Temperature; Hb; FiO2; PaO2; and PaCO2 
The mean time to target temperature (<35°C) in the intervention group was 
seven hours (421 ± 72 minutes) after randomisation, due to long lead times to 
initiation of TH following pre-randomisation hypertonic therapy. 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 2: Therapeutic Hypothermia Reduces Intracranial Pressure and Partial Brain 
Oxygen Tension in Patients with Severe Traumatic Brain Injury 
73 
There was no significant change in FiO2 from pre-cooling to target temperature 
in the intervention group (median 0.35 [0.30-0.55] vs. 0.30 [range 0.30-0.55] 
p>0.05) and there was no significant difference in FiO2 between the two 
groups. PaO2 and PaCO2 values were not significantly different from pre-
cooling to target temperature: Pre-cooling PaO2 16.1 ± 0.9 kPa, target 
temperature PaO2 16.3 ± 1.6 kPa, p >0.05; pre-cooling PaCO2 4.5 ± 0.01, 
target temperature PaCO2 4.5 ± 0.02 kPa, p > 0.05. There was no statistically 
significant difference in PaO2 or PaCO2 values between the two groups. 
Haemoglobin values were not significantly different between the groups and 
Hb did not change from pre-cooling to target temperature in the intervention 
group (10.1 ± 0.4 vs. 9.7 ± 0.4, p > 0.05).  
There was no significant difference in the number of osmotic agents used 
between the control and intervention groups (1, range 0-4 and 0-5 respectively, 
p>0.05). 
Intracranial Pressure 
A two-way repeated measures ANOVA revealed a difference between the two 
groups: F(3,45)=4, p < 0.02. A one-way repeated measures ANOVA 
demonstrated a statistically significant decrease in ICP in the intervention 
group: F(3, 24)=6.13, p < 0.01. Post-hoc analysis with t-tests show that in the 
intervention group, ICP decreased by 4.3 ± 1.6 mmHg (p<0.04), from 15.7 to 
11.4 mmHg from Time 0 to Time 1 (Figs. 15 and 16). The decrease in ICP was 
maintained from Time 0 to Times 2 and 3. There was no statistically significant 
difference in ICP in the control group between these times.  
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Figure 17: Boxplot of Intracranial Pressure versus Time in the Intervention 
Group. ICP = Intracranial Pressure. Time 0, Pre-Randomisation; Time 1, First 
hour of hypothermia (<35°C); Time 2, First episode of stable hypothermia; 
Time 3, Six hours of hypothermia. 
 
Figure 18: Changes in ICP with Time: intervention and control groups. Time 
0, pre-randomisation; Time 1, first hour of hypothermia (<35°C); Time 2, first 
episode of stable hypothermia (<35°C); Time 3, 6 hours of hypothermia 
(<35°C). Two-way repeated measures ANOVA demonstrates a difference 
between the groups F(3,45)=4, p <0.02. ANOVA, analysis of variance.  
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Partial Brain Oxygen Tension 
Multiple imputation was applied to perform a two-way repeat measures 
ANOVA which revealed no statistically significant change in PbtO2 between the 
groups (Fig 19). A one-way repeat measures ANOVA was run in the 
intervention group which did suggest a difference in PbtO2 with time F(3,18) 
4.60, p <0.02. Post-hoc analysis with paired t-tests demonstrated a statistically 
significant difference between Time 0 and Time 2 in the intervention group, 
where there was a decrease in PbtO2 of 7.8 ± 3.1mmHg (p < 0.05) from 30.2 
to 22.4 mmHg (Fig. 17). However, Friedman’s test was run after suggestion 
from my viva panel which did not suggest a statistically significant difference 
in the intervention group (P 0.12). See the thesis conclusion for a discussion 
about how the data was analysed. Furthermore, post-hoc analysis with a 
related-samples Wilcoxon signed rank test showed a not statistically significant 
decrease in PbtO2 from Time 0 to Time 2 (P 0.063). Three patients in the 
intervention group had a decrease in PbtO2 from >25 mmHg at Time 0 to <20 
mmHg at Time 3. There was no statistically significant difference between 
Time 0 and any other times in the control group or a statistically significant 
difference between the two groups in terms of the change in PbtO2 (Fig. 19). 
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Figure 19: Boxplot of Partial Brain Oxygen Tension versus Time in the intervention 
group. PbtO2, partial brain oxygen tension; Time 0, pre-randomisation; Time 1, first 
hour of hypothermia (<35°C); Time 2, first episode of stable hypothermia (<35°C); 
Time 3, 6 hours of hypothermia (<35°C). Mean decrease in PbtO2 from Time 0 to 
Time 2 is 7.8 ± 3.1 mmHg from 30.2 to 22.4 mmHg. 
 
Figure 20: Boxplot of Partial Brain Oxygen Tension versus Time in the control group. 
Time 0, pre-randomisation; Time 1, first hour of hypothermia (<35°C); Time 2, first 
episode of stable hypothermia (<35°C); Time 3, 6 hours of hypothermia (<35°C). 
There was no statistically significant difference between Time 0 and the other time 
points.  
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Starting ICP in the patients in this study was <20 mmHg because a single 
hypertonic treatment was given pending randomisation which also resulted in 
long lead times to initiation of cooling. TH reduced ICP from pre-cooling to the 
first episode of stable hypothermia (4.3 ± 1.6 mmHg, ~27%), despite pre-
treatment with hypertonic therapy. The reduction in ICP was maintained at six 
hours, which is consistent with previous studies (Table 5)  (227, 312-314, 340-
348). There was no further decrease in ICP with prolonged hypothermia which 
is also consistent with prior studies (349). The reduction in ICP is comparable 
to the reduction caused by mannitol and HSS, which are reported to reduce 
ICP by 10–51% and have similar efficacy (183, 350-356). Reported adverse 
effects of mannitol include renal failure, electrolyte abnormalities, acidosis, 
hypotension, and congestive heart failure. Reported adverse effects of HSS 
include renal failure and electrolyte abnormalities in addition to other 
theoretical concerns (357). Mannitol causes a short-term reduction in ICP with 
diminishing returns and the prolonged use of HSS over 72 hours has been 
shown to increase mortality (354, 358). Therefore, TH could help to reduce the 
number of therapies required if used in combination.  
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Table 5: Changes in Intracranial Pressure and PbtO2 with Temperature in 
Previous Studies. Summary of change in ICP and PbtO2 with temperature from 
previous studies for comparison. a Estimate of results from graphed data. ICP, 
intracranial pressure; n, number of patients in each study; PbtO2, partial brain 
oxygen tension.  
 
As discussed at the end of the Chapter I, TH is not a risk-free intervention, and 
is associated with arrhythmias, electrolyte disturbances, and pneumonia. This 
study supports others in finding that TH reduces ICP, but it did not evaluate 
mortality or neurological outcomes, and the use of hyperosmolar agents was 
not reduced. 
Partial Brain Oxygen Tension 
Both groups in this study demonstrated a decrease in PbtO2 with time. In the 
intervention group, there was a not statistically significant decrease of 7.8 ± 
3.1 mmHg from 30.2 to 22.4 mmHg. In the control group, no statistically 
significant decrease was seen from Time 0 to any other time points. It is worth 
remembering that half of the control group were not included in the Time 0 
analysis due to missing data (n=4/8). There was a decrease in PbtO2 in the 
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control group between Time 1 and 3 and Time 2 and 3 of 3.47 ± 1.02 and 3.48 
± 1.27mmHg, respectively. It could be that a statistically significant difference 
between would have been present if all data were included at Time 0. There 
was no statistically significant difference between the two groups.  
 
Figure 21: Changes in Partial Brain Oxygen Tension with Time: intervention 
and control groups. Time 0, pre-randomisation; Time 1, first hour of 
hypothermia (<35°C); Time 2, first episode of stable hypothermia (<35°C); 
Time 3, 6 hours of hypothermia (<35°C). There was no statistically significant 
difference between the two groups in terms of the change in PbtO2.  
 
Previous studies have investigated the effect of hypothermia on PbtO2 with 
conflicting results. Gupta et al., in a single-centre, non-randomised study of 30 
patients cooled to ≤33°C, observed a decrease in PbtO2 and concluded that 
decreasing brain temperature <35°C may impair brain tissue oxygenation 
(341). It has been argued that the sensor used to measure PbtO2 in this study 
(Paratrend 7, Diametrics Medical) was not corrected for temperature and did 
not reflect an accurate PbtO2. In contrast, Zhang et al., in a study of 18 patients 
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with severe TBI, found that hypothermia (31.5–34.9°C) increased PbtO2 from 
9.6 ± 6.8 to 28.7 ± 8.8 mmHg (mean ± SD) (346). Patients in this study received 
TH within 20 hours following TBI and had PbtO2 recorded within the first 24 
hours. Given the very low initial PbtO2 and subsequent increase within 24 hours 
following injury, it has been suggested that the increase was attributable to 
early changes in CBF and oxygenation rather than an effect of hypothermia 
(359).  
Decreased PbtO2 is associated with poor outcomes independent of intracranial 
hypertension and the combination of raised ICP and decreased PbtO2 appears 
worse than isolated intracranial hypertension (195). Normal levels of PbtO2 in 
neurosurgical patients are reported as between 23 and 35 mmHg, with lower 
values coming from probes sited deeper in brain tissue or in focal lesions (108, 
193, 360). While the decrease of PbtO2 in the intervention group is significant, 
the mean value did not decrease below the threshold of 15 mmHg 
recommended for intervention by the 2007 BTF guidelines, nor did it decrease 
below 20mmHg, the suggested threshold for compromised brain 
oxygen/moderate brain hypoxia (194). However, when looking at the individual 
value plots (Fig.20) for the intervention group, three patient’s PbtO2 decreased 
from >25mmHg before cooling to <20mmHg after six hours of hypothermia. It 
is unclear why certain patients exhibited this decrease in PbtO2 while others 
did not and it may be unrelated to temperature. Further investigation is 
warranted to identify subgroups of patients demonstrating decreased PbtO2 to 
identify potential causes. 
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Figure 22: Individual Value Plots of PbtO2 versus Time. 
 
Arterial blood gases were analysed using the alpha stat method to maintain 
autoregulation, which was consistent with current practice in the units that 
participated in the trial. This approach has been undertaken in other 
contemporary hypothermia trials, such as NABISH II and TTM (280, 361). 
There was no significant difference in the pre-cooling and target temperature 
PaCO2 and PaO2 values, which is important given the dependence of PbtO2 
upon systemic oxygenation and transport (110). If the decrease in PbtO2 was 
due to changes in PaCO2 and PaO2 with temperature (Gay-Lussac’s Law), I 
would expect to see changes in PaO2 and PaCO2. Therefore, the decrease in 
PbtO2 may be due to reduced CBF or a localised cause of decreased tissue 
perfusion.  
Anaemia has been associated with a decrease in PbtO2 after TBI (362). There 
was no difference in Hb concentrations between groups, or in the intervention 
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group at pre-cooling or target temperature to account for the change in PbtO2. 
Two patients in the control group and three patients in the intervention group 
had a Hb concentration <9g/dL, the level at which PbtO2 might be compromised 
(362). However, these patients were anaemic before randomisation. 
In a study of 31 patients with severe TBI cooled from ≥ 37°C to 33°C, Tokutomi 
et al. concluded that 35°C is the optimal temperature to reduce ICP whilst 
minimising unfavourable effects of hypothermia. Decreased ICP was most 
prevalent between 35°C and 36°C which coincided with a decrease in the 
incidence of jugular venous bulb oxygen desaturation. Oxygen consumption 
and delivery, measured through indirect calorimetry, also progressively 
decreased. Below 35°C oxygen delivery decreased more than the decrease in 
oxygen demand resulting in an overall deficit (349). A potential explanation for 
the decrease in ICP with hypothermia is a decrease in CBF (PaCO2 related), 
which could also explain the decrease in oxygen delivery (227, 313). The 
decrease in CMRO2 seen with hypothermia may be associated with decreased 
oxygen demand (363). Perhaps when patients are cooled below 35°C there is 
a decrease in ICP due to decreased CBF but there is a significant decrease in 
oxygen delivery causing an unwanted decrease in PbtO2. 
Study Limitations 
Due to the nature of the patient population and TH, it is not possible to blind 
researchers from the administration of TH. In addition, I was not blinded for the 
analysis of the two groups which could have led to bias of analysis. 
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I attempted to correct the time taken to reach hypothermia by comparing pre-
randomisation values with the different time periods, but must acknowledge 
that the mean time to target temperature was ~7 hours. Given that early 
initiation of TH is considered beneficial in improving efficacy, it could be that a 
greater decrease in both ICP and PbtO2 would have been seen in the 
intervention group if the time to reach target temperature was reduced (364-
366). In addition to this, it is likely that an intention to treat analysis would have 
given different results. I decided against an intention to treat analysis because 
of the small sample size and the majority of patients in the intervention group 
who would not have been hypothermic. Finally, there were missing data. The 
most apparent effect of the missing data is seen when analysing PbtO2 at Time 
0 in both the control and intervention groups as described above (Appendix 1). 
Conclusion and Recommendations 
TH appears to be effective at reducing refractory intracranial hypertension and 
could potentially reduce the number of hyperosmolar therapies required but 
does not appear to lead to better outcomes. TH below 35°C might reduce 
oxygen delivery more than oxygen demand leading to reduced cerebral 
oxygenation (manifest in this study as a decrease in PbtO2). It is unclear why 
some patients exhibit a greater decrease in PbtO2 than others. Analysis of 
observational PbtO2 data from patients admitted to the Edinburgh site is 
ongoing.  
The following recommendations for future research are based on information 
in the previous two chapters: 
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1. Emphasis on the importance of prospective multi-centre RCTs with a-
priori plans of analysis and published protocols prior to patient 
enrolment over retrospective database analysis. 
2. RCT investigating the effect of ICP monitoring versus no ICP monitoring 
in Western countries.  
3. RCT investigating the effect of PbtO2 monitoring versus no monitoring in 
Western countries. 
4. If a benefit is shown by either 2. or 3. then further RCTs analysing 
treatment thresholds are indicated. Equally, if harm is found then these 
monitoring modalities should be restricted to research.  
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Chapter 3: Delayed Cerebral Ischaemia after 
Subarachnoid Haemorrhage 
Introduction  
After reviewing changes in brain tissue oxygenation from traumatic brain injury 
I became interested in the effect of altered blood flow after acute haemorrhagic 
brain injuries. Specifically, my interest is in the vasoconstriction and delayed 
cerebral ischaemia (DCI) that occurs after subarachnoid haemorrhage (SAH), 
offering the possibility of early intervention. The remainder of this thesis 
concentrates on DCI after SAH and its potential causes and treatments. This 
chapter provides a brief explanation of the epidemiology and pathophysiology 
of SAH before explaining its relation to DCI. Aneurysmal SAH (aSAH) differs 
from TBI by having successful treatment options in the form of surgical clipping 
or interventional neuroradiological coiling. DCI, a complication which 
frequently occurs after SAH, shares many similarities with TBI: the 
pathophysiology underlying DCI remains elusive and there are limited 
treatment options. I outline current European and American guidelines on the 
management of SAH and DCI and discuss systematic reviews which highlight 
a lack of treatment for DCI. There are many potential treatments with some 
evidence from small, non-randomised trials, but conclusive evidence of effect 
is lacking. One such potential treatment, alpha calcitonin gene-related peptide 
(αCGRP), is alluded to in this chapter and is discussed fully in Chapter 4. 
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Subarachnoid Haemorrhage 
Subarachnoid haemorrhage is a subtype of stroke that only accounts for about 
5% of all strokes. However, because of its higher morbidity and mortality, its 
impact is said to equal that of ischaemic stroke, which accounts for 85% of all 
strokes (367, 368).  
The overall incidence of SAH is reported as 6-11 per 100,000 people per year 
but is as high as 20 per 100,000 people per year in Finland and Japan and 
was reported to be as high as 21.8 by a recent study in the US (369-372).  
SAH is the cause of one third of all stroke-related years of potential life lost 
before the age of 65. Of the 85-90% of patients who survive to reach hospital, 
20-40% will die within one month of the SAH (373-377). Contemporary studies 
report in-hospital mortality as 18-20% but do not report mortality at one year 
(374-376). Approximately 70% of all people with SAH will either die or require 
help for activities of daily living at six months after the initial injury (367).  
In addition to the clinical burden of SAH, in 2010 Rivero-Arias et al. reported 
an estimated economic burden of £510 million annually and a total loss of 
about 75,000 quality-adjusted life-years in the UK (378).  
There is a female preponderance to SAH over the age of 40 (3:2 ratio), but the 
opposite is true below the age of 40 (379). Overall age-standardised incidence 
rates per 100,000 were greater in women [14.8 (13.4 to16.3)] than in men [9.4 
(8.1 to 10.6)] throughout 1986 to 2005, with an overall female to male ratio of 
1.59. A recent systematic review reported an overall incidence of 11.5 per 
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100,000 person-years in women and 9.2 in men with an overall female to male 
ratio of 1.24 (380). 
Aneurysmal subarachnoid haemorrhage is the most common form of SAH, 
accounting for 85% (381). The remaining 15% are attributed to non-
aneurysmal perimesencephalic haemorrhage (10%) and various rare 
conditions (5%) (382). Modifiable risk factors that roughly double the risk of 
aSAH include hypertension, alcohol excess, cocaine use and smoking (383). 
The inherited conditions, Ehlers Danlos Type 4, polycystic kidney disease, and 
familial intracerebral aneurysms are also associated with aSAH. Modifiable 
risk factors are thought to account for two out of every three aSAH, whilst 
genetic factors account for only one in every ten aSAH (384).   
The Circle of Willis is the site of most aneurysms and these tend to occur at 
bifurcations. Ruptured aneurysms are most common at the anterior cerebral 
artery and the posterior communicating artery/internal carotid artery. Despite 
rupture risk increasing with the size of the aneurysm, most ruptured aneurysms 
are small (i.e. < 1 cm) (382).  
There appears to be a seasonal influence on the incidence of SAH with a peak 
incidence in the winter and a nadir in the summer months. A 2013 systematic 
review of 48 articles found that “SAH occurred less often in summer than winter 
(RR 0.89, 95 % CI 0.83-0.96), and was statistically significant more often in 
January than in the summer months of June-September” (385). However, 
there are contemporary publications demonstrating no seasonal variation in 
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the US, an increase in incidence in the summer months in England, and winter 
and spring peaks in Australasia (386-390).  
It is not clear why certain aneurysms rupture. An abrupt increase in transmural 
arterial pressure is associated in some ruptured aneurysms, but not all. 
Physical exercise, sexual intercourse and straining are only reported in about 
20% of SAH (382).      
Diagnosis 
Clinical features of SAH include sudden onset headache, which occurs within 
seconds in 75% of patients and is the only symptom in 30% of patients 
presenting to general practice (391, 392). Although an instantaneous 
headache was traditionally thought of as the principal diagnostic feature of 
SAH, Linn et al. found that this was only present in 50% of patients, with nearly 
20% reporting a gradual onset over five minutes (393). The headache can last 
for one-to-two weeks. Vomiting may be a concerning feature but it is also 
present in nearly half of all patients with non-haemorrhagic thunderclap 
headache. One in every 14 patients with SAH will have a seizure at onset, 
which is not a feature of non-haemorrhagic thunderclap headache or 
perimesencephalic headache (391, 394, 395). On admission to hospital, two-
thirds of patients with SAH will have reduced consciousness and half of these 
will be comatose (396). Neck stiffness, which takes three-to-12 hours to 
appear, is a common symptom and is caused by inflammation secondary to 
blood in the subarachnoid space (382). In summary, clinical features cannot 
be relied upon to differentiate between SAH and other similar causes of 
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severe, acute headache. Therefore, radiological and laboratory investigations 
are often required to rule out SAH.  
Traditionally, if a non-contrast CT head did not identify SAH then a lumbar 
puncture ≥12 hours after the onset of the headache, was performed to look for 
the presence of xanthochromia in the CSF. However, if performed within six 
hours of the onset of headache, a third generation non-contrast CT head has 
been reported as 98.5 -100% sensitive at identifying SAH (397, 398). Perry et 
al., in a multicentre prospective cohort study of 2,179 patients, found that of 
the 953 patients who had a CT head ≤6 hours after the onset of headache, all 
121 with SAH were identified (397). Backes et al., in a single centre 
retrospective study of 250 patients, found that of the 69 patients with a negative 
CT head ≤6 hours from the onset of headache, only one had a SAH found on 
subsequent LP (398). Blok et al. describe a multicentre retrospective study of 
760 patients who all had CT head ≤6 hours from onset of headache with a 
subsequent LP ≥12 hours (399). 52 of the 760 patients had bilirubin on LP but 
no SAH was identified on CT head. Only one of these 52 patients had a 
perimesencephalic nonaneurysmal SAH, none of them were found to have an 
aneurysmal SAH. In all three of these studies, there were no deaths or 
negative outcomes in patients who had a negative CT head performed ≤6 
hours after the onset of headache. Furthermore, no SAHs were missed in 
patients with normal neurology and a normal CT head at ≤6 hours. A 
subsequent paper by Sayer et al., looking at 2,248 patients who underwent LP 
after a normal CT head, demonstrated that for every 250 LPs performed after 
a negative CT head, one cerebrovascular abnormality will be detected 
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(number needed to tap = 250) (400). Therefore, it has been argued that in 
patients with a normal CT head ≤6 hours after the onset of headache, no focal 
neurological deficit and a normal GCS, a decision to discharge the patient 
without performing a LP is reasonable. On positive identification of SAH on CT 
or LP, a CT angiogram is performed to identify the location and configuration 

















































119 Patients had an LP after a negative CT head, of these 17 had a positive LP. Of the 17, 
6 had neurosurgical intervention (coil, clipping or ventricular drain); 10 had no cause for 










































1/69 patients in the ≤6-hour group had SAH from cervical AVM on LP. 5/76 patients in the 

















All 760 CT head scans were negative, every patient received an LP. 52/760 LPs had 
bilirubin, only 1/760 had a perimesencephalic non-aneurysmal haemorrhage.  
Table 6: Accuracy of CT Head at Identifying Subarachnoid Haemorrhage. NPV, negative 
predictive value; PPV, positive predictive value. CI, confidence interval; LP, lumbar puncture; 
CT, computed tomography.  
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 3: Delayed Cerebral Ischaemia after Subarachnoid Haemorrhage 91 
Grading 
The most commonly used SAH grading scales are the World Federation of 
Neurosurgeons Scale (WFNS) and Hunt and Hess scale, which are both 
clinical scales, and the Fischer scale, which is CT based (401-404). These 
grading systems offer a means of predicting prognosis and defining severity 
but suffer from observer variability. 
Grade 
WFNS 
(Clinical) Hess and Hunt (Clinical) Fisher (CT scan) 
1 GCS 15 
Asymptomatic or minimal 
headache 
No evidence of 
blood 
2 GCS 13-14 
Moderate to severe 
headache with no 
neurological deficit other 
than cranial nerve palsy 
Diffuse blood or 
thin layer of blood 
with all vertical 
layers <1mm 
3 
GCS 13-14 + 
motor deficit 
Drowsy, confused or mild 
neurological deficit 
 
Localised clots or 
vertical layers of 
blood ≥1mm 
4 GCS 7-12 
 
Hemiparesis, decerberate 




Diffuse SAH or 
non-subarachnoid 




5 GCS 3-6 
Deep coma, moribund 
appearance  
Table 7: Subarachnoid Haemorrhage Grading Scales. WFNS, World 
Federation of Neurosurgical Societies; GCS, Glasgow Coma Scale; CT, 
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Treatment of SAH 
Comprehensive review of the treatment of SAH is beyond the scope of this 
thesis, but a summary is presented below. 
Acute management of SAH focuses on cardiorespiratory stabilisation and 
cerebral perfusion following resuscitation council guidelines. If necessary, this 
can include intubation to maintain PaO2 >13 kPa and PaCO2 between 4.5-5.0 
kPa. Traditionally, it was advised that hypertension should not be treated 
unless MAP exceeded 130 mmHg or there was clinical or laboratory evidence 
of end-organ damage (382). However, 2011/12 guidance suggests that a 
systemic arterial pressure of <160mmHg (MAP <110 mmHg) has a lower risk 
of re-bleeding and that this should be the aim with a titratable agent in patients 
with unsecured aneurysms (405-407). Connolly et al. acknowledge the risks 
associated with lowering CPP but report a cohort study demonstrating no 
reduction in PbtO2 after intravenous nicardipine in neurologically critically 
unwell patients (408).  
Definitive management of the ruptured aneurysm is done by surgical clipping 
or endovascular coiling.  Microsurgical clipping was the main treatment of 
intracranial aneurysms prior to Gugliemi’s description of aneurysm occlusion 
by endovascular approach in 1991 (409). The ISAT trial, a multicentre RCT 
that randomised 2,143 patients with aSAH to microsurgical or endovascular 
repair, found a reduction in death at one year from 31% in the microsurgery 
arm to 24% in the endovascular arm (24% RRR, ARR 6-9% in favour of coiling) 
(410). Retrospective analysis demonstrated that aneurysmal neck diameter 
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and dome size were strong predictors of incomplete occlusion and subsequent 
aneurysm recurrence (409). As such, clipping is reserved for aneurysms with 
a wide neck or in locations such as the middle cerebral artery (MCA) (411). 
Complications 
In the 1980s The International Cooperative Aneurysm Study assessed the 
outcomes of surgical and medical management of 3,521 patients with SAH. 
The authors identified vasospasm and re-bleeding as the leading causes of 
morbidity and mortality after the initial bleed (412). Subsequently, 
hydrocephalus, intraventricular haemorrhage and medical complications have 
been implicated as additional contributors to worse outcomes (413, 414). More 
recently, Lantigua et al, in a prospective single centre trial, enrolled 1,200 
patients between 1996 and 2009 to revaluate the causes and mechanisms of 
in-hospital mortality after SAH (375). The authors found that most deaths or 
severe neurological disability were secondary to the direct effect of bleeding, 
followed by re-bleeding, medical complications and vasospasm.  
Re-bleeding 
After the initial haemorrhage, re-bleeding is one of the most important 
preventable causes of death in hospitalised patients (375, 415). The maximum 
risk for re-bleeding occurs early after the initial haemorrhage and early re-
bleeding is associated with worse outcomes than late re-bleeding (416). One 
third of rebleeds occur within three hours and up to half occur within six hours 
of the onset of headache (417, 418). Delayed aneurysm treatment, loss of 
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consciousness, decreased GCS and large aneurysms are all associated with 
an increased risk of re-bleeding (407).  
Hydrocephalus 
Acute hydrocephalus is reported to occur in 20-30% (411, 419), whilst chronic, 
shunt-dependent, hydrocephalus is reported to occur in roughly 10-50% of 
patients with aSAH (407). Hydrocephalus appears more commonly in those 
with poor grade SAH and is diagnosed on CT. Management is with CSF 
diversion (EVD or lumbar drainage) (407).  
Medical complications 
Severe non-neurosurgical complications of SAH occur in up to 40% during 
hospital admission (413). Fever and hyperglycaemia are independent risk 
factors of poor outcome and should be treated (407, 411). In addition to these 
complications, there is an increased risk of venous thromboembolism, 
hyponatraemia and pulmonary complications. Cardiac sequelae are common 
with poor-grade SAH secondary to increased sympathetic outflow and a large 
catecholamine release after brain injury. Independent of this, there is an 
autonomic neural stimulation from the hypothalamus. The hyperdynamic state 
and increased oxygen demands of the myocardium that this causes can result 
in a transient ischaemia. Subsequently many patients demonstrate short-lived 
ECG changes such as T-wave and ST segment abnormalities. These can 
mimic, or reflect, cardiac ischaemia depending on whether the changes are 
catecholamine dependent or related to hypothalamic stimulation (420). Up to 
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50% of patients develop clinically significant cardiac arrhythmias and it is 
necessary to keep such patients on cardiac monitors and undergo aggressive 
intervention to treat myocardial infarction and maintain a normal cardiac 
rhythm (421).   
Delayed Cerebral Ischaemia 
DCI has been stated as a major cause of morbidity and mortality in patients 
who survive the ruptured aneurysm (367, 407, 412, 422, 423). Lantigua et al., 
in the 2015 review discussed earlier, noted that “a robust association between 
vasospasm and in-hospital mortality is notably absent in the present study”. 
Furthermore, DCI from vasospasm was only confirmed in 5% of cases in their 
study and DCI as a complication was not an independent predictor of death. 
However, the authors go on to state that there is ample evidence that cerebral 
ischaemia from DCI is an important cause of morbidity after SAH (375, 424, 
425). DCI is still described as “the most important preventable cause of 
mortality and poor neurological outcome [in patients who survive the initial 
bleed]” (426).  
One of the difficulties in assessing the epidemiology and aetiology of DCI is 
the definition. Previous terms included DCI, delayed ischaemic neurological 
deficit (DIND), delayed neurological deficit (DND), secondary ischaemia and 
most commonly vasospasm. Contemporary articles suggest an associative, 
rather than causal, relationship between angiographic cerebral vessel 
narrowing and neurological outcome, and highlight the possibility of a multi-
factorial aetiology (422, 427-429). When assessing the incidence of DCI and 
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association between radiological vessel narrowing and DCI, it is not always 
clear whether an author is referring to DCI (based on the definitions below) 
when they state ‘vasospasm’ or merely an arterial narrowing visualised 
radiologically. The importance of this becomes apparent when performing a 
meta-analysis and trying to calculate therapeutic efficacy and diagnostic 
accuracy. In 2010 a consensus statement was released proposing a definition 
of DCI. In addition to this, the Neurocritical Care Society released a consensus 
definition for DCI and a separate definition of vasospasm: 
• DCI is a focal neurological impairment or decrease in GCS (≥2 points) 
that lasts for ≥1 hour, is not apparent immediately after aneurysm 
occlusion, and cannot be attributed to other causes by means of clinical 
assessment, blood tests or imaging. 
• Vasospasm is radiologically demonstrated cerebral arterial vessel 
narrowing with corresponding clinical symptoms and signs (430, 431).  
Between days three and ten after their initial haemorrhage, 30-40% of patients 
will suffer from DCI, and up to half of these patients will have a poor outcome 
(367, 396, 432). Risk factors for developing DCI include poor grade SAH, 
intraventricular haemorrhage, large amounts of subarachnoid blood, additional 
haematomas and smoking (423, 433, 434). There is moderate evidence (two 
high-quality studies as defined by the referenced systematic review) for an 
increased risk of DCI with hyperglycaemia, hydrocephalus, history of diabetes 
and early systemic inflammatory response syndromes (434).   
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DCI has an unclear aetiology which is thought to be multi-factorial.  Potential 
causes include cerebral vessel narrowing, early brain injury (EBI) and cortical 
spreading depolarisation (CSD).  
Cerebral Artery Narrowing 
Cerebral artery narrowing after SAH has been a focus of research since it was 
demonstrated by Ecker et al. on angiography over six decades ago (435). A 
decade after their publication, focal neurology was associated with vessel 
narrowing (436). Vasospasm appeared to be localised to the vascular territory 
of the aneurysmal bleed and proportional to blood load (403, 437). The onset 
of vessel narrowing commonly occurs around day three, is maximal on days 
six-to-ten and lasts for up to two weeks (438-440). The density, duration and 
volume of subarachnoid blood were found to be key predictors of vessel 
narrowing (403, 441). Narrowing of cerebral arteries may cause reduction in 
CBF distal to the constricted vessel contributing to secondary ischaemia and 
result in the delayed neurological impairment (442). The cause of vessel 
narrowing is not clear but is thought to involve an inflammatory response, 
decreased nitric oxide levels, oxyhaemoglobin release and an increased 
concentration of endothelin-1 (ET-1). Much of the evidence supporting these 
theories is from experimental in-vitro studies.  
Oxyhaemoglobin 
Oxyhaemoglobin causes the activation of platelets and coagulation with a local 
inflammatory response when it enters the subarachnoid space (443-445). 
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Arterial narrowing occurs when oxyhaemoglobin comes into contact with the 
abluminal side of cerebral vessels and is known to induce cerebral artery 
vasoconstriction both in vivo and in vitro in primates, which is not seen with 
methaemaglobin or bilirubin (407, 446-448). The mechanism by which 
oxyhaemaglobin does this is thought to be by decreasing the production of 
prostacyclin, increasing prostaglandin E2 in vessel walls and inhibiting 
endothelial-dependant relaxation. Lipid peroxidation is also caused by the 
oxidation of oxyhaemoglobin to methaemoglobin and can lead to 
vasoconstriction (449). Attempts to exploit these mechanisms to inhibit vessel 
constriction and improve outcomes have not been successful (450).     
Nitric Oxide 
Nitric oxide (NO) causes direct and indirect vasodilation. The decrease in 
bioavailability of NO after SAH is two-fold: When Hb is released after the 
breakdown of blood in the subarachnoid space it scavenges up available NO 
due to the high affinity that NO has for Hb (451, 452). In addition to this, the 
morphology of arteries changes after SAH such that there is a down-regulation 
of endothelial and neuronal NO synthase thus decreasing the production of 
NO (453-455). NO is then unable to counteract the effects of the 
vasoconstrictor endothelin 1 (ET-1) (456).  
Endothelin (ET) 
Endothelin is fundamental to maintaining the normal vascular tone of blood 
vessel walls. The concentration of ET-1 in plasma and serum increases 
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beyond normal levels within minutes after SAH and peaks around days three-
to-four. ET-1 is the most potent endogenous activator of vasoconstriction. 
There appears to be an excess release of ET-1 by astrocytes around the time 
of onset of ischaemic symptoms and concentrations are consistently elevated 
in patients with DCI (457, 458). However, ET-1 concentrations within the 
normal range have been reported in patients with radiological evidence of 
cerebral artery narrowing who do not have DCI (459-461). Increased ET-1 
may, therefore, signify ischaemic damage rather than cause arterial vessel 
narrowing in DCI (428). Treatments focussing on endothelin receptor 
antagonists are discussed later in this chapter.  
Alpha Calcitonin Gene-Related Peptide 
Alpha calcitonin gene-related peptide (CGRP) is an endogenous neuropeptide 
and a potent vasodilator. αCGRP appears to be released, and is subsequently 
depleted, after aSAH to combat cerebral vasoconstriction which has led to the 
theory that exogenous αCGRP may be beneficial in managing DCI (462-464). 
CGRP is discussed in more detail in the next chapter. 
Radiological Evidence 
There is a strong correlation between radiological cerebral vessel narrowing 
and DCI (465, 466). Brown et al. found that 31% (17 of 54) of patients with 
moderate-to-severe vasospasm (determined by attending neuroradiologists 
but the severity is not defined in the publication) had delayed infarcts, 
compared with only 4% (three of 80) of those without vasospasm (465). It is 
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unclear whether this correlation represents causation or association. As many 
as 70% of patients will demonstrate cerebral vessel narrowing on angiography 
after SAH, but only 40% of these patients manifest neurological deficits and 
only 30% are diagnosed with DCI (467-470). There are several possible 
reasons for this. Cerebral vessel narrowing is not synonymous with DCI and 
hence the need for precise definitions (431). The patients who are most likely 
to develop DCI (WFNS Grades IV and V) are difficult to assess clinically due 
to being sedated and mechanically ventilated (423). As such, DCI is probably 
under-diagnosed in these patients. Furthermore, neurological deficits may not 
be directly proportional to the degree of radiological vessel narrowing (442).  
Vasospasm, as identified by transcranial Doppler (TCD) and angiogram, only 
has a positive predictive value of 67% for identifying cerebral infarcts on CT 
(471). One might expect this to be higher if cerebral vessel narrowing was the 
primary cause of DCI. However, there are a few points to consider. Firstly, 
cerebral infarction on CT is not required for a diagnosis of DCI (431). Secondly, 
the rate of cerebral infarction on CT in patients with cerebral vessel narrowing 
ranges between 24-35% (472, 473) but is as high as 81% on MRI (474) 
suggesting that we may not be identifying cerebral ischaemia after DCI on CT 
images. Another inconsistency with correlating infarcts and vessel narrowing 
is that as many as 25% of delayed infarcts on CT either occurred in patients 
who had no evidence of vessel narrowing or occurred in separate territories to 
the narrowing (465, 475, 476). Angiogram and TCD are not 100% sensitive in 
identifying vessel narrowing and one study found that these imaging modalities 
only agreed on the diagnosis of vasospasm in 73% (95% CI, 63% to 81%) of 
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cases. Therefore, it may be that vasospasm was underdiagnosed in patients 
who were later found to have delayed infarcts on CT (471).  
It is unclear whether microvascular constriction is the cause of DCI and there 
may be a stronger correlation between microvascular constriction and 
decreased regional CBF than there is with large vessel constriction (477-479). 
Pial arteries constrict on exposure to blood or microtrauma in animal studies 
(480) and constriction of intraparenchymal arterioles occurs after aSAH which 
may contribute to DCI (479). Spectral imaging has demonstrated constriction 
of small vessels within the first 72 hours after aSAH and cerebral arterioles 
have been directly observed contracting after aSAH (481, 482). Catheter 
angiography and TCD may not be identifying this microvascular vessel 
narrowing occurring in patients with DCI (483).  
CT perfusion (CTP) and DSA (digital subtraction angiography, the gold 
standard for identifying cerebral vessel narrowing) are reported to have similar 
test characteristics according to one retrospective comparative study (484). 
CTP is reported to have an 84% sensitivity, 79% specificity and 88% positive 
predictive value for identifying DCI (485). The rate of CTP deficits is higher in 
patients with DCI and such patients exhibit worse cerebral perfusion (on CTP) 
than in those without DCI, even before they developed focal neurology (486). 
CTP has also shown that it is possible for areas of poor perfusion to recover, 
giving hope that DCI could be partially reversible (487).  
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Early Brain Injury 
Damage that occurs to the brain within the first 72 hours after the haemorrhage 
is termed Early Brain Injury (EBI). Due to the timing of damage, most of the 
evidence supporting this theory is from experimental data suggesting 
physiological changes that occur after the haemorrhage. Following the 
haemorrhage there is intracranial hypertension and subsequent decrease in 
CPP which halts CBF and causes cerebral ischaemia and oedema (414, 488, 
489). At ictus, the intracranial hypertension may exceed SBP and the rate of 
increase and peak ICP appears to be proportional to the amount of arterial 
blood extravasating into the subarachnoid spaces from the aneurysm (490-
492). Subsequent hydrocephalus and CSF outflow obstruction further elevates 
the ICP (493, 494). Intracranial hypertension appears to occur in two ways 
after SAH. The most commonly observed form is an increase in ICP to about 
the arterial diastolic pressure which then decreases to just above the patient’s 
baseline ICP (491). This usually reflects a small volume haemorrhage with 
cerebral oedema. The second form is a sustained increase in ICP secondary 
to acute hydrocephalus or a progressive haematoma (493, 494).  
Cerebral oedema after SAH is a poor prognostic indicator. It is often present 
on admission CT scans and by day six it is present in up to 20% of patients  
(414, 495, 496). Cerebral autoregulation is frequently impaired after SAH (60, 
497, 498) and can become dependent on CPP and blood viscosity. As such, 
any change in ICP or systemic arterial pressure can worsen oedema and 
ischaemia.  Generalised cerebral ischaemia occurring shortly after the SAH 
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may cause disruption to the BBB and an inflammatory response, both of which 
contribute to cerebral oedema. In addition to this, cell death mechanisms are 
initiated and neuronal cell death appears to occur as early as 40 minutes after 
the haemorrhage (499-501). High concentrations of pro-inflammatory 
cytokines and vasoactive factors such as interleukin 6 and tumour necrosis 
factor-α in the CSF and serum correlate with increased frequency of DCI and 
negative outcomes after SAH (502, 503). 
As noted above, oxyhaemoglobin may contribute to DCI and it has been 
argued that removing blood from the subarachnoid space may improve 
outcomes (449, 504). Intrathecal administration of thrombolytics and 
continuous cisternal drainage have been investigated with reports of success. 
Results of the EARLYDRAIN trial comparing continuous lumbar-CSF drainage 
with standard treatment are awaited (trial completed but results not yet 
published) (505, 506). A meta-analysis investigating the use of intrathecal 
thrombolytics suggested a reduction in the incidence of DCI but these findings 
were not statistically significant after excluding one study, which included 
intrathecal nimodipine in addition to thrombolytic therapy (507).   
One of the limitations with the EBI theory is that it relies heavily on 
experimental data. Without evidence to support the theory in a clinical setting 
it is difficult to know how much of this data can be translated to humans  (508, 
509). Furthermore, the theory involves multiple complex pathways which are 
individually described but likely related. It may be that no treatment effect is 
observed when a single-target model is used (510). The results of a systematic 
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review and meta-analysis of intracranial in vivo animal studies of EBI and 
delayed cerebral arterial vessel narrowing after aSAH are awaited (511).  
Cortical Spreading Depolarisation 
Cortical spreading depolarisation as described by Leao in 1944, is a gradual 
depolarisation across grey matter at a rate of 2-5 mm/min (512). CSD has been 
investigated in TBI, migraine, malignant stroke, SAH and intracranial 
haemorrhage and is not a new theory (513, 514). The mechanism is thought 
to involve Na+ and Ca2+ pumps of a cellular membrane being exceeded by a 
cation influx. This is then followed by water entering the cell and decreasing 
the extracellular space by roughly 70%, resulting in depressed EEG activity 
(hence the alternative name, cortical spreading depression) (512, 515). MRI 
during migraines have shown what is thought to be a ‘spreading oligemia’, a 
wave of decreased blood flow propagating across the brain (516). To 
counteract the passive influx of cations across the membrane, the ATP-
dependent Na2+ and Ca2+ pumps must expend more energy, which requires 
an increase in CBF. It is thought that in healthy tissue CSD causes a transient 
hyperperfusion, but when there is a dysfunction of the vasculature, 
microvascular spasm can occur causing ‘cortical spreading ischaemia’ (515). 
In an experimental model, Shin et al. demonstrated that peri-infarct spreading 
depolarisations caused vasoconstriction and reduced CBF in the ischaemic 
cortex and expanded infarct size (517). The timing of CSD episodes after SAH 
coincide with the chronology of DCI, occurring between days five-to-seven 
after the haemorrhage, suggesting that CSD is associated with the 
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development of DCI (518). There is limited clinical evidence that repeated CSD 
appears to occur before DCI with little evidence of ‘vasospasm’ on DSA, albeit 
in a small sample (13 patients) (519). The main difference between cerebral 
vessel narrowing and CSD as a cause for DCI appears to be that the vessel 
narrowing caused by CSD is microvascular (whereas most of the vessel 
narrowing originally attributed to vasospasm is large vessel narrowing seen on 
angiography and TCD). The biggest problem with both theories is that so far 
no treatment to ameliorate this vessel narrowing has been shown to be of any 
benefit.   
Treatment of DCI 
Single H Therapy: Is Induced Hypertension the Key? 
Induced hypertension has been used for symptomatic DCI since the 1970s 
and was bundled together with hypervolaemia and haemodilution as ‘triple H 
therapy’ in the 1980s (520, 521). Induced hypertension may improve 
neurological symptoms, and the use of vasopressors to augment BP is still 
used as a treatment for DCI (522). Evidence to support hypervolaemia and 
haemodilution is lacking (521-524). Some small (n<25) clinical and 
experimental trials have observed an increase in CBF after a 0.9% sodium 
chloride bolus of 15ml/kg/hour, and vasopressor-induced hypertension has 
improved CBF, PbtO2 and neurological deficits (525-529). A systematic review 
from 2011 (ten publications, no RCTs) found that hypertension was associated 
with increased CBF and neurological symptom reversal was seen in two-thirds 
of treated patients (522). Unfortunately, like many of the interventions in SAH, 
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there has been no published RCT evaluating the efficacy of induced 
hypertension in the treatment of DCI. The HIMILAIA (hypertension induction in 
the management of aneurysmal subarachnoid haemorrhage with secondary 
ischaemia) trial, a multi-centre RCT investigating the effect of induced 
hypertension in the treatment of aSAH, was terminated early due to insufficient 
enrolment and it seems unlikely that there will be another such trial (530). Pilot 
data from the HIMILAIA trial showed that noradrenaline-induced hypertension 
was not associated with a statistically significant increase in CBF when 
compared with controls (CBF assessed by CT perfusion, mean increase in 
SBP 12 mmHg, n=25) (531). The American Heart/Stroke Association 
(AHA/ASA), in their 2012 guidelines, advise that hypertension is 
recommended in patients with DCI unless they are hypertensive at baseline or 
their cardiac status (no definition given) precludes it. They list this as a Class I 
recommendation (benefit thought to be greater than risk) with level B evidence 
(evidence from non-randomised studies) (407). The 2013 European Stroke 
Organisation guidelines acknowledge that there is no evidence from controlled 
studies for induced hypertension or hypervolaemia to improve outcome in 
patients with DCI (Class IV: uncontrolled studies, case series, case reports or 
expert opinion). Furthermore, they go on to state that induced hypertension is 
associated with increased cerebral oedema, haemorrhagic transformation in 
areas of infarction (532), reversible leukoencephalopathy (533), myocardial 
infarction and congestive heart failure (534). Despite this, hypertension is still 
used as a treatment for DCI (426).   
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Hypervolaemia may cause worse outcomes in patients with aSAH (526). 
Prophylactic hypervolaemia to maintain CPP was shown not to prevent DCI 
and had no improvement on CBF (535). It has also been associated with 
increased risk of pulmonary oedema, decreased PbtO2, and has been found to 
worsen outcomes (526, 536, 537). As such, the Neurocritical Care Society 
guidelines recommend isotonic fluids to maintain a euvolaemic state and 
avoiding hypervolaemia (430).  
A restrictive strategy to maintain a haemoglobin level above 70 g/L after SAH 
is advocated based on evidence from an RCT on general critical care patients 
that was published in 1999 (538). Anaemia is present in up to half of all patients 
with SAH and is associated with brain tissue hypoxia and worse outcomes 
(539-541). Neurocritical care society guidelines advise a transfusion threshold 
of 80 g/L in SAH patients without DCI and 90-100 g/L in those with DCI 
unresponsive to first-line therapies (430). The ongoing RCT SAHaRA 
(Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and 
Outcome) aims to evaluate red cell transfusion from 100 g/L down to 80 g/L in 
aSAH patients and determine the most appropriate target (542). The same 
research team are also conducting a systematic review and meta-analysis to 
summarise the existing evidence regarding red cell transfusions in aSAH 
patients (543).     
Nimodopine 
A 2007 Cochrane review assessed sixteen trials (n = 3,361) and found that 
calcium channel antagonists reduced the risk of poor outcome after aSAH 
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(relative risk 0.81, 95% CI 0.72 to 0.92, NNT 19) (544). However, the only 
statistically significant evidence was for oral nimodipine. Oral nimodipine 
remains the only intervention with evidence from RCT and meta-analysis that 
reduces the incidence of secondary ischaemia and improves outcomes after 
aSAH (RR 0.67, CI 0.55 to 0.81). The evidence for oral nimodipine is based 
on one large double-blind RCT, the British Aneurysm Nimodipine Trial of 1989. 
The trial enrolled 554 patients with aSAH who received surgical clipping 
between 1985 and 1987 and randomised them to placebo (n = 276) or 60mg 
oral nimodipine every four hours for 21 days (n = 278). No patients received 
radiological coiling. Treatment was started within 96 hours of SAH (main 
exclusion criteria was admission to the neurosurgical unit over 96 hours after 
SAH). In patients given nimodipine the incidence of cerebral infarction on CT 
was 22% (61/278) versus 33% (92/276) in the controls, a relative reduction of 
34% (95% CI, 13-50%). Poor outcomes at three months were also reported to 
be reduced by 40% in the nimodipine group (relative risk given in paper, 95% 
CI, 20-55%) (25). Without data from this trial the results of the Cochrane review 
were no longer statistically significant (407). Oral nimodipine, 60mg every four 
hours for three weeks, is now standard care due to its possible benefit, modest 
risks and low cost. The Cochrane review found no statistically significant 
results to support the use of other calcium channel antagonists, magnesium 
sulphate or intravenous nimodipine (544).  
Calcium channel antagonists were initially explored as an aid to post-
ischaemic reperfusion because increased calcium in vascular smooth muscle 
cells was thought to cause vasospasm (545, 546). However, nimodipine’s 
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action seems independent of any effect on large vessel narrowing as 
determined by angiography (547, 548). The mechanism of action of nimodipine 
also appears to be unique to aSAH as demonstrated by a 2006 systematic 
review which found no benefit from nimodipine after traumatic SAH (549). 
Furthermore, it was thought that nimodipine may exert its effect by stopping 
calcium influx at a neuronal level, but no beneficial effect has been seen from 
administration in patients after ischaemic stroke or TBI (550-552). There are 
two properties unique to nimodipine which could explain why it appears to 
improve outcomes whilst other calcium channel antagonists do not. Firstly, 
nimodipine may reduce the incidence of microthrombosis by increasing 
endogenous fibrinolytic activity (553). Secondly, there is experimental 
evidence that intravenous nimodipine decreased cortical spreading ischaemia 
induced by red blood cell products (554). It may be that these properties are 
responsible for the improved outcomes seen with nimodipine after SAH. 
Alternatively, it may be that the benefits from nimodpine seen in the British 
Aneurysm Nimodipine trial are not reproducible and are not reflective of 
patients receiving coiling.  
Intrathecal Calcium Channel Blockers 
Nicardipine, a dihydropyridine calcium channel blocker, has been administered 
via the intrathecal route with varying results. One case series of 177 patients 
examined the effects of intrathecal nicardapine (555). Patients with Fisher 
grade III aSAH undergoing aneurysmal clipping and cisternal drainage within 
48 hours of the aSAH received 4 mg intrathecal nicardipine every 12 hours on 
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days three-to-14 post-operatively. 11.3% of these patients had radiographic 
evidence of vessel narrowing and 5.7% had clinical signs of DCI. The authors 
note a significant reduction in ‘vasospasm’ but also recognise that 18.6% of 
patients required a shunt operation. Shibuya et al. demonstrated a decreased 
incidence of DCI and angiographic vessel constriction by 20 and 26% 
respectively after prophylactic administration of 2mg IT nicardipine via a 
cisternal drain when compared with control patients (556). More recent trials 
also report positive findings but are limited to cases of refractory ‘vasospasm’ 
and have very small sample sizes (n=<10) (557, 558).  However, nicardipine 
is associated with probable vasodilation-associated headaches, intracranial 
infections and hydrocephalus. Positive long-term outcomes from large RCTs 
are lacking. The NEWTON trial is a phase I/IIa multicentre RCT administering 
IT nimodipine microparticles in patients with aSAH (559). The trial uses EG-
1962, a sustained delivery system of nimodipine in microparticles. These will 
be injected into the ventricles through an EVD in patients undergoing coiling 
or clipping of ruptured aneurysms. It is thought that systemic effects are less 
likely to occur as nimodipine concentrations are much lower in the plasma than 
CSF (560).  
Magnesium 
Hypomagnasaemia is common after SAH and has been associated with more 
cisternal and ventricular blood, a longer duration of unconsciousness and a 
worse WFNS score at admission. Hypomagnasaemia occurring between days 
two-to-12 also appears to predict DCI (561). Magnesium sulphate, a non-
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competitive inhibitor of calcium channels, has been shown to attenuate 
cerebral vessel narrowing and reduce the size of ischaemic lesions in 
experimental models of SAH (562). Unfortunately, trials such as IMASH and 
MASH-2, which recruited 1,531 patients between them, demonstrated no 
benefit in clinical outcome from intravenous magnesium sulphate (563, 564). 
A subsequent meta-analysis concluded that there was no benefit from 
prophylactic magnesium sulphate in this group of patients and a post-hoc 
analysis of the IMASH trial reported worse clinical outcomes with high plasma 
concentrations of magnesium (565, 566). As such, the Neurocritical Care 
Society guidelines now advise against the routine use of magnesium in 
patients with aSAH (430). 
Endothelin-antagonists 
Endothelin antagonists have been shown to significantly reduce cerebral 
vessel narrowing. Unfortunately, they have not been shown to improve 
neurological outcomes (567-570). These results, and a 2011 meta-analysis of 
pharmacological interventions treating vasospasm, have led contemporary 
authors to question the relevance of vessel narrowing and look toward a multi-
factorial aetiology for DCI. The 2011 meta-analysis examined 14 studies (n = 
4,235) and found that despite a reduction in radiological vasospasm (RR 0.80, 
95% CI 0.70 to 0.92), there was no statistically significant effect on adverse 
outcomes (RR 0.93, 95% CI 0.85 to 1.03) (567). The authors acknowledge 
difficulties with the variety of DCI definitions and conclude that the lack of 
improved outcomes could result from methodological problems, sample size, 
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insensitivity or poor clinical outcome measures (567). The CONSCIOUS trials 
(1, 2 and 3, Clazosentan to Overcome Neurological Ischaemia and Infarction 
Studies) were multicentre RCTs investigating the effect of the endothelin 
antagonist, clazosentan, on vasospasm after aSAH. CONSCIOUS-1 
demonstrated that 15mg/h of clazosentan reduced moderate to severe 
angiographic cerebral vessel narrowing assessed by blinded evaluation of 
DSA (RRR 65%, 95% CI, 47% to 78%; P<0.0001) (570). Clazosentan was 
investigated further in patients receiving surgical clipping (CONSCIOUS-2) or 
coiling (CONSCIOUS-3) for aSAH. In CONSCIOUS-2, patients were 
randomised to clazosentan 5mg every hour (n = 768), or placebo (n = 389), for 
up to 14 days. The trial showed that clazosentan at 5mg/hour had no significant 
effect on morbidity or mortality, incidence of new infarcts or DCI. Furthermore, 
clazosentan was associated with an increased incidence of hypotension, 
pulmonary complications and anaemia (568). CONSCIOUS-3 was stopped 
early due to the results from CONSCIOUS-2 (569).  However, before being 
stopped, CONSCIOUS-3 randomised 571 patients (189 to placebo; 194 to 
5mg/h of clazosentan; and 188 to 15mg/h clazosentan). The 15mg/h group 
had a significantly reduced incidence of vasospasm-related morbidity and all-
cause mortality compared with the placebo group (15 vs 27%; p = 0.007). No 
effect on clinical outcome was detected (as measured by the extended 
Glasgow Outcome Scale). The authors argue that, due to being stopped 
prematurely, the study was underpowered to detect a difference in clinical 
outcome (569). 
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A systematic review and meta-analysis, investigating endothelin receptor 
antagonists after experimental aSAH in animal studies, found no improvement 
in functional outcomes despite changes in cerebral vessel diameter (571). The 
review concluded that vasospasm is not a clinically relevant outcome measure 
in experimental aSAH studies and that there was insufficient animal data to 
support progression to the CONSCIOUS trials (571). The REVERSE 
(Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral 
Vasospasm in Adult Subjects with Aneurysmal Subarachnoid Haemorrhage) 
trial is an ongoing prospective, multicentre Phase II trial aiming to assess 
whether clazosentan can reverse angiographically-confirmed cerebral 
vasospasm in patients with aSAH (Clinical trials: NCT02560532). Outcome 
measures include successful reversal of angiographic vasospasm within three 
hours post-administration and reversal of global vasospasm within 24 hours 
post-administration.   
Nitric oxide donors 
Sodium nitroprusside and nitroglycerine (NO donors) have been shown to 
reverse cerebral artery narrowing (537, 572). However, these NO donors 
cause hypotension and expose NO to oxyhaemoglobin and 
deoxyhaemoglobin leading to the formation of methaemoglobin, S-nitroso-
haemoglobin and ferrous-nitrosyl-haemogloin (453). Unfortunately, although 
intravenous, intra-arterial and intrathecal routes of administration have been 
tested, NO has a limited role in DCI treatment. Furthermore, the bulk of 
evidence to support NO donors is from animal studies investigating ischaemic 
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stroke and more research is needed (573). Inhaled NO is a selective 
pulmonary vasodilator and, contrary to intravenous use, does not cause 
hypotension. A reduction in ischaemia-reperfusion injuries in extrapulmonary 
organs after cardiac injury has been demonstrated in experimental studies of 
NO inhalation. These have also been supported by proof-of-concept human 
trials (574). As such, NO inhalation is being investigated as a post-cardiac 
arrest treatment and it has been suggested that investigation of NO as a 
treatment of secondary brain injury is warranted based on this evidence (575). 
Endovascular Therapy 
There is a large amount of conflicting evidence to dispute cerebral vessel 
narrowing as the primary cause, or predictor, of DCI (422). Evidence to support 
the involvement of vessel narrowing in DCI comes from endovascular therapy, 
one of the interventions for DCI that may show some promise. Endovascular 
therapy has become common practice in some centres (375, 426, 576-578) 
and can be divided into intra-arterial infusion of vasodilators (most commonly 
verapamil or nimodipine) and mechanical dilation (375, 426, 576-578). A 2015 
review looking at the frequency and variability of endovascular treatments in 
32 countries found that angioplasty was performed by 83% of non-US 
responders and 91% of US responders in the treatment of vasospasm (578). 
The AHA/ASA guidelines for the management of aSAH acknowledge 
endovascular intervention for patients with DCI not responding to 
haemodynamic augmentation, but do not offer guidance on its use (407). The 
success rate of percutaneous transluminal angioplasty (PCTA) for proximal 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 3: Delayed Cerebral Ischaemia after Subarachnoid Haemorrhage 115 
vessels has been reported as over 90% and the effect is persistent (579). 
There is documented improvement in CBF after PCTA and evidence from 
observational studies that intervention within two hours from neurological 
deficits results in better outcomes (580, 581). A 2011 systematic review and 
meta-analysis of 49 articles relating to interventional techniques to treat 
vasospasm did find an improvement in outcomes. 24 of the 27 publications (n 
= 1,028) reporting the use of transluminal balloon angioplasty demonstrated 
not only an improvement in vessel diameter, but also an improvement in 
neurological deficits. Twelve case series reported good angiographic and 
clinical results in those administered papaverine approximate to the region of 
vessel narrowing (582). Both techniques were associated with significant side 
effects and the quality of the studies was reported as very low to moderate 
(based upon the GRADE classification system) (583). There has been one 
published RCT which looked at PTCA as a treatment in patients with low-grade 
SAH and large amounts of cisternal clot and there have been no RCTs 
investigating the various intra-arterial vasodilators (584). There does appear 
to be weak evidence to support the use of endovascular therapy in the 
treatment of DCI with radiological evidence of cerebral vessel narrowing. 
However, robust RCTs are needed for both PCTA and intra-arterial 
vasodilators. These treatments are currently reserved for patients with DCI 
refractory to medical interventions, the benefit of which is not without doubt 
(426). Any treatment benefit of endovascular therapies may be masked by 
slow intervention times. Therefore, any future RCT must focus on timely 
diagnosis and delivery. 
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The evidence supporting endovascular therapies raises a few questions. 
Firstly, is the evidence strong enough to support endovascular intervention or 
are small sample studies exaggerating the treatment effect? High-quality 
RCTs are needed. Secondly, if there is a genuine beneficial effect from 
endovascular treatment, why is there not the same improvement in outcomes 
with pharmacological intervention? It has been suggested that there is an early 
acute peripheral vasospasm of the microvasculature, not detectable by 
conventional angiography, and a later, more localised vasospasm (585). It may 
be that early endovascular intervention, targeted to patients with radiological 
evidence of vasospasm, is beneficial because it is treating localised ischaemia. 
Pharmacological intervention, not targeted at patients with localised 
ischaemia, is not beneficial in those with global ischaemia. Alternatively, it may 
be that any benefit from pharmacological intervention is masked by negative 
side effects.  
Thromboembolism 
There appears to be increased levels of von Willebrand factor and platelet-
activating factors after SAH, which may contribute to the increased 
thromboemboli seen in patients with DCI (586-589). An autopsy study of 
thromboemboli after aSAH in 28 patients demonstrated a significant increase 
in microclot burdens and histological evidence of ischaemia in those with DCI 
(589). The authors of that study argue the finding suggests that microthrombi 
may contribute to DCI. There is also evidence supporting this theory from trials 
of tranexamic acid in the treatment of rebleeding after SAH. The incidence of 
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post-aSAH rebleeding has been significantly reduced following tranexamic 
acid administration. However, tranexamic acid may have caused an increased 
incidence of DCI separate from large vessel narrowing, possibly by inducing 
microthrombosis (590-593). Trials of antiplatelet agents in the management of 
microthrombosis after aSAH have been largely negative, including those 
investigating prophylactic low molecular weight heparin (594, 595). The 
ULTRA trial (ultra-early tranexamic acid after subarachnoid haemorrhage) is a 
multicentre RCT randomising patients to standard treatment or standard 
treatment plus tranexamic acid within the first 24 hours (596). The primary 
outcome is functional outcome measured on the modified Rankin Scale. The 
trial is ongoing (NCT02684812). 
Summary 
The true aetiology and epidemiology of DCI is not yet understood (375). A 
comprehensive review of 223 publications in 2006 found 41 randomised trials 
investigating 16 different treatments for DCI. Perhaps unsurprisingly, the 
review demonstrated that the only proven therapy for DCI was oral nimodipine 
(450). A subsequent 2016 review reported 11 interventions which have not 
been demonstrated to improve neurological outcomes after SAH (426). Even 
the effect of oral nimodipine is not without doubt, although I suspect it is 
extremely unlikely that a further study to assess its efficacy will ever be 
performed. Another systematic review, also from 2016, assessed all relevant 
articles published between January 1st, 2010 and December 1st, 2015 (49 
studies) and gives a more positive outlook. One of the findings from this review 
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was that only 18% (9/49) of the included studies had a sample size exceeding 
100 patients, 53% had a sample size less than 50 (26/49) and the authors 
acknowledge that many of the treatments remain to be tested in larger RCTs 
(597). Ongoing trials not mentioned in the above text include those 
investigating oral sulforaphane (as SFX01, NCT 02614742); subcutaneous 
Kineret (an interleukin-1 receptor antagonist, ISRCTN 45931429); 
intraventricular injection of nimodipine (560); and intraventricular fibrinolysis 
(ISRCTN 13230264). 
The radiological evidence for DCI is conflicting at best. Endovascular therapy 
strongly supports vessel narrowing as a cause of DCI but a large multi-centre 
RCT is needed which seems likely to face recruitment difficulties. The disease 
almost certainly has a multi-factorial aetiology. Of the three theories explaining 
the cause of DCI, it is my opinion that cerebral vessel narrowing is the most 
tangible and the most likely to yield a treatment modality that improves 
outcomes. 
One intervention which showed promise in the early 90s was αCGRP. This 
peptide has been investigated intravenously in humans and administered into 
CSF in animal studies with some evidence of improved neurological outcomes. 
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Chapter 4: Calcitonin Gene-Related Peptide 
In Chapter 3 I summarised previous research into treatments for DCI and 
emphasised that the only intervention with RCT/meta-analysis evidence of 
efficacy is oral nimodipine. There is a need, not only for a better understanding 
of DCI, but also an intervention that shows improvement in mortality and 
neurological outcomes. One potential intervention which interests me is alpha 
calcitonin gene-related peptide (αCGRP), an endogenous peptide and potent 
microvascular dilator. αCGRP was trialled in the early 90s and found to be 
effective at dilating cerebral vessels after SAH, both in animal studies and 
human trials. After a European RCT assessing its effect in 1992, further 
research has been lacking. In this chapter I describe the current understanding 
of the normal physiological role of αCGRP and give a brief outline of its role in 
disease. There is a systematic review and meta-analysis of the effect of 
αCGRP on cerebral vessel narrowing after SAH in animal studies and a 
summary of the three previous human trials of αCGRP after aSAH. I present 
my findings from a retrospective study which analysed CSF concentrations of 
αCGRP in patients with suspected aSAH undergoing LP to assess for 
xanthochromia. Finally, the protocol for a dose-finding and tolerability study in 
humans with aSAH is included.  
Calcitonin Gene-Related Peptide 
Calcitonin gene-related peptide is an endogenous 37-amino acid neuropeptide 
that is mainly associated with C and Aδ sensory fibres. These fibres have 
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nociceptive functions but also have a perivascular efferent function. In addition 
to the association with sensory fibres, CGRP is localised to non-neuronal 
tissues. The peptide has been investigated for its involvement in hypertension, 
atherosclerosis, heart failure, wound healing, migraines and SAH and there 
are multiple comprehensive reviews of its function (598-601). Despite this, the 
function of CGRP is still not fully understood.   
CGRP was discovered in the early 1980s when alternative splicing of the 
calcitonin gene in the thyroid of ageing rats lead to CGRP production (602, 
603). It was subsequently isolated in the plasma of patients with medullary 
thyroid cancer (604).   
Key findings around this time included CGRPs presence in neuronal tissue, its 
potent vasodilatory properties and its expression and activation in the cerebral 
circulation (605, 606).  
In humans, CGRP exists in α and β isoforms (occasionally referred to as 
CGRP I and II) which are synthesised from two genes on different sites of 
chromosome 11 (607). These genes are CALC (calcitonin) I and CALC II. 
CALC I undergoes alternative splicing to form either calcitonin or αCGRP. The 
CALC II gene is responsible for the production of βCGRP (608, 609). Aside 
from three amino acids, the α and β isoforms of CGRP are identical in humans 
and share similar biological properties (609, 610). Although there appears to 
be a degree of overlap, αCGRP is present throughout the central and 
peripheral nervous system, whereas the β isoform is expressed in the enteric 
nervous system. The β form was thought to be restricted to the enteric system, 
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and it is expressed up to seven-fold more than αCGRP in the intestine (611). 
However, βCGRP has been shown to be released with αCGRP in the vascular 
system to a lesser extent and has been found in the adventitia of mesenteric 
arteries in animal studies (612, 613). The detailed structure of CGRP with its 
amino acid sequence and its antagonist, CGRP8-37, have been extensively 
covered elsewhere (598, 599).  
Experimental models demonstrate upregulated CGRP synthesis following 
nerve damage and in tissues undergoing an inflammatory response (614). 
Capsaicin, the chili extract which causes pain and erythema on contact, is able 
to cause the release of CGRP and another neuropeptide, substance P (615, 
616). It is thought that this occurs via capsaicin’s action on transient receptor 
potential vanilloid 1 (TRPV1) receptors found on sensory C and Aδ-fibers. 
Capsaicin acts as a TRPV1 receptor agonist and can lead to the depletion of 
neuropeptides such as CGRP from nerve terminals (614). After such depletion, 
nerve growth factor (NGF) is required in the synthesis of new neuropeptides, 
such as CGRP. NGF is released from local inflammatory cells such as 
macrophages and keratinocytes and it is thought that NGF is the primary 
stimulant of CGRP synthesis following nerve damage and inflammatory 
responses  (614, 617).   
CGRP is stored in vesicles within the nerve terminal and is released after 
depolarisation by calcium-dependent exocytosis, a mechanism identified by 
the use of capsaicin, but other TRPV1 agonists, such as rutaecarpine and 
anandamide have also been shown to cause release of CGRP (618-621). 
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Rutaecarpine-mediated CGRP synthesis is associated with a hypotensive and 
cardioprotective response (620) whereas anandamide-mediated synthesis 
has been associated with mesenteric vasodilation (622). Other agents have 
been implicated in CGRP synthesis to a lesser extent, such as transient 
receptor potential ankyrin 1, angiotensin II and noradrenaline (598, 623).   
αCGRP has a half-life of approximately seven-to-ten minutes in the human 
blood circulation, and there are multiple theories regarding its metabolism 
(624, 625). Substances implicated in the degradation of CGRP include 
tryptase (626), the endopeptidase neprilysin (627, 628), insulin-degrading 
enzyme (628, 629) and endothelin-converting enzyme 1 (629). In addition to 
these possible routes of metabolism, there is some evidence to support 
reuptake of CGRP into nerve terminals. An experimental study investigating 
CGRP-induced dilation of basilar arteries repeatedly administered capsaicin to 
cause CGRP release from perivascular terminals of capsaicin-sensitive nerve 
fibres. After three capsaicin challenges and a loss of vasodilatory response, 
the CGRP-depleted segments of basilar artery were incubated with CGRP. 
After incubation, there was a return to the previous levels of capsaicin-induced 
vasodilatory response suggesting that CGRP reuptake had occurred (630). 
Other experimental studies have found similar responses (631, 632).   
The structure and function of the CGRP receptor is covered in-depth 
elsewhere (598, 599) but a brief summary is given here. G protein-coupled 
receptors (GPCR) are cell-surface proteins that interact with an extracellular 
stimulus and transduce the stimulus to produce a reaction inside the cell (633). 
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Calcitonin receptor-like receptor (CLR) is a type of GPCR and is the main 
functional part of the CGRP receptor. However, CLR requires receptor activity-
membrane proteins (RAMP) to bind with CGRP and transduce a signal (634). 
There may be two, or more, distinct CGRP receptors, CGRP1 and CGRP2. The 
distinction between these two receptors is based upon their different 
responses to the CGRP antagonist CGRP8-37. CGRP1 is strongly antagonised, 
whilst CGRP2 is not. CGRP1 is made up of CLR and RAMP1 and is thought to 
be responsible for cardiovascular effects, as evidenced by positive inotropic 
effects in rat and guinea pig atrium (635, 636). CGRP2 is less well defined.    
αCGRP is the most potent microvascular vasodilator known with an effect up 
to ten times higher than potent prostaglandins and up to 100 times greater than 
vasodilators such as ACh and SP (637). Picomole amounts of αCGRP cause 
increased blood flow and erythema in human skin which lasts between five-to-
six hours (638). This dilatory effect has been demonstrated in kidney, coronary 
and cerebral vessels and is inhibited by CGRP receptor antagonists (600). 
CGRP causes a reduction in systemic BP in both animal and human studies 
with hypertensive and normotensive subjects (639-641). In what is thought to 
be a response to the hypotension caused by CGRP, there is a positive 
inotropic and chronotropic effect after intravenous administration in animal 
studies (642, 643). When CGRP is administered into the cerebral ventricles in 
animal studies it causes hypertension by activation of noradrenergic 
sympathetic nerves (644). 
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CGRP is thought to cause vasodilation by endothelium- and nitric oxide (NO)-
dependent and -independent pathways. The independent pathway is most 
common. After administration of CGRP there is a rise in cyclic adenosine 
monophosphate (cAMP) and relaxation occurs without endothelium. This 
suggests that CGRP directly stimulates adenylate cyclase in smooth muscle 
to cause cAMP production. cAMP then causes phosphorylation and opening 
of K+ channels leading to relaxation. This action is persistent in animal and 
human studies of cerebral vessels that have been stripped of endothelium 
(645, 646).  
Dependent pathways involve CGRP acting on an endothelial receptor to 
increase cAMP and production of NO. NO enters smooth muscle cells and 
activates guanylate cyclase which promotes cGMP and ultimately vasodilation 
(647).  
Involvement in Disease 
CGRP has been investigated for its potential role in pulmonary hypertension, 
heart failure, atherosclerosis, sepsis, neurogenic pain, skin conditions, ageing, 
arthritis, diabetes and obesity (598). I have discussed the application of CGRP 
in hypertension, migraine and subarachnoid haemorrhage below as these 
appear to be the most widely documented. For a comprehensive review, 
Russel et al. offer an excellent description of the role of CGRP in diseases 
other than SAH (598).  
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Hypertension 
The role of CGRP in hypertension has been evaluated in a number of 
experimental models and there is some evidence that CGRP actions are 
important in restricting the onset of hypertension (598). A worsening 
cardiovascular response is seen with the use of the CGRP receptor antagonist 
CGRP8-37 in experimental models of hypertension. Such models include salt-
induced hypertension, L-NAME-induced (N(G)-Nitro-L-arginine-methyl ester) 
hypertension and subtotal nephrectomy hypertension (648-650). CGRP and 
angiotensin II appear to work together to alter vascular tone and blood 
pressure in animal studies (639, 651). There are also human trials 
demonstrating that infusion of angiotensin II causes dose-dependent 
increases in plasma concentrations of CGRP combined with the increase 
blood pressure caused by angiotensin II (652). It has been argued that CGRP 
is released in response to hypertension but there is no evidence that this 
increase in plasma CGRP is functional. Furthermore, the association between 
CGRP and hypertension is not clear in experimental or human studies. CGRP 
receptor antagonists do not appear to affect blood pressure or resting heart 
rate, both in animal (653, 654) and human studies (655, 656).  Lu et al. used 
knockout mice to assess the effect of αCGRP deletion and found that there 
was no difference in blood pressure at baseline, after exercise, or following a 
phenylephrine infusion when compared with wild-type mice (657). Therefore, 
the cardiovascular effects of CGRP reduction/antagonism may only become 
apparent in the diseased states discussed in experimental models above. 
From the current evidence, it has been stated that CGRP does not appear to 
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have a significant role in the regulation of normal blood pressure in humans 
(598).  
Migraine 
Migraine is characterised by primary episodic headaches associated with 
nausea, phono- and photophobia. The pathophysiology appears to be a 
primary neuronal dysfunction and the previous theory of vasodilation causing 
the headache and vasoconstriction causing the aura is no longer accepted 
(658-661). Cortical-spreading depolarisation, the self-propagating wave of 
neuronal depolarisation that spreads across the cortex discussed in Chapter 
3, is theorised to cause the aura, alter BBB permeability and activate trigeminal 
nerve afferents (516, 662). It is the activation of trigeminal nerve afferents 
which is thought to cause inflammatory changes in the meninges causing the 
pain associated with migraines (663). The trigeminovascular system, which 
has sensory neurons innervating cerebral vessels, is thought to play a large 
role in the pathophysiology of migraine. Upper cervical nerve roots converge 
with the trigeminal nerve explaining why migraine headaches often include the 
anterior and posterior areas of the head and neck (664, 665). The trigeminal 
ganglion releases vasoactive neuropeptides on stimulation, such as substance 
P, neurokinin A and CGRP, the latter of which is said to be the main mediator 
of trigeminal pain (666, 667). CGRP is released in cortical tissue during CSD 
depolarisation and three different CGRP receptor antagonists have had a 
dose-dependent inhibitory effect on CSD, suggesting that CGRP has a role in 
this phenomenon (668). Furthermore, intravenous CGRP has been shown to 
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induce migraine symptoms in patients known to have migraines (669, 670). As 
such, CGRP antagonists may be a useful treatment for migraine, although no 
treatment has reached the market. There have been at least 11 varieties of 
CGRP receptor antagonists developed with studies of oral, intranasal, 
subcutaneous, and intravenous administration and assessment of acute and 
prophylactic treatment  (598). An early CGRP receptor antagonist, 
Olcegepant, was shown to have no effect on haemodynamics and had a 
response to migraines that was comparable to available triptans in a small 
multicentre double-blind RCT (655, 656, 671-673). Unfortunately, due to the 
high molecular weight of the CGRP-antagonist, it was only able to be 
administered intravenously. An oral variant, telcagepant, was subsequently 
developed, showing good oral bioavailability and good efficacy in Phase II 
trials (620, 674). Telcagepant underwent multiple phase III trials, including a 
multi-centre RCT of 1,380 patients randomised to telcagepant, placebo or 
zolmitriptan. Telcagepant was found to be as effective as zolmitriptan with 
fewer adverse events (620). A subsequent trial of telcagepant as a 
prophylactic treatment of migraine was stopped early due to two patients 
developing elevations in serum transaminases (clinical trials NCT00797667). 
Merck have since stopped their development of telcagepant which appears to 
be due to the change in transaminases (675). There are several other oral 
variants of CGRP receptor antagonists still being developed and results of 
phase III trials are awaited but as yet there is no available CGRP antagonist 
or antibody available for the treatment of migraine (676, 677).    
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Subarachnoid Haemorrhage 
Early experimental models investigating CGRP as a treatment for cerebral 
vasospasm after SAH were in the late 1980s. The hypothesis for treatment 
was that CGRP would dilate constricted cerebral vessels and thus improve 
neurological outcomes following DCI. Unfortunately, most of the models were 
limited to assessing vessel diameter. A few included neurological outcome as 
a secondary measure (678). The basis for this research was not limited to 
CGRP’s potent microvascular vasodilatory properties. There is also an 
association with altered concentrations of CGRP after SAH. Experimental 
studies demonstrate that innervation of the cerebral circulation by CGRP-
immunoreactive fibres is decreased after SAH which is not present in controls 
(based on estimations of the number of fibres present) (462, 464, 679, 680). 
Nozaki et al., in a single-injection model of SAH in dogs, assessed CGRP 
immunoreactivity in perivascular nerve fibres of pial arteries. Suppression of 
CGRP in cerebrovascular nerve fibres was first detected 
immunohistochemically on the third day after SAH, peaked on days seven-to-
14 and recovered to normal by day 42 (464). It has been argued that the 
reduction in CGRP may be due to release of the peptide from perivascular 
nerve terminals caused by subarachnoid blood. The dilatory effect of CGRP 
on the basilar artery has also been observed to be greater in those animals 
with SAH as compared with controls (679). Observational studies of the MCA 
in posthumous humans have shown that patients dying from SAH had 
significantly lower levels of CGRP in these arteries when compared with 
arteries from patients who had died of myocardial infarction (681). In 1995 Juul 
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et al. measured concentrations of CGRP in plasma from the external jugular 
vein (n=20) and CSF (n=14) of patients with SAH who had their aneurysm 
clipped and received nimodipine. They compared these values with healthy 
controls (n=14 for external jugular vein, n=12 for CSF) and found that serum 
CGRP concentrations were significantly higher in the SAH group (30 ± 1 
versus 19 ± 5 pmol/l, mean ± SEM, p<0.05). In contrast, the CSF concentration 
of CGRP was detectable in the SAH but undetectable in the controls (463). 
Endogenous CGRP appears to be released and subsequently depleted in 
response to cerebral vasoconstriction after SAH, suggesting that exogenous 
CGRP may be beneficial in managing DCI. There is some experimental 
evidence that CGRP may have another protective role separate from 
vasodilation. One animal study in rats (n=144) utilised a middle artery 
occlusion model to assess the effect of CGRP on neurobehavioural scores 
(measured on a five-point scale) and infarction size (observed by 2,3,5-
triphenyltetrazolium chloride staining). The study demonstrated not only a 
reduction in infarction range but also an improvement in neurological function 
after CGRP administration. This effect was blocked by the CGRP antagonist 
CGRP8-37 (682). The concentration of CGRP in neurons of brain tissue is 
increased following cerebral ischaemia and CGRP appears to have a 
protective function in neuronal cells (683, 684). The mechanism of action of 
CGRP in this role is unclear but appears to be related to mitogen-activated 
protein kinase (a serine/threonine/tyrosine-specific protein kinase that 
regulates cell functions) signal transduction pathways including the p38 and c-
Jun N-terminal kinase pathways (685, 686). Specifically, Yang et al. suggest 
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that a reduction in c-Jun N-terminal kinase and p38 phosphorylation, and an 
increase in extracellular signal-related protein kinase phosphorylation 
(detected by western blotting), were responsible for the improved 
neurobehavioral scores and decreased infarct range seen in their study (682). 
Systematic Review and Meta-Analysis of Animal 
Studies  
The following systematic review and meta-analysis of animal data comes from 
a collaboration between myself, Dr Caroline Begg, Professor Peter Andrews 
and Professor Malcolm Macleod (see acknowledgements). An open-access 
protocol for the review is available online (Appendix 2) (678). The manuscript 
is under review. 
At the time of writing there are 21 pre-clinical studies investigating the effect of 
αCGRP on cerebral arteries after SAH (599, 678). All 21 of these studies 
appear to demonstrate an increase in cerebral vessel size or amelioration of 
vessel constriction after administration of CGRP. A review of CGRP and its 
potential role in the treatment of DCI has been published but there has been 
no systematic review or meta-analysis of the effect of CGRP on cerebral vessel 
diameter or neurobehavioral outcomes in animals or humans (599). 
Systematic review provides a less biased assessment of findings from animal 
studies (687). This approach was used to summarise data from publications 
reporting in vivo animal studies that investigated the effects of αCGRP after 
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experimental SAH. The study protocol has been published elsewhere but is 
briefly outlined below (Appendix 2) (678). 
Search Methods and Study Selection 
In January 2015, two electronic databases (MEDLINE via PubMed Central, 
and EMBASE via OvidSP) were searched using the key words “alpha 
calcitonin gene-related peptide”, “αCGRP” and “subarachnoid haemorrhage” 
in combination using the Boolean operator [AND]. The search was restricted 
to “other animals”. Two investigators independently screened the abstracts 
and titles to identify those that met our inclusion criteria (Flynn and Begg). Any 
differences were resolved by discussion with a third reviewer (Andrews). We 
included in vivo animal studies describing the effect of αCGRP in animal 
models of SAH where outcome was reported as a change in arterial diameter 
and the articles were published in English.  We also included studies which 
examined in vivo SAH and αCGRP administration with post-mortem in vitro 
measurements of artery diameter.  
Data Extraction 
Two investigators (Flynn and Begg) independently extracted data relating to 
species of animal and weight; method of inducing SAH (single injection, double 
injection or clot placement); whether the basilar artery (BA), MCA, anterior 
cerebral artery (ACA) or internal carotid artery (ICA) were measured; the 
method of measurement (angiography, in vitro measurement or direct in vivo 
visualisation); anaesthetic agent used; dose of αCGRP and time of 
administration from SAH; reporting and method of randomisation; reporting 
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and method of blinding; animal welfare guideline statement; statement of 
sample size calculation; whether there was a statement of potential conflicts 
of interest and the use of animals with comorbidities. Study quality was 
assessed using the CAMARADES 10-item quality checklist (688). One point 
was awarded for each of: (1) publication in a peer-reviewed journal, (2) 
statement of control temperature, (3) randomised intervention allocation, (4) 
intervention allocation concealment, (5) blinded assessment of outcome, (6) 
avoidance of anaesthetics with marked intrinsic neuroprotective properties 
(ketamine), (7) statement of a priori sample size collection, (8) statement of 
compliance with regulatory requirements, (9) conflicts of interest statement, 
and (10) use of animals with comorbidities.  
 
Figure 23: Flowchart of Study Selection. SAH, subarachnoid haemorrhage; 
αCGRP, alpha calcitonin gene-related peptide.  
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 4: Calcitonin Gene-Related Peptide 133 
For meta-analysis, we recorded arterial diameter for intervention and control 
groups as a percentage from baseline (mean values and a measure of 
variance with the number of animals per group). Where a single control group 
was used for multiple treatment groups, we adjusted the size of the control 
group entered into the meta-analysis by dividing the size of the control group 
by the number of treatment groups served (689).  
Two of the nine publications did not report quantitative data in their text, only 
presenting graphed data (690, 691). Mean values with standard error of the 
mean (SEM) were estimated from the graphs of these studies using Universal 
Desktop Ruler for Windows (AVPSoft).  
Statistical Analysis 
Meta-analysis was performed using normalised mean difference with a 
random effects model (689). Univariate meta-regression was used to explore 
associations of animal species, sex, strain and quality issues. Meta-regression 
of transformed data using a three-component cubic spline was used to assess 
dose-response. Where multiple experiments were performed in the same 
publication, these were treated as separate studies (689). Results are 
presented as the mean ± standard error unless otherwise stated. Statistical 
analysis was performed with STATA 14 (Statacorp LP). 
Results 
We identified 142 publications from our initial search. After combining 
MEDLINE and EMBASE results and deleting duplicates, 57 publications 
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remained. Titles and abstracts were then screened for eligibility by two authors 
(Flynn and Begg) resulting in 21 publications investigating αCGRP and 
cerebral vessel narrowing (690-710).  After examining the full papers of these 
abstracts and removing those with in vitro αCGRP administration (n=12) and 
those that lacked SAH models, nine eligible publications remained (690-692, 
696, 697, 701, 708-710). The nine publications included in the review were 
published between 1989 and 2013 (median year 1996). From the nine 
publications, 20 experiments were included in meta-analysis (Fig.19).  
Characteristics of Studies 
The total number of animals examined was 193 and the median number of 
animals used per experiment was nine (interquartile range (IQR) six-to-14). 
The median number of study quality checklist items scored was four (IQR two-
to-six). No studies used animals with comorbidities; reported a statement of 
potential conflicts of interest or stated an a priori sample size calculation. 40% 
of studies reported control of body temperature. 20% described a randomised 
treatment allocation and 45% reported allocation concealment. Half of the 
experiments used a blinded assessment of outcome and half used an 
anaesthetic agent other than ketamine. All studies were published in peer 
reviewed journals and 70% reported compliance with local animal welfare 
guidelines. In 16/20 (80%) of the experiments, SAH was induced by 
autologous blood injection by either single or double injection methods, the 
remainder were induced with blood clot placement. Further study 
characteristics are presented in Tables 8 and 9.
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Table 8. Study characteristics 
Publications, no. 9 
Experiments, no. 20 
Animals, no. 193 
Median number of animals per experiment, median 
(IQR) 9 (6 to 14) 
   
Species, no. (%) of experiments   
   Rabbit 12 (60) 
   Dog 5 (25) 
   Rat 2 (10) 
   Monkey 1 (5) 
    
SAH induction, no. (%) of experiments   
   Autologous single injection method 12 (60) 
   Autologous double injection method 7 (35) 
   Autologous blood clot placement 1 (5) 
    
Vessel examined  
   Basilar artery 19 (95) 
   MCA, ICA and ACA 1 (5) 
   
Method of visualising vessel diameter   
   Angiography 16 (80) 
   In-vitro sections 3 (15) 
   Direct in-vivo visualisation 1 (5) 
  
Preparation of αCGRP  
   CGRP in solution  13 (65) 
   Gene transfer 4 (20) 
   Slow-release tablet 3 (15) 
  
Timing of αCGRP administration   
   Before SAH 3 (15) 
   < 1 day after SAH 1 (5) 
   1 – 3 days after SAH 16 (80) 
   
Time of outcome assessment after administration of 
CGRP  
   < 1 hour 4 (20) 
   1-3 days   12 (60) 
   5-7 days 4 (20) 
   
Study quality (median (IQR)) 4 (2-6) 
Table 8: CGRP Study Characteristics. IQR, interquartile range; n, number; SAH, 
subarachnoid haemorrhage; CGRP, alpha calcitonin gene-related peptide 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 4: Calcitonin Gene-Related Peptide 136 
 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 4: Calcitonin Gene-Related Peptide 137 
Treatment Effect 
All 21 publications reporting in-vivo and in-vitro experiments demonstrated a 
dilation of cerebral arteries after αCGRP administration. Of the 20 eligible in 
vivo experiments included in meta-analysis, there was a 40.8 ± 8.2% increase 
in cerebral vessel diameter in the αCGRP group compared with controls 
(p<0.0005, 95% CI 23.7 to 57.9, I2 96% Figure 2). There was also a significant 
dose-response to αCGRP in the ten experiments which administered a single 
dose into the cerebroventricular system (Fig 22).  
 
Figure 24: Change in Cerebral Vessel Diameter per Experiment. Experiments 
ranked by effect of alpha calcitonin gene-related peptide on change in vessel 
diameter. Error bars = 95% CI for individual estimates. The horizontal area 
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represents the 95% interval for the global estimate. 
 
Figure 25: Dose-Response Relationship. Dose A = 10-12 mol/kg of alpha 
calcitonin gene-related peptide (αCGRP), 3.1 ± 14.2%. Dose B = 10-11 mol/kg 
αCGRP, 32 ± 7.8%. Dose C = 10-10 mol/kg αCGRP, 67 ± 9.7%. The error 
bars represent standard error whilst the shaded grey area represents the 
standard error of the global estimate. Differences were statistically significant 
(P <0.05). 
 
The effect size tended to be lower in studies that reported randomisation, 
blinded assessment of outcome, blinded induction of SAH and use of an 
anaesthetic agent without intrinsic neuroprotective properties. However, none 
of these observations reached statistical significance. There was also a trend 
towards lower effect size in studies reporting compliance with more quality 
checklist items. This ranged from 57.3 ± 10.7% (p <0.05) from experiments 
with a quality score of one, to 28.1 ± 9.1% (p<0.01) from experiments with a 
quality score of six (Fig.22).   
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Figure 26: Study Quality Score versus Reported Efficacy: Relationship 
between quality score of studies and estimated efficacy of alpha calcitonin 
gene-related peptide at dilating cerebral arteries. Error bars represent 
standard error whilst the grey area represents the global estimate. 
Differences were not statistically significant (P >0.05).  
 
Neurological Outcome and Adverse Effects 
Four studies reported an effect on neurological outcome after αCGRP 
administration (692, 696, 697, 708). The standardised mean difference was 
1.31 (95% CI -0.49 to 3.12, Q 40.5, n=65 animals) in favour of αCGRP. Tian 
et al. reported neurological outcome based on a comprehensive scoring 
system (0-48, 0 = best score, 48 = worst score) measured three times daily 
and based upon the assessment of four functions which has been used 
elsewhere (708, 711). The mean neurological outcome on day seven for the 
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αCGRP group was significantly better than for the control group (10.67 ± 1.16 
versus 22.33 ± 2.08 respectively, p < 0.001). Imaizumi et al. assessed 
neurological outcome based on food intake and a slope tolerance test on days 
two, three and four post-SAH (696). No significant difference was found 
between the αCGRP and control groups for either assessment. Inoue et al. 
reported no significant difference in food intake, observable hemiparesis, 
consciousness disturbance or response to stimulation between the αCGRP 
and control groups (697). Ahmad et al. reported neurological outcome from 
grade I (normal) to grade III (unable to stand and presented abnormal posture) 
in addition to performing a slope tolerance test. Two rabbits in the control group 
were grade II (slow in response but able to walk) and III respectively, all other 
rabbits were normal and there was no statistical difference between the groups 
in the slope tolerance test. In all studies where it was measured, food intake 
was decreased after SAH but there was no significant difference between the 
αCGRP and control groups. Inoue et al. noted a significant decrease in weight 
in their αCGRP group compared with the control group on day 14, but noted 
no other adverse effects and were unable to explain this change in weight. 
Eight publications reported physiological parameters which might be 
associated with adverse events. There was no significant difference in 
systemic arterial pressures or arterial blood gas results between the aCGRP 
or control groups. Imaizumi et al. observed that all animals tended to have an 
increased respiratory rate for approximately six hours after intrathecal injection 
of αCGRP or vehicle and demonstrated a high blood pH and low PaCO2, but 
no difference between the groups (696). Both Nozaki and Toshima et al. 
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demonstrated a decrease in MAP when αCGRP was administered 
intravenously, which was not seen by intrathecal administration (709, 712). 
The study by Toshima et al. demonstrated a marked decrease in MAP 
following intravenous administration of αCGRP that was not seen with 
intracisternal administration (~70 mmHg versus ~40 mmHg at 30 minutes after 
αCGRP administration).  
Other effects of αCGRP were also reported. Sun et al. observed a reduction in 
cortical cell death, decreased endothelial death and upregulated vascular 
endothelial growth factor with evidence of angiogenesis after αCGRP 
administration (691).  
Discussion of Animal Data 
Intrathecal administration of αCGRP dilates cerebral arteries in a dose-
dependent manner in animal models and appears to be associated with fewer 
systemic effects than intravenous administration, chiefly the avoidance of 
hypotension. Furthermore, the effect of αCGRP on cerebral arteries appears 
to be more pronounced in the context of SAH, possibly because sensitivity of 
the artery to αCGRP may be greater owing to the depletion of endogenous 
αCGRP after SAH (704, 713). Alternatively, it may be that these arteries have 
a higher capacity for dilation after being constricted following SAH. In addition 
to the decreased systemic side effects seen by intrathecal administration, this 
route exposes αCGRP to the abluminal side of the blood vessel wall in a way 
more akin to its endogenous action. αCGRP is able to dilate cerebral arteries 
independently of endothelial cells, which are morphologically damaged after 
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SAH and so avoids a problem associated with endothelin antagonists (714, 
715).  
Laban et al., in their systematic review of experimental SAH studies of ERAs, 
demonstrated a 54% improvement in vessel diameter after administration of 
ERAs, but no significant effect on mortality, and no studies reported effects on 
functional outcomes (571). The authors concluded that there was no 
neurobehavioural data to support progression from pre-clinical to clinical trials 
for ERAs. In contrast to ERAs, some of the experiments in this review did 
examine neurobehavioural scores. Whilst there is not a large amount of data, 
there is a positive signal consistent with a substantial effect. Similarly, there is 
some human data to support improved outcomes with CGRP after SAH which 
will be discussed in the following section (640, 716).  
Limitations of Studies 
There were no female-only experiments and most experiments in this review 
used the single haemorrhage model of SAH (60%). The other forms were 
single injection and clot placement. Animals rarely develop a vessel narrowing-
related ischaemic neurological deficit from any of these methods.  Megyesi et 
al. note that this is probably because animal brains have a plentiful collateral 
blood supply (717). Whilst this is probably irrelevant for measuring the effect 
of αCGRP on vessel diameter, it becomes more problematic when trying to 
assess neurological outcomes. Another translational problem arises from the 
times of administration of αCGRP and assessment of neurobehavioural 
outcomes. In humans, DCI is said to occur most commonly between days 
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three-to-ten and cerebral vessel narrowing is maximal between days six-to-ten 
after ictus (718). The experiments assessed in this review administered 
αCGRP before and up to three days after SAH and assessed the response 
within hours to one week after administration (Tables 8 and 9).  Megyesi et al. 
also note that the best model of vasospasm seems to be the primate model in 
which a blood clot is placed around a large cerebral vessel (717). Only one of 
the studies we analysed uses this model (719). More recently, Titova et al. in 
their systematic review, state that dog models of SAH are considered superior 
and that the ability of murine models to reflect human vasospasm is disputed 
(720). Finally, the median quality score of the studies was low (four) and an 
increased effect size was seen in studies with a lower quality score. This effect 
size may be expected to be lower with more high quality studies.    
Human Trials 
There have been three clinical trials of αCGRP administration in humans with 
SAH. All three of these trials have involved intravenous administration of 
αCGRP. To my knowledge, following a Medline search, there has been no 
intrathecal or intranasal delivery of CGRP in humans, although intranasal 
delivery of a CGRP-receptor antagonist may be investigated (721, 722).  
Johnston et al. (1990) 
In a multicentre RCT, Johnston et al. administered intravenous αCGRP to 15 
patients (11 women, four men; mean age of 48 years; range 22-70) with 
neurological deficits after surgical clipping of ruptured aSAH (716). Patients 
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received αCGRP and placebo 24 hours apart in random order. 0.035 µg/min 
of αCGRP was administered and the infusion rate was doubled every ten 
minutes until either a clinical response was observed or the maximum dose 
(1.15 µg/min) was reached at one hour. If no side effects were observed, the 
maximum dose was continued for 20 minutes. Neurological deficits, as 
measured by the modified Glasgow Coma Scale, improved in nine patients 
with no adverse effects: one improved on both treatments, eight improved on 
αCGRP but not placebo and one improved on placebo but not αCGRP. Thus, 
of the nine patients who showed a treatment preference, eight favoured 
αCGRP.  
Systolic BP decreased by 35.7 mmHg during αCGRP infusion (p < 0.05 
compared with placebo; 95% CI 9.2 to 75.8 mmHg) and MAP decreased by 
21.3 mmHg (p < 0.01 compared with placebo; 95% CI 9.8 to 46.6 mmHg).  
Cerebral arterial vessel narrowing prior to administration of αCGRP was not 
measured, nor was the effect of αCGRP on cerebral diameter/flow velocities. 
However, the researchers excluded hydrocephalus, haematoma and those 
with additional aneurysms from their inclusion criteria and the patients 
demonstrated neurological deficits post-surgery consistent with DCI (716).   
The European CGRP in SAH Trial (1992) 
The largest of the three trials was the European CGRP in SAH Trial which 
examined 117 patients in a multicentre RCT. Patients with a post-operative 
focal neurological deficit or decrease in GCS >1 not attributable to a non-
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ischaemic cause on CT were randomised to intravenous CGRP or standard 
care. 62 patients were randomised to an infusion of 0.6 µg/min of αCGRP for 
a minimum of four hours to a maximum of 10 days in those with a satisfactory 
neurological response (mean age 49.1, 63% female). If the patients developed 
hypotension, the infusion rate was decreased to 0.45 µg/min, then 0.3 µg/min 
if there was no improvement. The remaining 55 patients were assigned to 
standard care (mean age 48.4, 62% female). Outcome, measured on the 
Glasgow outcome score, at three months was good in 66% of those treated 
with αCGRP and 60% in the controls; the relative risk of a poor outcome in 
αCGRP treated patients was 0.88 (95% confidence interval 0.60 to 1.28).  
The European CGRP in SAH Trial was limited by the large number of patients 
who had αCGRP discontinued. Hypotension was a common side effect of 
αCGRP. 41 patients in the CGRP group discontinued treatment. This was due 
to hypotension (19), lack of improvement at four hours (17) or later (four), or at 
the patient’s request (one). The authors commented that “systemic 
intravenous infusion of αCGRP is not the ideal route” and that “subarachnoid 
instillation may be more rational, since the peptide is normally found on the 
adventitial rather than the endothelial side of the cerebral vessel wall” (640). 
Juul et al. (1994) 
In a non-randomised study, Juul et al. studied five patients (three males, two 
females; median age 44, range 40-77 years) after aSAH and surgical clipping 
of the aneurysm. Patients had Doppler sonography evidence of cerebral 
vasoconstriction in the postoperative period, as measured by haemodynamic 
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index (MCA velocity compared with internal carotid artery velocity on 
ultrasound) (723).  Synthetic human αCGRP (CB 003, Celltech, UK) in 0.9% 
sodium chloride was infused at a rate of 0.6 µg/min. Patients were monitored 
with Doppler sonography before infusion; immediately after the start of the 
infusion; at regular intervals during the infusion; and one hour after stopping 
the infusion. Infusion times varied between 1.5 and 52 hours depending on 
clinical response. Patients demonstrating a larger change in haemodynamic 
index had shorter infusion times. A significant reduction was found in the 
haemodynamic index during the αCGRP infusion (P < 0.05) when compared 
with before infusion, suggesting amelioration of vasoconstriction. There was 
no change in the haemodynamic index on the contralateral side. No clinically 
or statistically significant changes were observed in BP or conscious level 
during the αCGRP infusion. A significant increase in heart rate was observed 
during the infusion as compared to before and after infusion (90 ± 4 (SEM) vs, 
76 ± 5 beats per minute, P <0.05). Cardiac ultrasound data showed a mean 
cardiac output increase of 1.9 litres/min, and a mean decrease in total 
peripheral resistance of 538 dynes s/cm5 consistent with systematic 
vasodilation.  
This study was performed in a single centre with a small sample size, patients 
were not randomised and investigators not blinded and there is no clear 
indication from the publication why different times were used to stop the 
infusion. Because of this the total dose of αCGRP cannot be calculated.  
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Summary 
Intrathecal αCGRP dilates cerebral arteries in a dose-dependent manner in 
animal models whilst showing a positive (but not statistically significant) signal 
towards improved neurological outcomes. This route also appears to be 
associated with fewer systemic effects than intravenous administration. In 
human trials, a non-statistically significant improvement in outcome for the 
CGRP group was seen in the European CGRP in SAH trial and Johnston et 
al. observed a statistically significant treatment preference for CGRP versus 
placebo in their small study (640, 716). All three human trials demonstrated 
systemic effects of intravenous infusion. αCGRP receptors of the perivascular 
nerve endings are located on the abluminal side (adventitia-media) of the 
arterial walls. The abluminal sides of the cerebral arteries lie in the 
subarachnoid space and are accessible via CSF administration. Moreover, 
αCGRP has a high molecular weight with poor penetration through the BBB 
(599). Systemic administration of αCGRP to treat cerebral vasospasm possibly 
did not result in adequate therapeutic concentrations in the cerebral 
subarachnoid space. It may be that the observed systemic effects 
(hypotension, tachycardia and facial flushing) occurred due to a high 
intravenous dose being required to achieve adequate CSF concentrations. It 
is my belief that repurposing αCGRP to CSF administration will reduce the 
volume of distribution and circumvent the first-pass effect, thereby reducing 
the effective dose and side-effects. Lumbar spinal administration of drugs 
results in greater variation of drug concentration in the cerebral subarachnoid 
space. Peak concentrations are achieved within minutes but there are some 
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data suggesting that rarely this may occur as late as three-to-four hours after 
administration and require a higher volume of study agent (724-726). 
Therefore, administering the peptide via an EVD/access device, which would 
be otherwise clinically indicated, is preferred to the lumbar spinal route. One 
of the challenges of translating animal data and methods to human trials is the 
invasive nature of the intrathecal route. Previous human trials with intravenous 
administration of αCGRP have used a continuous infusion owing to the short 
half-life of αCGPR in the systemic circulation (approximately seven to ten 
minutes) (625). However, when administered into the cerebrospinal fluid as a 
single dose in animal models, the effects of αCGRP have continued for four to 
six hours (690, 696). Therefore, a continuous infusion of αCGRP into the CSF 
may not be necessary. Furthermore, Toyoda and Sun et al. demonstrate novel 
approaches to administering αCGRP, one via gene-transfer and the other by 
intranasal delivery (691, 710). If intraventricular administration of αCGRP in 
humans ameliorates cerebral vessel narrowing and avoids the adverse effects 
seen with intravenous delivery, both gene-transfer and intranasal delivery offer 
potential alternatives without the difficulties associated with an intraventricular 
drain. However, the next step should be a dose-tolerability study of αCGRP 
administered into the cerebral ventricles.  
Cerebrospinal Fluid Concentrations of CGRP  
None of the human trials described above measured CSF concentrations of 
αCGRP or cerebral artery size before, during or after administration of αCGRP. 
Therefore, we cannot accurately determine dose-tolerability effects or the 
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efficacy of the peptide from these trials. There are four previous studies that 
examined the concentration of CGRP in the CSF of patients with SAH (463, 
727-729).  
The first of these is a 1991 study published in Chinese and has a translated 
abstract briefly outlining the concentrations of CGRP in the CSF of patients 
with cerebral vascular disease as measured by radioimmoassay. 
Unfortunately, a full translation was not available. As such, there is no 
information about the study participants, the timing of CSF analysis or the 
assay used. The authors report that αCGRP concentration in the CSF of 
patients with ischaemic cerebrovascular disease was 152 ± 60 pg/ml (mean ± 
no indication whether this represents SEM or SD), not significantly different 
from their control value of 45 ± 9 pg/ml. In patients with haemorrhagic 
cerebrovascular disease the concentration was 3,965 ± 680 pg/ml, significantly 
higher than in the ischaemic and control group (728).  
Juul et al. (1995) observed significantly increased concentrations of αCGRP in 
patients with SAH but no correlation with cerebral haemodynamic changes 
(463). 34 patients were enrolled to this single-centre study, 14 for CSF 
sampling and 20 for external jugular venous blood sampling. 30 of the patients 
had surgical clipping of their aneurysm and the remaining four were not 
operated on. 14 healthy volunteers had blood sampling and 12 separate 
volunteers had lumbar CSF sampling. Doppler ultrasound was performed at 
one-to-three-day intervals to measure flow velocity at the MCA and ICA. CGRP 
was detected in low amounts in the CSF of SAH patients (4 ± 2 pmol/l, mean 
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± SEM) but was not detected in the CSF of controls. The highest level of CGRP 
was detected in a patient who had severe vasospasm and later died (14 
pmol/l). The authors state that the highest venous CGRP levels were found in 
patients with the highest velocity index values on Doppler (used as a marker 
for vasospasm).  
Schebesch et al. (2013) collected daily CSF from day one to day ten after onset 
of SAH in 12 patients with ventricular drains (727). All patients had an early 
CT, DSA and daily transcranial Doppler, targeting the MCA and ACA (cerebral 
vasospasm was considered present with a flow velocity >160 cm/s). 12 
consecutive patients with spontaneous SAH were included (seven female, five 
male; mean age 49.3 years; median GCS 12). Five patients received surgical 
clipping whilst seven underwent coiling. Vasospasm, as identified by 
transcranial Doppler, was present in seven patients, and six patients 
developed an ischaemic stroke. 29 spinal CSF samples, obtained by lumbar 
puncture before spinal anaesthesia administration prior to orthopaedic and 
urological procedures, acted as a control group (15 female, 14 male; mean 
age 52.8 years, range 19-81 years). CSF samples were centrifuged for ten 
minutes at 2000g immediately after sampling and supernatants were stored at 
-80°C prior to enzyme immunoassay. Levels of αCGRP were significantly 
higher in the SAH group than the control group. The authors note that, in 
contrast to Juul et al., they could readily detect a baseline level of αCGRP in 
their control group and attribute this to the lower sensitivity of the 
radioimmunoassay used. Furthermore, CGRP levels were significantly higher 
from days one-to-four in patients who did not develop cerebral vasospasm and 
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patients without subsequent cerebral ischaemia. The authors did not present 
values of CGRP in their publication, only presenting a graph. Universal 
Desktop Ruler for Windows (AVPSoft) has been used to estimate values from 
the presented graph. Based on these estimates the mean value of CGRP for 
days one-to-ten, for patients with and without vasospasm was 0.39 ± 0.15 
ng/ml (range 0.1 – 0.84 ng/ml; the authors do not state whether they use SD 
or SE). The control value was 0.1 ng/ml (no deviation given).  
A further study by Schebesch et al. (2014) assessed the concentration of 
CGRP in plasma after SAH (729). 33 consecutive patients with SAH (Fisher 
Grade III or IV) had serum samples taken daily from day one-to-ten for CGRP 
analysis. Patients had DSA and Transcranial Doppler (cerebral vasospasm 
was considered present with a flow velocity >150 cm/s). Plasma CGRP levels 
appeared significantly higher in patients with anterior circulation aneurysms (p 
<0.001), and higher levels of CGRP were observed in patients coiled as 
opposed to untreated or surgically treated patients (p <0.001). Furthermore, 
higher levels of CGRP were found in patients with ischaemia as compared with 
those without ischaemia (p 0.038). The authors note that the concentration of 
CGRP in serum correlated with the anatomical location of the ruptured 
aneurysm and suspect that this could be caused by disruption of nerve fibres 
at the site of the ruptured aneurysm. It is also argued that the higher levels of 
serum CGRP in the coiled group could be due to mechanical manipulation of 
the aneurysm-bearing artery leading to excessive CGRP release. The authors 
go on to state that CSF CGRP levels were lower in controls than in patients 
with SAH (463, 727). On days one-to-four after SAH, CGRP levels in the CSF 
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were significantly lower in the vasospasm group than SAH patients without 
evidence of vasospasm. In the serum, higher levels of CGRP were correlated 
with a higher rate of ischaemia.  
The studies report values with pg/ml, pmol/l and ng/ml. For comparison, the 
amount of CGRP in each study has been converted to nanograms (Table 10).  
Concentration of CGRP in the CSF of patients with SAH versus controls 
Publication Wang et al (1991) Juul et al (1995) Schebesch et al (2013) 
Control Group (pu) 45 ± 9 (pg/ml) Undetectable 0.1 (ng/ml) 
Ischaemia Group (pu) 152 ± 60 (pg/ml) - - 
SAH Group (pu) 3965 ± 680 (pg/ml) 4 ± 2 (pmol/l) * 0.39 ± 0.15 (ng/ml) † 
Control Group (ng) 6.75 ± 1.35 Undetectable 15 
SAH Group (ng) 595 ± 102 2.27 ± 1.14 58.7 ± 22.4 
Highest recorded value (ng) 697 7.96 * 126 
 
Table 9: CSF Concentrations of CGRP in SAH Patients: Outline of results from 
three publications reporting levels of CGRP in CSF of controls and patients 
with subarachnoid haemorrhage. Publication units (pu) have been converted 
to nanograms (ng) for comparison. SAH: subarachnoid haemorrhage; CGRP: 
calcitonin gene-related peptide; CSF: cerebrospinal fluid. * mean ± SEM. † 
mean values estimated from graph in publication using Universal Desktop 
Ruler for Windows (AVPSoft); the measure of variance was not defined in this 
study. A CSF volume of 150mls and 3789.36 for the atomic weight of CGRP 
have been used for conversion.   
Due to the small number of samples and studies reporting the CSF 
concentration of CGRP in patients with SAH I analysed CSF samples in 
Edinburgh. I anticipated a concentration between undetectable and 15 ng in 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Chapter 4: Calcitonin Gene-Related Peptide 153 
the control samples and between 1.13 and 697 ng in the positive samples 
based on the above data (Table 10). This data could then be used for de-
risking a proposed exogenous dose of CGRP. Furthermore, if the results were 
as expected, we would have confirmation that this method of analysis is 
suitable for use in a toxicity study.  
In response to my PhD viva in September 2017 I have added a sample size 
estimation for the following CSF study. The question I am asking is ‘how many 
CSF samples do I need to estimate the change in CSF concentrations of 
CGRP in patients after a subarachnoid haemorrhage with an α value of 0.05 
and a β value of 0.20’ (730). I have used Minitab to determine the sample size 
for a two-sample t-test, assuming the data produced is normally distributed. I 
have used data from Schebesch et al. to estimate this because it presents a 
control value and the difference between the control value and SAH value is 
smaller than that from the Wang et al. paper (727, 728). Therefore, it should 
provide a conservative estimate (i.e. larger sample size) than using the Wang 
et al. data. The calculation was based upon a standard deviation of 22.4ng. A 
95% confidence interval and a minimum difference of 20ng were used in the 
calculation. The resulting estimated required sample size is 21 for each group 
(total sample size 42). The mean difference in the Schebesch et al. paper was 
43.7ng. Using this as a minimum difference gives an estimated sample size of 
6 for each group (12 in total). Given that the mean difference between the 
control and SAH groups in the Wang et al. paper was 588ng, I think using 20ng 
and a sample size of 42 is very conservative (727, 728).   
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Retrospective Analysis of CSF Concentrations of 
CGRP in Humans after SAH 
Between September 2015 and August 2016, I retrospectively analysed 
diagnostic CSF samples prospectively collected from patients being 
investigated for aSAH at the Western General Hospital and Royal Infirmary of 
Edinburgh. This was arranged with NHS Lothian BioResource/Tissue 
Governance (Research Ethics Council reference: 13/ES/0126. Sample 
request reference: SR526). This route of obtaining samples for analysis was 
chosen due to time constraints and ease of access to samples without the 
need for a complex trial protocol and a comprehensive research ethics 
application and approval. The limitation to this form of study is that I have no 
knowledge of patient identifiable information and am unable to access patient 
records. Clinical information (but not patient identifiable information) has been 
provided by NHS Lothian upon request.   
Methods 
CSF samples were obtained by LP and stored at -20̊C in NHS laboratories for 
up to six months. LP was undertaken as a diagnostic procedure in patients 
with suspected aSAH as part of routine clinical practice. The samples were 
allocated for research by the Western General Hospital and Edinburgh Royal 
Infirmary laboratories as they became available to laboratory staff.  
Inclusion Criteria 
• Males or females aged over 18 years; 
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• CSF samples taken as a diagnostic procedure in patients with 
suspected or identified aSAH. 
Exclusion Criteria 
• Intracranial pathology other than aSAH; 
• Any severe or unstable concomitant condition or disease (e.g. known 
neurological deficit, cancer, haematological disease, coronary disease 
or psychiatric disorder) that is likely to affect the CGRP concentration in 
control patients. 
CSF samples were stored for analysis between September 2015 and February 
2016. CSF samples were analysed by enzyme immunoassay (Bertin Pharma 
Human CGRP Enzyme Immunoassay (EIA) kit, bought through Bioquote UK) 
in April 2016. Analysis was performed by Dr Forbes Howie at the Queen’s 
Medical Research Institute, Edinburgh.  
Results 
22 CSF samples were analysed by EIA. 12 samples were positive for 
xanthochromia, 10 were negative. Of the 12 positive samples, none of the 
patients had positive CT imaging demonstrating SAH. αCGRP was not 
detected by EIA in any of the samples. 
Sample 
No. Xanthochromia Sex Age CGRP 
CT/CTA 
Result 
1 Positive M 74 Undetectable Negative 
2 Positive M 53 Undetectable Negative 
3 Positive F 48 Undetectable Negative 
4 Positive F 35 Undetectable Negative 
5 Positive M 79 Undetectable Negative 
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6 Positive M 57 Undetectable Negative 
7 Positive M 70 Undetectable Negative 
8 Positive F 44 Undetectable Negative 
9 Positive F 38 Undetectable Negative 
10 Positive F 31 Undetectable Negative 
11 Positive F 52 Undetectable Negative 
12 Positive F 67 Undetectable Negative 
13 Negative F 44 Undetectable Negative 
14 Negative M 59 Undetectable Negative 
15 Negative F 71 Undetectable Negative 
16 Negative F 63 Undetectable Negative 
17 Negative M 63 Undetectable Negative 
18 Negative F 68 Undetectable Negative 
19 Negative F 47 Undetectable Negative 
20 Negative F 33 Undetectable Negative 
21 Negative F 55 Undetectable Negative 
22 Negative M 52 Undetectable Negative 
Table 10: Study Demographics and Results. No., number; CGRP, calcium 




The assay kit states that “CSF may be assayed if diluted at 1:20 in EIA buffer”. 
From the above literature, we anticipated a value between undetectable and 
15 ng in the control samples and between 1.13 and 697 ng in the positive 
samples (463, 727, 728, 731). As such, the negative samples were diluted 1:5 
with buffer and the positive samples were diluted 1:5 and 1:25. The standard 
curve for the EIA kit was as expected (Fig.23) and the control value was 153 
pg/ml for a target value of 165 pg/ml. In contrast to previous studies, αCGRP 
was not detected in any of the samples.  
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Figure 27: Standard Curve for CGRP Kit. CGRP, calcitonin gene-related 
peptide.  
There are multiple unknowns associated with using samples from the 
BioResource in this study. Specific examples include: method of lumbar 
puncture; time for sample collection to storage; the number of times the sample 
was analysed prior to being placed in storage. The background history of the 
patients is unknown, including history of migraine, cluster headaches or 
depression (all of which have been associated with alterations in serum 
αCGRP concentrations (732-734). Potential reasons why CGRP was not 
detected in these samples include: 
1. CGRP is an unstable compound in CSF and due to the time of storage 
and time at temperatures higher than -20̊C the peptide denatured:  
After LP, CSF should be immediately transported for analysis as part of routine 
clinical care but I have no record of this. Furthermore, I do not know if the 
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sample was immediately frozen upon receipt and how long the sample was 
out of the freezer for initial laboratory analysis. The samples were 
subsequently transported from their initial laboratories to research laboratories 
in dry ice but were exposed to room temperature for a short time during 
transfer.  
2. Insensitive RIA kit: 
The RIA kit produced a control value (kit control, not CSF sample control) that 
was close to the target value and an expected standard curve. However, as 
Schebesch et al. suggest in their analysis of the 1995 Juul et al. study, it may 
be that failure to detect any CGRP was due to the sensitivity of the 
radioimmunoassay (463, 727). It seems prudent to use the same enzyme 
immunoassay as that used by Schebesh et al. for future analysis and 
comparison (727).  
3. The concentration of CGRP was below recordable levels: 
It is possible that the concentration of CGRP in the CSF was below detectable 
levels. I think this is unlikely given that there are multiple previous studies 
demonstrating detectable levels of CGRP in SAH patients and controls (463, 
727, 728, 732). None of the positive CSF samples were associated with 
positive CT imaging. It could be argued that this is expected, given that patients 
would not routinely receive an LP for diagnosis if they already had a positive 
CT. One might expect subsequent CTA demonstrating an aneurysm. Based 
on previous results of CSF concentrations of CGRP in controls, I expected EIA 
to detect CGRP even in those patients without pathology (463, 727, 728).  
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4. Incorrect analysis technique and inappropriate dilution. 
Dr Howie is an expert in peptide analysis with significant experience in this 
field. The choice of dilution was made in discussion with Dr Howie and seemed 
appropriate after reviewing previous evidence of concentrations (Table 10). It 
is possible that a flawed analysis technique led to these results, but seems 
unlikely.  
Although this study was not helpful in de-risking our proposed dose of 
exogenous CGRP, it did highlight the importance of performing a pilot study 
assessing CSF concentrations of CGRP. I recommend that a reproducible 
method of analysis must be successful before starting a Phase II trial. 
Evidence for this could come from patients who routinely receive ventricular 
access devices for hydrocephalus where CSF would otherwise be discarded. 
I would recommend control samples coming from routine diagnostic lumbar 
puncture as part of a prospective trial instead of using the BioResource. Such 
a study could be organised through the Edinburgh EMERGE research team in 
the ED and the medical receiving units at the Western General Hospital and 
Royal Infirmary of Edinburgh. An extra 1ml of CSF could be taken during 
routine LP. I recommend immediate storage of samples at -40̊C and using 
Phoenix Pharmaceuticals EIA Kit, Burlingame, CA, USA. Furthermore, I would 
recommend seeking ethical approval for patient identifiable information in 
future research to prevent limitation of clinical information.     
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Chapter 5: Protocol for a Dose-Finding and 
Tolerability Study of Intraventricular αCGRP 
Administration in Patients with aSAH  
 
The purpose of the systematic review and CSF concentration study presented 
in this thesis were to help develop a tolerability study investigating intrathecal 
administration of αCGRP. As part of that study, our research team also aimed 
to gather some dose-response data as evidence to support trial progression. 
An abridged version of the research protocol for this dose-toxicity study of 
exogenous CGRP administered into the cerebral ventricles, via ventricular 
access device or EVD, is included below. What is written here excludes 
introductory information already discussed in this thesis and regulatory 
information required in the formal protocol. The full trial protocol will be 
submitted to BioMed Central Trials. 
 
The protocol was the basis for an invited full submission to the Medical 
Research Council’s (MRC) Developmental Pathway Funding Scheme in 2016. 
The protocol was informed by the NHS Lothian’s Research and Development 
team, the First in Human committee in Edinburgh and the Medicines and 
Healthcare Products Regulatory Agency (MHRA, see Appendix 3 for MRC 
application).  
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Study Objectives 
The study objectives are to assess the dose tolerability response and the 
pharmacokinetics (plasma, CSF and urine) of αCGRP after CSF 
administration. This will provide information to design a therapeutic study of 
αCGRP given into the CSF for DCI after aSAH.  
 
Research Questions 
1. What is the dose-tolerability response for CSF αCGRP? 
2. What is the CSF, plasma and urine concentration and half-life of 
αCGRP after CSF administration? 
3. What is the dose-response for CSF αCGRP on cerebral vessels as 
measured by Doppler ultrasound and CT angiogram? 
Endpoints 
The primary endpoint is tolerability at each of the seven dose levels and we 
define tolerability by observing the following factors: 
1. Haemodynamic instability including hypotension and tachycardia; 
2. Reduction in GCS; 
3. Clinical evidence of a seizure; 
4. Death;  
5. Spontaneous hyperventilation;  
6. Facial flushing.  
Pharmacokinetic endpoints: 
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1. CSF, plasma and urine αGCRP concentrations obtained throughout the 
course of the study;  
2. Final dose administration. 
Study Design 
This is a clinical trial of an investigational medicinal product (CTIMP) to assess 
the pharmacokinetics and dose tolerability response of αCGRP after CSF 
administration using a three-plus-three traditional escalation rule, including 
seven increasing doses: 
 
1. Two doses below the level at which an effect is expected (on 
vasoconstricted cerebral arteries after aSAH);  
2. Three doses at the level an effect is expected; 
3. Two doses above the level an effect is expected. 
 
Blood, CSF and urine will be sampled at baseline and after drug administration 
(see ‘dosing and sampling’). 
 
The patients will be those admitted to Critical Care at the Western General 
Hospital, Edinburgh, due to a ruptured aneurysm, confirmed by DSA or CTA, 
that has been secured by endovascular coiling or surgical clipping. Patients 
enrolled into the study will have a clinically indicated EVD/ventricular access 
device which will be used for administration of αCGRP. Patients will be 
continually monitored in Critical Care. 
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Number of Patients Recruited 
The target recruitment rate is one to two patients per month. This is based 
upon recruiting a minimum of 21 and maximum of 42 patients within 18 
months. Feasibility studies were carried out at the Western General Hospital 
in 2011 and 2015. These demonstrated that three patients per month were 
eligible of whom two of these would have consented to be in the study. This 
finding was consistent between patients and relatives giving consent in the 
case that patients lacked capacity. Assuming a recruitment rate of two per 
month and allowing a week between each dose level for analysis and trial 
meetings, we anticipate that the dose escalation can be completed within 18 
months. 
 
Justification of Dosing Schedule  
The minimal anticipated biological effect level (MABEL) approach is taken in 
the absence of human data to allow determination of no observed adverse 
effect level (NOAEL). The best study to determine MABEL is Inoue et al. in 
monkeys (Macaca fascicularis) (719).  
 
Inoue et al. created a tablet from microspheres containing αCGRP (αCGRP, 
molecular weight 3790; Bachem, Feinchemikalien, Buben) by using an in-
water drying method through a water/oil/water emulsion before mechanically 
compressing the microspheres to form a tablet 2mm thick and 6mm in diameter 
(697). In Hartmann's solution, in vitro, there was no αCGRP release from the 
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tablet for the initial six days. During the next four days, there was a significant 
release of αCGRP; approximately 4mcg of αCGRP each day. Similarly, when 
the tablet was placed in the cisterna magna of rabbits, the maximal 
concentration of αCGRP in the CSF was seen on day six. 
The same team then produced experimental SAH in ten cynomolgus monkeys 
by placing a clot around the internal carotid artery bifurcation on day zero using 
the method of Espinosa et al (735). The ten monkeys were split into three 
groups. Five of the monkeys (αCGRP Group) received αCGRP tablets 
containing 400mcg of αCGRP which were placed in the CSF. Two of the 
monkeys (Placebo Group) received placebo tablets placed in the same 
position. The last three monkeys (SAH Group) received no intervention after 
their experimental SAH.   
 
The radioimmunoassay (RIA) analysis of the CSF for αCGRP concentration 
was performed before experimental SAH was induced and on day seven and 
14 for each animal in the three groups. The non-αCGRP SAH Group showed 
no detectable αCGRP in the CSF at any time point. In the αCGRP Group 6.5 
± 5.4 nmol/L (mean ± standard deviation, n = five) was detected in the CSF on 
day seven. It was otherwise undetectable.  
 
In the non-αCGRP groups (SAH + Placebo groups) arterial narrowing was 
present on day seven at the ICA, MCA and ACA, and was partially resolved 
by day 14. In the αCGRP group, arterial narrowing was significantly 
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ameliorated both at the MCA and ACA and on average (81.7, 81.1, and 75.7%, 
P < 0.05, 0.03, and 0.02, respectively).   
 
 
Table 11: Change in Cerebral Artery Diameter: Inoue et al. 1996 
 
Calculation of dosing schedule 
 
The concentration of αCGRP in the CSF of humans appears to be higher 
after SAH and ranges from 0.10 to 0.84 ng/ml (15-125 ng assuming a CSF 
volume of 150 mls in adults) (727). 
To achieve the minimum CSF concentration of 23 nanomoles/litre, that we 
predict will have biological effect, requires 3.45 nanomoles, assuming 
complete CSF distribution, or 0.575 nanomoles if retained within the lateral 
ventricle (unlikely to occur, but may reflect a peak concentration). The following 
information has been used to calculate the expected ‘no effect’ level of 10-13 
mol /kg CGRP: 
• The molecular mass of αCGRP is 3789.36g (~4000g)    
• 4000g of αCGRP = ~1 mole 
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• 4 mcg of αCGRP = ~1 nanomole 
• Macaca fascicularis have a CSF volume of 3ml/kg and weigh 4-8kg; 
CSF volume and body weight are approximately 10% of human values. 
• Study dosing was approximately 4 mcg/day (1 nanomole) to give very 
low levels, measurable at day seven of 6.6 ± 5.4 nanomoles/litre. 
• Prior studies from the same manuscript suggest that a minimum CSF 
concentration of 23 nanomoles/litre is the minimum effect level for 
αCGRP in CSF to cause vasodilation (26).  
• Humans have a CSF volume of approximately 150mls (or 2mls/kg) and 
we assume complete CSF distribution. 
• Therefore, the minimum effect level for αCGRP in CSF is found by 
150/1000 = 0.15. 
• 0.15 * 23 = 3.45 nanomoles (13.8 mcg). 
• However, the concentration of αCGRP in the CSF of humans after SAH 
ranges from 0.1 to 0.84 ng/ml (15 to 125 ng assuming a CSF volume of 
150 mls in adults) (727). The concentration in control patients is 0.1 
ng/ml (15 mcg). 
• Therefore, we have started at five doses below this effect level. 
Doses (example doses in micrograms based upon a 75kg adult): 
No effect level: 
1. 10-13 mol/kg (0.03 mcg) 
2. 3x10-13 mol/kg (0.09 mcg) 
Possible effect level:  
3. 10-12 mol/kg (0.3 mcg) 
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4. 3.0x10-12 mol/kg (0.9 mcg) 
5. 10-11 mol/kg (3 mcg) 
Effect level: 
6. 3.0x10-11 mol/kg (9 mcg) 
7. 10-10 mol/kg (30 mcg). 
Anticipated effect size:  
We anticipate little or no effect from our first three doses according to the 
MABEL approach. We expect partial to complete reversal of cerebral vessel 
narrowing from our sixth dose of CGRP, which would be consistent with 
previous animal studies.  
Dosing and Sampling 
• A maximum of one patient will be studied per day; 
• Each patient will only receive one dose of αCGRP; 
• The administration is a bolus dose, not a continuous infusion; 
• The study will start with the lowest dose, which will be given to three 
patients, and will progress to the next, higher dose after review and 
approval by the Data Monitoring Committee (DMC); 
• There are seven dose levels in total. 
The study will start with the lowest dose, which will be administered to three 
patients. Each patient will receive a single dose of αCGRP given into the CSF. 
Escalation from the starting dose for the following patients will follow a 
traditional escalation rule using a 3+3 design. αCGRP will be administered as 
per the local site protocol for this route of administration. Those administering 
αCGRP will be on the intrathecal register and competent at performing this 
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role. CSF, blood and urine will be sampled at intervals for 24 hours. 
Immediately after the intervention: 
• Patients will continue to be monitored and managed in Critical Care with 
side effects documented. 
• CSF drainage will be stopped for one hour, during which time 
transcranial Doppler flow velocities will be continually assessed from 
the MCA with a EZ-Dop scanner (Compumedics, Singen, Germany). 
Thereafter, transcranial Doppler measurements will be taken every 30 
minutes up to six hours.  
• Immediately after the drain is open (hour one), blood, urine and CSF 
samples will be taken. They will then be taken again each hour for five 
hours and once again 24 hours after the administration of the peptide. 
The samples will be anonymised with a study number, spun and frozen 
at -80°C in an alarmed freezer.  
• A repeat CTA will be performed two to four hours after the intervention 
in an NHS CT scanner close to the Critical Care area which would be 
routinely used for patients if required. αCGRP will be given to patients 
during daytime hours to ensure staff are present to facilitate use of the 
scanner.  
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Figure 28: Sampling Schedule. Time in hours. Time 0 = the time at which 
CGRP is first administered. Doppler sonography of the MCA will be 
continuous for the first hour and then performed half-hourly until hour 6. It will 
not be performed at hour 24.  
 
Stopping Rules and Decision Making 
 
Recruitment will be suspended after any serious adverse event (SAE) and 
further dosing stopped. A DMC review will be undertaken to decide if further 
doses can be given to subsequent patients. Escalation to a higher dosing level 
will only occur after a DMC review.  
 
The dose escalation will be stopped if cardiovascular SAEs are observed in 
two or more patients out of three at the same dose and associated with CSF 
administration of αCGRP. The study will not be stopped following a single 
cardiovascular SAE after administration as this may be unrelated to αCGRP. 
However, recruitment will be suspended and the DMC will review every SAE. 
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The study will only continue once the DMC are satisfied it is safe to do so. The 
study will be stopped should cardiorespiratory arrest, intracranial haemorrhage 
or death occur. In addition, if the DMC deems that the SAE is serious enough 
to suspend the study for any reason other than those listed above, it will be 
suspended. The justification for this is to balance the risks to the patients in 
this study against the potential information for future patient benefit gained by 
the research. Stopping the study due to one SAE potentially unrelated to 
αCGRP in a critically ill patient group, may unnecessarily deny future patients 
with this severe disease, who currently have few options for treatment, an 
intervention which has the potential to reduce morbidity and mortality.    
 
A 3+3 approach will be taken, beginning at dk=1. Each dose will be allocated 
to a minimum of three patients. If an SAE is reported at one dose, the DMC 
may request a further three patients be studied at that dose to assess 
tolerability before progressing to the next, higher dose (Fig.25). 
  
• Assuming the study is not stopped early, a minimum of 21 patients will 
be needed for the study if the DMC does not request any repeat dosing 
prior to progression from one dose level to the next. Calculation: 7 
doses x 3 patients at each dose = 21 patients.  
• A maximum of 42 patients will be needed for the study if every dose is 
required to be repeated in a further three patients prior to progression 
due to one SAE at each dose level. Calculation: 7 dose levels x 6 
patients = 42 patients.  
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• Males or non-pregnant females aged over 18 years;  
• Patients with a ruptured aneurysm, confirmed by DSA or CTA which has 
been secured by endovascular coiling or surgical clipping;  
• World Federation of Neurological Surgeons (WFNS) grade I-IV measured 
prior to the patient undergoing endovascular coiling and which does not 
worsen to grade V after the patient has undergone the procedure (Grade 
V = GCS <7); 
• CSF access device or EVD clinically indicated; 
• Written informed consent to participate in the study must be obtained from 
the closest relative or welfare guardian prior to initiation of any research 
procedures. 
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• SAH due to causes other than saccular aneurysm; 
• Multiple aneurysms among which the ruptured one cannot be identified 
and/or all are not secured during coiling; 
• No end-of-procedure DSA; 
• Refractory hypotension (BP < 90mmHg); 
• Multiple organ failure; 
• Any severe or unstable concomitant condition or disease (e.g. known 
significant neurological deficit, cancer, haematological disease, coronary 
disease or psychiatric disorder), which would affect assessment of the 
safety or efficacy of the intervention (investigator's opinion).  
 
Informing Potential Patients about the Trial 
 
The clinical team responsible for patient care will identify potential patients. 
Specifically, this will be a neurovascular clinical nurse specialist who has 
expertise in aSAH.  Often, patients who require EVD/access devices after 
aSAH do not have capacity. Because of this, a clinical nurse specialist will 
describe the study to relatives of the patient, or their welfare guardian, and 
provide verbal information with the information leaflet. If the relative/welfare 
guardian would like the patient to take part or would like further information at 
this stage, a member of the research team will discuss this with them. These 
researchers will confirm eligibility, explain the study further and obtain consent. 
Particulars of the staff informing the patients and the date and time of this will 
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be recorded in the subject pre-screening log, including a record of further 




The synthesis of αCGRP is carried out using standard solid phase chemistry 
at a Good Laboratory Practice (GLP) compliant manufacturing site, Bachem 
AG, Hauptstrasse 144, 4416 Bubendorf, Switzerland. No materials at risk of 
transmitting transmissible spongiform encephalopathy are used in the 
manufacturing process. αCGRP manufacture and filling, under aseptic 
conditions, and Qualified Person release are performed by Bachem according 
to Good Manufacturing Practice (GMP). The quality of the product is controlled 
by ensuring compliance to internal specifications set with due regard to 
European guidance on the control of Investigational Medicinal Products 
(IMPs). Once delivered, the pharmacy team at the Western General Hospital, 
Edinburgh, will dilute αCGRP to specific doses. 
 
αCGRP is to be stored frozen at -20°C (+/- 5oC). Stability studies are being 
conducted to confirm the stability of αCGRP formulation over the proposed 
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• Drugs with anti-cholinergic side effects: e.g. Atropine, Benztropine 
(Cogentin), Biperiden, Ipratropium (Atrovent), Oxitropium (Oxivent), 
Tiotropium (Spiriva), Glycopyrrolate (Robinul), Oxybutynin (Ditropan, 
Driptane, Lyrinel XL), Tolterodine (Detrol, Detrusitol), Chlorphenamine 
(Chlor-Trimeton), Diphenhydramine (Benadryl, Sominex, Advil PM), 
 Dimenhydrinate (Dramamine), Orphenadrine, Trihexyphenidyl, 
Dicyclomine (Dicycloverine); 
• Angiotensin Converting Enzyme inhibitors (to be omitted on the day of 
surgery and for the duration of the study); 
• Angiotensin Receptor Blocking Agents (to be omitted on the day of 
surgery and for the duration of the study); 
• Drugs that may cause facial flushing. E.g. Nitroglycerin, Nifedipine, 




Administration of αCGRP into the cerebral ventricles via the ventricular access 
device/EVD best fits a single compartment model. The ventricles are the 
central compartment wherein the drug-in-study is administered and this is also 
the bio-phase or effect compartment. Systemic circulation, where CSF (along 
with the dissolved αCGRP) will be transported, is the peripheral compartment 
and is not context sensitive. Some αCGRP undergoes cleavage at the Leu16-
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Ser17 bond through neutral endopeptidase present in CSF, leaving behind 
inactive metabolites. Metabolism of αCGRP from the systemic circulation is of 
no relevance to CSF concentrations because transport into the systemic 
circulation is not context sensitive and there is no redistribution of αCGRP back 
into the cerebral ventricles. Therefore, the volume of distribution (Vd) of 
αCGRP after administration in the CSF will be given by ‘Vd = amount of 
αCGRP administered in ventricular CSF / concentration of αCGRP measured 
in CSF’. The clearance (CL) of αCGRP from ventricular CSF will be given by 
‘CL = amount of αCGRP administered in ventricular CSF / area under the curve 
(AUC)’.  
 
AUC can be integrated from the graph of decaying concentration of αCGRP 
over time. Elimination half time (t½) of αCGRP administered in CSF will be 
given by ‘t½ = 0.693 x Vd / CL’, where 0.693 is the natural logarithm of 2. From 
the known values of Cmax, Vd and CL the loading dose and maintenance 
infusion rate for a phase II trial can be derived as ‘loading dose = Cmax x Vd’ 
and ‘Maintenance infusion rate = Cmax x CL’. 
 
Descriptive analysis will be presented including any AE, SAE or withdrawals. 
Where available, this AE/SAE/withdrawal information will be presented in 
relation to the timing of doses. We will analyse dose response based on CTP 
and TCD results. Dose response curves will be produced after each cohort, 
showing the levels of αCGRP found in blood, CSF and urine for all subjects. 
Pharmacokinetic and pharmacodynamic analysis will be ongoing throughout 
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months seven-to-24 whilst we collect data from each group of patients. For the 
pharmacokinetic/pharmacodynamic modelling we expect a steady-state 
condition in the CSF and a fixed-effect model. The questions we will attempt 
to answer are:  
 
1. What is the dose-response? 
2. What is the minimally effective dose? 
3. How many adverse events are expected at higher doses? 
4. What is the half-life of αCGRP in the CSF? 
5. How much αCGRP crosses the BBB? 
6. Is αCGRP renally excreted? 
 
Definitions of SAEs/AEs 
 
The following events are considered life-threatening and/or likely to prolong 
existing hospitalisation and are therefore SAEs: 
  
1. Haemodynamic instability including: SBP decrease >25 mmHg; a MAP 
decrease >20 mmHg; heart rate increase to >150 bpm.  
• A BP SAE will be recorded after three confirmed non-invasive BP 
measurements with change assessed from baseline (time zero), or any 
symptomatic hypotension (a reduction in BP associated with symptoms, 
including lightheadness); 
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• A heart rate SAE will be a heart rate greater than 150 bpm, sustained for 
more than five minutes, or any symptomatic tachycardia (an increase in 
heart rate associated with symptoms including chest tightness). 
2. Reduction in GCS >2 points or one motor point; change in pupil response 
or size 
3. Clinical evidence of a seizure. 
 
The following will be recorded as Adverse Events (AEs) 
 
1. Spontaneous hyperventilation; PaCO2 < 4.0 kPa, monitored using a 
TOSCA device (Radiometer Medical, Åkandevej 21, DK-2700 Brønshøj, 
Denmark). This is possible after cerebral ventricular system injection (736). 
2. Facial flushing. If observed, an assessment of the involvement one-to-four 
facial quadrants will be made and an assessment of intensity of rubor made 
(mild, moderate, intense).  
 
End of Study 
 
The end of the study is defined as 24 hours from the administration of αCGRP 
after the final set of samples have been taken, or 24 hours after an SAE. The 
Investigators and/or the trial steering committee and/or the co-sponsor(s) have 
the right at any time to terminate the study for clinical or administrative reasons. 
The end of the study will be reported to the Research Ethics Council and 
Regulatory Authority within 90 days, or 15 days if the study is terminated 
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prematurely. The investigators will inform participants of the premature study 
closure and ensure that the appropriate follow up is arranged for all participants 
involved. A summary report of the study will be provided to the Research Ethics 
Council and Regulatory Authority within one year of the end of the study. 
 
Response to Protocol and Summary 
 
The proposed study has been presented to Edinburgh University Research 
Governance (ACCORD) and is supported pending funding. Unfortunately, the 
research proposal was not successful at the full application stage for Medical 
Research Council funding, (panel score 21/30: 4, 5, 4, 4, 2). The responses 
were mostly positive and included well-reasoned comments which are 
discussed below: 
 
“The Schebesch et al. study from 2013 demonstrated a clear difference 
between vasospasm and non-vasospasm patients’ CSF CGRP levels in the 
first four days (727). However, the study only measured CGRP in CSF up to 
ten days in aSAH patients. Given the risk of DCI persists up to 14-21 days, it 
would be useful to measure CGRP levels up to these time points or until the 
external ventricular drain/access device is removed.” 
 
The reviewer makes a valid suggestion, and one that would be appropriate in 
a separate study of changes in αCGRP concentrations in patients with aSAH 
and EVDs or VADs. There are a few problems with applying this to our 
proposed study. The half-life of αCGRP is four-to-six hours in the CSF (690, 
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696) and seven-to-ten minutes in the systemic circulation (624, 625, 736, 737). 
Therefore, any change in αCGRP concentration from a single intrathecal bolus 
of αCGRP is unlikely to alter the CSF concentration for as long as 14-21 days. 
The risk of ventriculitis will increase with repeated CSF sampling. Finally, the 
cost of the project will increase significantly with continued monitoring.   
 
“There should be a specified time point for recruitment (e.g. 48 hours from 
ictus). This is based on the Schebesch et al. paper from 2013 suggesting that 
the difference in CGRP levels persisted for only four days (727). This is likely 
to affect recruitment targets.” 
 
I agree that there should be criteria to exclude patients whose ictus is greater 
than ten days. However, as the reviewer has already pointed out, the risk of 
DCI can persist up to 14-21 days. Therefore, although the CGRP levels have 
been shown to be higher in the first four days in patients who did not go on to 
develop vasospasm in the 2013 Schebesch et al. paper, this does not mean 
that patients already with DCI, or at risk of developing DCI, (i.e. patients 
beyond day four) would not benefit from CGRP.  
 
“In addition to GCS and seizures, new neurological deficits should also be part 
of the AEs. In addition, an indication of ICP and draining from the EVD should 
be examined as changes in the blood flow can affect ICP.” 
 
I agree with the first part of this comment. New neurological deficits should be 
included as AEs. It remains unclear whether monitoring ICP has any genuine 
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beneficial impact on outcomes in TBI patients (see Chapter 1). Patients with 
an EVD do not routinely have their ICP measured at the Western General 
Hospital and a drain set to allow CSF outflow in the case of hydrocephalus 
would not be demonstrating a genuine physiological ICP (i.e. if the patient’s 
ICP rises above the level of the drain then CSF will flow out of the drain to 
lower ICP). The study could include a measure of CSF drainage from the EVD. 
In the case of patients with a ventricular access device, it may not be in the 
patient’s best interest to have an ICP monitor inserted (see evidence of ICP 
monitoring benefit/risks of infection in Chapter 1).  
 
“Outcome assessment: Having recruited the patients, it would be sensible to 
collect some preliminary outcome data – in my view, although CT perfusion 
will be helpful, the main outcome measure that should be collected in this 
preliminary study is daily or twice-daily TCD measures for as long as clinically 
possible. Additional data on the presence/absence of clinical DIND will be 
useful to collect as well.” 
 
The proposed study is a dose-toxicity study, but I agree that evidence of 
efficacy would be beneficial to progress to the next phase, which is why we 
have proposed CTP and regular TCD. A clinical neurological score 
assessment should also be included. This would not only be beneficial for 
evidence of efficacy but also as a measure of incidence of DCI and its clinical 
course in this group of patients.   
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“The frequency of CSF sampling produces a high risk of introducing CSF 
infection in these patients, with potentially devastating consequences. There 
must be a clear protocol to reduce infection associated with drug 
administration and CSF sampling in these patients. CSF infection should also 
be monitored as part of the safety. Is there any indication of the effect of CSF 
infection on CGRP levels?” 
 
The reviewer raises a valid point, which is why CSF sampling is limited. To my 
knowledge, there is no data on the effect of CSF infection on CSF CGRP 
concentrations. It would be worthwhile doing a subgroup analysis if any 
patients did develop a ventriculitis to determine if there is a change in CGRP 
concentrations with infection. There are both intrathecal drug administration 
and CSF sampling protocols which are included in the full trial protocol.  
 
“Intrathecal use limits the population it can be applied to. Typically, only a third 
of treated SAH patients will have this access. The question arises if the 
anticipated future application is for this same patient group who are having an 
EVD sited for other reasons or another group. It is also unclear if it is expected 
to be used prophylactically or as a treatment of established vasospasm? If 
repeated doses are planned for prophylactic treatment this will clearly require 
further study. If CGRP is proposed as a single treatment for established 
vasospasm, then it will further limit the treatment to a very select group of 
patients. One could imagine if successful that this might be expanded to the 
two-thirds of SAH patients without EVD by administration by lumbar drain 
although it is uncertain with SAH in situ if the drug distribution within the CSF 
in that scenario will be the same. It would be helpful to have more clarity on 
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what the expected ultimate mode of use of the drug would be to understand 
what percentage of SAH patients this will really be applicable to. Furthermore, 
while vasospasm represents a contribution to outcome the degree is unknown 
but sample size calculations from Loch MacDonald make rather depressing 
reading for following this approach.” (738). 
 
The reviewer raises a good point, especially regarding the potential limitations 
of the lumbar intrathecal route in SAH patients. The purpose of our proposed 
trial is to assess dose response and toxicity. I think if we are able to establish 
a safe dose of CGRP and demonstrate a degree of efficacy at this stage then 
we can start to think about how we can apply CGRP as a treatment. If effective, 
CGRP could be used as a treatment of established vasospasm in patients with 
EVDs, although as the reviewer correctly states, this limits the intervention to 
a small group of patients. There are multiple ways that CGRP could be altered 
to change administration:  
 
1. A slow release preparation could be developed similar to the 
microspheres developed by Inoue et al. and Ahmad et al. (692, 697). 
Ideally, this would be administered at the time of surgical/radiological 
intervention but could potentially be administered via EVD. 
 
2. A continuous infusion could be administered via EVD/VAD (with the 
associated limitations already mentioned). 
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3. There is animal data from Sun et al. that intranasal delivery of CGRP 
attenuated vasospasm in rats. Intranasal delivery offers a mode of non-
invasive delivery suitable for both prophylactic treatment and 
intervention in established DCI (691, 739).  
 
4. There are a small number of animal studies successfully demonstrating 
amelioration of vessel narrowing after gene transfer of CGRP. While 
this route of administration appears a long way from human trials, it 
offers another potential route in the future (708, 740, 741). Interestingly, 
Toyoda et al., demonstrated some prophylactic benefit from gene 
transfer of CGRP in rabbits that were administered a viral-encoded 
gene five days prior to experimental SAH. Basilar artery contraction was 
23% (±11%, p<0.02) less than those who had received vehicle (710).  
 
The referenced paper of Loch MacDonald, which quotes the incidence of DCI 
as 12-30% and a required sample size of over 5,000, assumes a small 
treatment effect and is more relevant to a future Phase III trial than an initial 
dose-toxicity study. I agree that it does make depressing reading but this is not 
a reason to stop seeking better treatments for DCI. The paper also highlights 
the importance of a unified definition of DCI as mentioned in Chapter 2.  
 
• “The applicants make passing reference that CGRP dilates small vessels of 
the microcirculation but do not provide any evidence for this or explain its 
importance. The reason it is important is that the existing drug studies have 
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clearly established that treating large vessel vasospasm does not ameliorate 
outcome. Clazosentan was highly successful at resolving large vessel 
vasospasm with extremely impressive dose response curves reducing from 
66% to 23% but ultimately did not alter outcome. Conversely Nimodipine had 
a small effect on outcome (33% vs 20% poor outcome) but its action was not 
through large vessel dilation as evidenced by rates of vasospasm. The 
implication from statements that CGRP acts on small vessels is that it will not 
fall into the same trap as Clazosentan in acting as a highly effective large 
vessel vasodilator but not altering outcome, but no evidence is provided that 
it acts on the microcirculation specifically. This may be available and would be 
highly beneficial to the rationale for the study.” 
 
The evidence I have provided in Chapter 3 is to highlight that cerebral vessel 
narrowing may be involved in the pathogenesis of DCI despite the findings of 
the CONSCIOUS trials. DCI may also be related to microvascular 
vasoconstriction not visualised by DSA. I cannot find any animal models of 
SAH and DCI assessing the microvascular effects of αCGRP. All in vivo 
studies included in our systematic review assessed large vessel changes 
(most commonly basilar artery changes, one measured ICA/MCA/ACA 
changes). However, Kobari et al. have demonstrated that αCGRP dilates small 
parenchymal vessels through a specific αCGRP receptor in a non-SAH model 
in cats (742). In addition to demonstrating its dilatory effects, Clazosentan was 
also associated with pulmonary complications, anaemia and hypotension 
which may have contributed to its apparent lack of efficacy. It will be interesting 
to read the results of the REVERSE trial (Clinical trials NCT02560532). 
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αCGRP has not been associated with such side effects in animal studies or 
human trials. 
 
The two factors that are likely preventing a CGRP trial going forward are: 
1. The CONSCIOUS trials appear to have demonstrated no outcome benefit 
from an agent that ameliorates cerebral vessel narrowing, thereby leading 
many to question its relevance (571). 
2. The proposed route of delivery appears high-risk in a critically unwell patient 
group. 
The arguments for evaluating the effect of intrathecal αCGRP include: 
1. It acts on the abluminal side of blood vessels and so is still able to dilate 
morphologically damaged vessels after SAH. 
2. Systemic effects are likely to be limited from this route of delivery. 
3. Unlike endothelin receptor agonists, there was a positive signal towards 




• If nimodipine is beneficial in the treatment of aSAH then understanding 
how it exerts its beneficial effects is crucial. This could help explain the 
pathophysiology of DCI and lead to improved treatment.  
 
• It is not uncommon to observe patients with suspected DCI receiving 
both nimodipine and inotropic support to reach a target SBP. The use 
of an inotropic agent, or fluid therapy, to achieve a SBP is without a 
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strong evidence base. Small, non-randomised trials do support the use 
of induced hypertension in the management of DCI. However, there is 
no guidance on whether SBP or MAP should be targeted or what the 
target should be. The use of inotropes and fluid therapy to achieve a 
SBP is not without risk. The only Cochrane review of an aspect of triple 
H therapy was of volume expansion (hypervolaemia) in 2004 (743). The 
last systematic review of haemodynamic therapies was conducted in 
2011 (522). Therefore, an updated systematic review and meta-
analysis would be useful. A trial randomising patients with DCI (as per 
the definition in Chapter 3) to induced hypertension with multiple targets 
or normotension is required. The difficulty, apart from recruitment failure 
as experienced by the HIMALAIA trial, is choosing how any target is 
maintained, with fluid therapy or inotropic support, and whether patients 
would still receive nimodipine or not. Designing a prospective RCT to 
maintain euvolaemia and use inotropic support to achieve two target 
temperatures versus no induced hypertension with retrospective 
analysis of fluid therapy is one option. Such a trial is likely to need to be 
multi-centre to achieve adequate recruitment.       
  
• A trial examining the effects of intrathecal αCGRP in patients with DCI 
should be undertaken for the reasons discussed above. It may be that 
such a trial is only possible through commercial routes. 
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Conclusion and Reflection 
 
This thesis, in part, summarises the preparatory work involved in clinical 
research and is an example of the difficulties associated with delivering a 
clinical trial. I have submitted two applications to the First in Human (FIH) 
committee with associated meetings and revisions to our application based on 
comments. Our research team has had three meetings with ACCORD (NHS 
Lothian/University of Edinburgh research sponsor); a teleconference and an 
advisory meeting with the MHRA; and I have submitted three separate 
applications to the Medical Research Council (MRC, two provisional, one full 
application). Each of these applications takes a significant amount of work (see 
appendix 3 for MRC summary application) and includes a detailed cost-
analysis in addition to a full trial protocol. To complete an application involves 
not only the primary investigators, but is also dependent upon the aid of people 
in university and NHS finance departments, NHS research and development 
staff, commercialisation staff, laboratory staff (both NHS laboratory for storage 
and private laboratories for RIA), statisticians, senior clinicians included in the 
research team who are not directly involved in the application or initial stages 
of research and commercial pharmaceutical representatives. In addition to 
this, two review papers were published and original research (requiring ethical 
approval) was undertaken to support these applications.   
 
An argument against our proposed trial which was put forward by the First in 
Human committee and ACCORD was that investigating CGRP in a vulnerable 
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patient group was associated with two problems. Firstly, that side effects in 
critically unwell intubated and sedated patients may be missed. Secondly, that 
these critically unwell patients would be more likely to have serious adverse 
events than healthy volunteers. As such, it was recommended that a study 
involving spinal administration of CGRP in healthy volunteers as a dose-
tolerability study should be conducted instead. My argument against this is that 
it is unethical to administer CGRP to healthy volunteers for tolerability analysis 
when these patients would not even receive a theoretical benefit from its 
administration and would receive the risk of hypotension and headache. In 
contrast, patients with poor-grade SAH who have developed DCI have an 
extremely poor prognosis with little or no treatment options. In these patients, 
CGRP would offer a potential treatment benefit. Furthermore, poor-grade SAH 
patients with DCI are routinely managed on ICU with invasive monitoring and 
one-to-one nursing care where physiological effects of CGRP are unlikely to 
go unobserved. The external reviewers for the MRC did not raise similar 
concerns. There appeared to be three main limitations to our applications 
being successful: 
 
1. Administering a pharmacological agent directly into cerebral CSF 
appears inherently unsafe despite our attempts to provide evidence that 
other agents are delivered by this route;  
2. The cost of the peptide was prohibitively expensive (see Appendix 3 for 
costs); 
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3. There was perceived to be insufficient evidence to support a clinical trial 
of intrathecal CGRP. I think that this is chiefly due to results from the 
CONSCIOUS trials. 
 
Outcomes after SAH have improved in the last 40 years despite a lack of 
innovative treatments and a wealth of unsuccessful interventions (426, 470, 
597). I think this is due to improved adherence to guidelines and basic clinical 
care in addition to increased management in specialist centres. Although SAH 
outcomes have improved, DCI remains a significant cause of morbidity and 
mortality after aSAH and an effective treatment is lacking. There are ongoing 
clinical trials as discussed in Chapter 3 (e.g. NEWTON, ULTRA, SAHaRA, 
REVERSE and EARLYDRAIN) and the results of these are keenly awaited 
(506, 542, 560, 596). Unfortunately, I do not think I will be able to add to this 
list by investigating intrathecal CGRP as a treatment option for DCI unless a 
commercial partner is interested and willing to fund the research. I will, 
however, undertake a systematic review of studies investigating hypertension 
as a treatment for DCI. This could form the basis for a RCT investigating 
induced hypertension in patients with DCI.  
 
Having now finished writing this thesis and having attempted to conduct a 
clinical trial I realise that the bulk of the work may not be in running the trial 
and the write-up. The hardest part of conducting clinical research might be in 
convincing investors to provide funding and convincing regulatory committees 
to approve the trial.  
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Reflection on PhD 
 
The following section has been included in response to the thesis viva in 
September 2017. It is intended to describe what I have learnt from undertaking 
a PhD, including study design and data analysis. I have tried to present a 
chronological account of my PhD and in doing so respond to some points made 
in the viva. I first discuss the analysis of PbtO2 data and the difficulties I had 
with missing data and statistical analysis. I go on to outline the process of 
applying for local committee and funding approval. Finally, I discuss my 
experience of undertaking a PhD at this stage of medical training.  
 
In 2013 I started a Masters in Medical Sciences (MMedSci) degree led by Dr 
Richard Weller at the University of Edinburgh. I had finished my Foundation 
Year 2 training and wanted to undertake a postgraduate research degree and 
thought that this would be a good introduction to research. I approached 
Professor Andrews, at the Western General Hospital ICU, and enquired about 
potential research opportunities in neuro-intensive care. My interest was in 
clinical research and I was aware that Professor Andrews was the Chief 
Investigator for the Eurotherm3235 trial. We discussed various research 
projects and agreed that I would investigate two. Firstly, I would conduct a 
subgroup analysis of PbtO2 data from patients in the Eurotherm3235 trial 
(Chapter 2). Secondly, I would investigate CGRP as an intervention for 
delayed cerebral ischaemia after subarachnoid haemorrhage (Chapters 3-5). 
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The proposal was that I would develop a clinical trial whilst also analysing 




This work was conducted in collaboration with Professor Andrews and Dr 
Rhodes at the Western General Hospital, Edinburgh. The benefit of conducting 
this part of my PhD was that it allowed me to carry out original analysis of the 
effect of temperature on PbtO2 in patients with TBI. The research involved 
patients in an unblinded multi-centre, randomised-controlled trial where 
funding and regulatory milestones had been achieved. Furthermore, my 
analysis was not post-hoc, but was instead prospective analysis of data from 
the Edinburgh centre. Our results were presented at the 4th International 
Hypothermia Conference prior to the New England journal publication by 
Andrews et al (279, 744). Whilst Eurotherm3235 was investigating outcome 
data from the use of hypothermia in TBI, I was interested in the changes in 
PbtO2 values. The reference to ICP changes supported previous findings rather 
than contributing new information  (227, 312-314, 340-348). 
 
With regards to study design, Eurotherm3235 serves as an example of a multi-
centre, randomised controlled trial that successfully recruited 387 patients 
based upon a sample size calculation with an a priori statistical analysis plan. 
However, my analysis of data from patients recruited to Eurotherm3235 
revealed a problem with the implementation of study design. Specifically, the 
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mean time to reaching target temperature was approximately seven hours 
from randomisation (Chapter 2). Furthermore, this delay was seen in the 
Edinburgh trial centre, where one might expect to find the least delay in 
reaching target temperature due to the centre’s prior experience in inducing 
hypothermia. In our Therapeutic Hypothermia publication it was proposed that 
long lead times to induce hypothermia were due to pre-randomisation 
hypertonic therapy (745). As discussed in Chapter 2, I attribute the delay in 
reaching target temperature to the realities of conducting clinical research. It 
would be interesting to see if there was a difference between the time of 
randomisation and the time recorded for the administration of cold saline. 
There are many possible causes for delays: 
 
• Staffing: an example is staff breaks where 1:1 nursing care (one nurse 
to one patient) becomes 1:2 or 1:3. It is possible that patients met 
criteria for randomisation and were randomised but there was a delay 
in starting cooling due to staff waiting for the end of a break. This may 
sound trivial or inappropriate, but many staff members working on 
wards will be aware that patient care can be affected by staff breaks. 
Furthermore, it is not difficult to imagine that at the end of a break the 
patient may be due intravenous antibiotics, fluid changes etc. It may be 
that initiating cold fluids came at the end of a list of interventions. This 
can be mitigated with research nurses prioritised to randomisation and 
ensuring the intervention begins quickly. However, the reality of clinical 
work is that predicting when patients will become eligible is challenging. 
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Furthermore, the times that patients meet criteria for cooling may be 
outside the hours of 0800 to 1700.     
• Equipment preparation: Here I refer to the storage and administration 
of cold saline. Ideally this would be stored within close reach and be 
administered rapidly to achieve target temperature.  
• Other interventions interfering with administration of cold fluids: e.g. 
patients going to CT scan shortly after randomisation.  
• Variables that may affect the rate of cooling such as fevers, body mass, 
seizures etc.  
• Education: I believe this is key to overcoming some of the issues 
mentioned above. In an environment where patients and research 
participants will be managed by a non-research clinical team there 
needs to be some incentive for staff to facilitate research without 
compromising clinical care. I suspect that if staff members understand 
the importance of why different variables are being recorded, or why 
interventions are being instigated, then there would be more of an 
incentive for these to happen. Furthermore, the unblinded nature of the 
study allows for bias and complacency. By this I mean that the urgency 
of instigating an intervention may become less important the less 
clinical staff believe in its efficacy.   
 
Eurotherm3235 prospectively enrolled patients. My own analysis was 
retrospective and was not blinded. Because I was analysing brain and core 
temperatures in addition to PbtO2 and ICP, I could establish which patients 
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were in the control or intervention groups. If another investigator had been 
included to analyse the data we could have separately examined changes in 
these variables, although the investigator examining core temperature would 
always know which patients were in which group. 
 
One aspect of joining a clinical trial that was already being delivered that I 
found difficult was defending a study that I had not designed. This is not meant 
as a criticism of the trial, nor is it necessarily problematic. The act of responding 
to criticisms was a positive experience. I believe that the peer review process 
in its purest form should be a positive, thought-provoking exercise used to 
better our understanding of research. However, one difficulty I experienced 
was that my understanding of the study design was not as strong as it would 
have been had I been involved in the study design process from conception. I 
may have been able to answer criticisms more readily had I been involved in 
the initial decisions. For example, the decision to use cold saline to induce 
hypothermia and the associated potential risk of pulmonary oedema or 
increased CPP with an increased MAP. Had I been involved in this decision I 
might have better understood the practical applications and the previous 
evidence supporting its use and the alternatives available (Chapter 1) (339). 
This is just one example, there were many other small areas of study design 
that perhaps took me longer to understand than it would have taken if I had 
been involved in the study’s conception. There was also a benefit to me 
experiencing this difficulty. When I came to write the αCGRP protocol, I was 
aware that what appears obvious to the research team is not always clear to 
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someone outside of the research team reading the protocol. This became 




ICP, PbtO2, and chart data were recorded from TBI patients enrolled in the 
Eurotherm3235 study. Patient data from the Licox monitor was recorded and 
timestamped on excel spreadsheets. I looked through all excel spreadsheets 
to identify accurate Licox recordings and excluded inadequate data for PbtO2, 
ICP and brain temperature (e.g. erroneous negative values, those without the 
analysis time period). I also examined ICU charts for each patients’ ICU stay 
and recorded core temperature, blood gas analysis, ICP treatments, whether 
patients were paralysed and whether patients received NMDA receptor 
antagonists. Each patient’s hour data was averaged (see Appendix 1 for 
example of raw data). Prior to analysis, the research team met with a local 
research statistician at the Welcome Trust Clinical Research Facility, who 
directed statistical analysis. It was decided that due to the small sample size, 
correcting for non-parametric data was not required. This analysis was 
questioned by reviewers of the published work and our response was 
accepted:  
 
“A repeat measures ANOVA was used to take into account 
measurements at different time periods from the same subjects after 
discussion with our local statistician. We do not have multiple covariates 
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for analysis and therefore have not used the mixed methods approach. 
While we acknowledge that there may be a relationship with our 
outcome and other variables, due to the sample size of the study and 
lack of multiple covariates for analysis we are unable to examine this 
further.” 
 
I have summarised the statistical tests and results here for easy reference. For 
exact values see Chapter 2: 
Intracranial Pressure 
Within Group Control Tests: One-way repeat measures ANOVA: no 
statistically significant difference with time.  
Within Group Intervention Tests: One-way repeat measures ANOVA: 
statistically significant difference with time. T-tests run to determine when the 
difference was.  
Between Groups Tests: Two-way repeat measures ANOVA: statistically 
significant difference between the groups with time.  
PbtO2 
Within Group Control Tests: One-way repeat measures ANOVA: no 
statistically significant difference with time. T-tests documented to 
demonstrate that there was also a decrease in PbtO2 in the control group.  
Within Group Intervention Tests: One-way repeat measures ANOVA: 
statistically significant difference with time. T-tests run to determine when the 
difference was. 
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Between Groups Tests: Unable to run two-way ANOVA due to missing 
data. No statistically significant difference between the two groups based on 
unpaired t-tests.  
Based upon my PhD supervisors, Professor Andrews and Dr Rhodes, a local 
statistician (Cat Graham, see publication acknowledgements) and journal peer 
review accepting this method of analysis, the work has been published and 
presented in this viva (please see Appendix 2 for the publication) (745). A 
repeat measures ANOVA was used because it accounts for measurements 
from the same subject repeated over multiple time points without treating the 
data from different times as though they are from independent subjects (746). 
I thought that the ideal test would have been a two-way repeat measures 
ANOVA if the data was normal. However, I could not run a two-way repeat 
measures ANOVA in Minitab or SPSS for PbtO2 due to data missing in 
comparison fields (see Appendix 1 for example of missing data). Therefore, I 
performed two one-way repeat measures ANOVAs (once for the intervention 
group and once for the control group) to determine if there was a statistically 
significant difference within the two groups for PbtO2. Then, to check between 
the groups I performed post-hoc analysis with t-tests. This seemed to be the 
best I could do with repeat measure data and did not seem controversial to 
me. I do acknowledge that not performing intention-to-treat analysis is 
controversial. However, I do not think that intention-to-treat analysis would 
have reflected the effect of hypothermia on PbtO2 because of the delay in 
reaching target temperature (Figure 30). 
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Figure 30: Time to first episode of hypothermia. Time taken for patients to 
reach the first episode of hypothermia (≤35°C) measured in hours (<35C) 
 
The principal arguments discussed in the viva regarding the statistics used in 
the second chapter of the thesis were, as I recall them: 
 
1. Based on the graphs presented (Figures 16 to 18, Chapter 2), the data 
did not appear to be parametric and therefore performing ANOVA and 
t-tests was not appropriate. It was suggested that the Kruskal-Wallis 
test may have been more appropriate. 
 
2. Performing multiple t-tests was incorrect as it will have produced a 
seemingly statistically significant result if performed enough times. 
 
With regards to the first point, the original intention to treat data, when looking 
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both the ICP and PbtO2 data (Figures 30 to 33). Furthermore, the F-test in 
ANOVA has been shown to be robust when assuming normality in terms of a 
Type I error (747-750). However, I agree that the graphs presented in Chapter 
2 do suggest that the data does not look normally distributed. I had discussed 
this with a statistician, Cat Graham, and had been advised to perform 
parametric tests. 
 
I performed probability tests to look at the data prior to running the statistical 
tests in chapter two. I have reproduced the graphs of these tests below. The 
first four graphs (Figures 30 to 33) demonstrate that the data points appear 
normally distributed but also that the Anderson Darling test gives a P value of 
greater than 0.05, suggesting that we cannot assume the data is not normally 
distributed. It is important to note that this is for the intention to treat mean data 
for the hour prior to randomisation to twenty hours after (hour -1 to hour 19).  
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Figure 31: Probability Plot for partial brain oxygen tension (PbtO2) in the 
control group. Data points look approximately normally distributed within the 
confidence interval and Anderson Darling test P value > 0.05. 
 
Figure 32: Probability Plot for partial brain oxygen tension (PbtO2) in the 
intervention group. Data points look normally distributed and Anderson 
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Darling test P value > 0.05.
 
Figure 33: Probability Plot for ICP in the control group. Data points look 
normally distributed and Anderson Darling test P value > 0.05. 
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Figure 34: Probability Plot for ICP in the intervention group. Data points look 
normally distributed and Anderson Darling test P value > 0.05. 
 
The data from the four different time points that were used in Chapter 2 (the 
hour prior to randomisation; the first hour of hypothermia; the first episode of 
stable hypothermia (defined as two consecutive hours); finally, six consecutive 
hours of hypothermia) also appears generally normal and non-normality 
cannot be assumed based on the Anderson Darling test (Figures 34 to 37). 
Indeed, the only graphs which do not demonstrate normal data are those 
concerning PbtO2 and ICP in the control group (Time 3 in Figure 35 and Time 
2 in Figure 37).  
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Figure 35: Probability plots for partial brain oxygen tension (PbtO2) in the 
intervention group. Time periods as per Chapter 2 Data.
 
Figure 36: Probability plots for partial brain oxygen tension (PbtO2) in the 
control group. Time periods as per Chapter 2 Data. 
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Figure 37: Probability plots of intracranial pressure in the intervention group. 
Time periods as per Chapter 2 Data. 
 
Figure 38: Probability plots of intracranial pressure in the control group. Time 
periods as described in Chapter 2. 
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To summarise, the data can be assumed to be normally distributed apart from 
one block of data in the control group for PbtO2 and one block of data in the 
control group for ICP (751). Being pragmatic about this, the risk of performing 
a parametric test with non-parametric data is of having a Type I error 
(incorrectly rejecting the null hypothesis). In Chapter 2 I reported that, in terms 
of PbtO2, “there was no statistically significant difference between the two 
groups” and that “there was no statistically significant difference in ICP in the 
control group”. Therefore, concern regarding a type I error is unnecessary 
because the null hypothesis is accepted. The following is taken from a 
wonderful paper by Geoff Norman which appears to be inspired by a paper 
highlighting the importance of “inappropriate statistical dogmatism” (752). The 
main point taken from this publication is that, despite their use being a common 
criticism of papers, parametric tests assuming normality are very robust. 
 
“For the standard t tests ANOVAs, and so on, it is the assumption of 
normality of the distribution of means, not of the data. The Central Limit 
Theorem shows that, for sample sizes greater than 5 or 10 per group, the 
means are approximately normally distributed regardless of the original 
distribution. Empirical studies of robustness of ANOVA date all the way back 
to Pearson (1931) who found ANOVA was robust for highly skewed non-
normal distributions and sample sizes of 4, 5 and 10. Boneau (1960) looked 
at normal, rectangular and exponential distributions and sample sizes of 5 
and 15, and showed that 17 of the 20 calculated P-values were between .04 
and .07 for a nominal 0.05. Thus, both theory and data converge on the 
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conclusion that parametric methods examining differences between means, 
for sample sizes greater than 5, do not require the assumption of normality, 
and will yield nearly correct answers even for manifestly nonnormal and 
asymmetric distributions like exponentials.” (748, 749, 753) 
 
With regards to performing a Kruskal-Wallis test, there is another reason, apart 
from the data being generally normal: the Kruskal-Wallis test assumes 
independence of observations and does not account for repeat measures and 
as such may actually increase the chance of a type I error (754). As mentioned 
earlier, the reason to use a non-parametric test in non-normal data is to reduce 
the risk of a type I error. Thus, it would be counterproductive to use the Kruskal-
Wallis test for this data. An example of a non-parametric test allowing for 
repeat measures is Friedman’s test. However, Friedman’s test is equivalent to 
a non-parametric one-way ANOVA and so could not be used to test differences 
between the groups. Both the Kruskal-Wallis test and Friedman’s test are 
omnibus tests and so require post-hoc analysis. 
 
I have stated that the concern about chosing the wrong tests lay in the potential 
for making a type I error and that I had accepted the null hypothesis is the data 
which failed the Anderson Darling test. However, I did report three statistically 
significant ANOVAs in chapter 2. These included a within groups effect on 
PbtO2 in the hypothermia group; a within groups effect on ICP in the 
hypothermia group and a between groups effect on ICP. For completeness, I 
have repeated these tests with non-parametric analysis using SPSS. For this 
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I used Friedman’s test, as it is able to account for repeat measures. This test 
demonstrated a within group difference in ICP for the hypothermia group (P 
0.04) but no statistically significant difference in the change in PbtO2 in the 
hypothermia group (P 0.12).  I have used the related-samples Wilcoxon signed 
rank test for post-hoc analysis. This showed that the decrease in PbtO2 from 
Time 0 to Time 2 in the intervention group was not statistically significant (P 
0.06). It is worth pointing out that the risk of using non-parametric tests in 
normal data is of having a type II error. If the new analysis is accepted then 
the summary is: 
 
• Statistically significant decrease in ICP seen within the hypothermia 
group and between the groups. 
• No statistically significant decrease in PbtO2 either within or between the 
groups. A non-statistically significant trend towards decreased PbtO2 in 
both. 
 
This analysis does not change my ICP discussion points in Chapter 2 as non-
parametric testing is consistent with parametric testing, nor does it change my 
PbtO2 discussion.  
 
The second point raised was regarding using t-tests across multiple time points 
(although the same argument can be applied to almost any test with an α of 
0.05). Indeed, the argument made was that if I had run 20 t-tests I would 
inevitably have a seemingly statistically significant result (I believe this was 
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based upon a p value of 0.05 x 20 = 1). In response to this: multiple t-tests 
were not run to achieve a statistically significant result. The ANOVA was run 
to identify whether there was a statistically significant difference within the 
groups. The ANOVA is an omnibus test and requires a post-hoc test (I chose 
the t-tests in this instance) to identify where (in this case, when) the statistical 
difference might be. The concern of using multiple t-tests is that it increases 
the chance of making a Type I error (the incorrect rejection of a true null 
hypothesis). Whilst that risk might be 5% with one t-test, it is not quite 15% 
with three t-tests (it is approximately 14.26%) (755, 756). This is why a repeat 
measures ANOVA was performed in the first instance rather than multiple t-
tests. However, the one-way repeat measures ANOVA was not able to 
determine where the significance lay within the groups or time points, only that 
there is a significant difference. I think I did not explain this clearly in Chapter 
2. With any repeat measures data there will exist this problem. To identify at 
what point there was a statistically significant result requires multiple tests. A 
single test (the ANOVA in this case) can be run to determine if there was any 
statistically significant difference between the groups, but it cannot state when. 
This is likely to occur often in clinical trials because we measure changes over 
time, not solely ‘before and after’. One way to counteract this is to use 
Bonferroni correction, which divides the α by the number of hypotheses being 
tested. This correction reduces the statistical power (increases the chance of 
a false negative) and can be conservative if the statistics are positively 
correlated. 
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Managing missing data 
 
Missing data is likely to occur in a multi-centre trial involving the recording of 
multiple variables by different staff members with multiple recording devices. 
Missing data reduces the power of a trial and the effect of missing data is larger 
in smaller studies with less data. Increasing the target sample size can partially 
compensate for this and as such perhaps more attention should be paid to 
missing data in study design (i.e. increasing sample size, educating staff 
regarding the importance of data recording and collection) (757).    
 
Missing data can be classified based on the following assumptions first 
described by Rubin (758, 759): 
 
• Missing completely at random (MCAR) 
 
The missing data is not related to the value being obtained or the observed 
responses. An example of this would be missing PbtO2 or ICP data due to 
equipment failure where values were not recorded onto the software program. 
This occurred, and still does occur on the intensive care unit due to faulty 
cables. Another example would be loss of blood results due to samples being 
lost in transit. The benefit of MCAR data loss is that the analysis remains 
unbiased. Power may still be lost in the design, as mentioned above.  
 
• Missing at random (MAR) 
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This is said to be a more realistic assumption and occurs where missing 
responses are dependent upon observed responses, but are not related to the 
specific missing values. For example, that a PbtO2 value is missing may be 
independent of the value of PbtO2 but it might be dependent upon the ICP that 
led to the patient being transferred for a CT scan. One could argue that in this 
example ICP and PbtO2 are not independent variables and so it is not MAR, 
but the important thing about MAR is that the missing variable is not directly 
responsible.    
 
• Missing not at random (MNAR) 
 
Missing not at random data refers to data that is missing specifically because 
of that variable. An example would be missing ICP data due to a patient being 
taken to CT because of refractory intracranial hypertension.  
 
There are different methods of handling missing data, some of which I have 
discussed below. The best solution is to prevent data loss by good study 
design or retrieve missing data. If this is not possible, or data are lost despite 
good study design one must rely on data imputation, replacing missing values 
with substitute values. It is not always clear which method of imputation is best 
each is associated with limitations (757): 
 
1. Prevent data loss through good study design.  
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2. Try to obtain missing data: this is possible with missing values 
which can be obtained from paper charts or laboratory 
recordings but is not possible when the initial record keeping is 
at fault. 
 
3. Listwise deletion: delete all data from participants with any 
missing data. This is only practical if there is a very large sample 
and if the data is missing at random. 
 
4. Averaging: replace missing data with the sample mean as a 
conservative estimate. The problem with this method is that it 
artificially reduces the variability of the data. 
 
5. Attempt to estimate the missing data based on observed data. 
This is essentially making ‘educated guesses’ based on previous 
values. This is easier when there are a limited number of 
variables, but with multiple possible values and large variability it 
becomes more problematic.  
 
6. Common point imputation: this can be used with scaled data 
where one uses the middle point or the most commonly chosen 
point (e.g. on a scale of 1 to 5, choosing 3 or the most commonly 
chosen point).   
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7. Regression substitution (imputation): multiple regression 
analysis can be used to estimate a missing value. Using this 
method relies on having enough data to be able to accurately 
create stable regression equations. The existing variables are 
used to make a prediction on what the missing value would be. 
However, no novel information is added. Therefore, the sample 
size is increased and the standard error is reduced.   
 
8. Multiple imputation: perhaps the most popular approach. 
Statistical packages such as SPSS have multiple imputation 
calculators that can create plausible values based upon any 
correlation between missing data. In addition to this, it 
incorporates random errors into the predictions. The method 
resembles regression substitution but instead of a single value 
being produced, a series of plausible values are produced 
containing a degree of variability. Not only is a missing value 
produced, multiple imputed data sets are produced and are used 
for standard analysis. The user receives multiple analysis results 
to produce a single overall result. The advantage of multiple 
imputation is that it restores the natural variability of the missing 
values and incorporates uncertainty into the analysis. It can be 
used with small sample sizes or large samples with a large 
amount of missing data. 
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One option for my missing PbtO2 was to perform multiple imputation on the 
data thus enabling a two-way repeat measures ANOVA in SPSS. Performing 
multiple imputation may also make interpreting normality from a probability plot 
easier due to increasing the sample size. I have performed multiple imputation 
for the PbtO2 data to create five versions of the data (five complete data sets, 
six including the original with missing data). A two-way repeat measures 
ANOVA of this data showed no statistically significant difference between the 
two groups with time (Wilk’s Lambda 0.808, P 0.411).  
 
Summary of Statistical Analysis 
 
I found it difficult to analyse the data in this study for the following reasons: 
• There are missing data. 
• There are repeat measures in the same patients. Variables were 
measured over different time points from the same patient. This 
becomes difficult when running ANOVA because the tests often 
assume data is not linked. As such, repeat measures ANOVA was 
used. Because of missing data, I could not run a two-way repeat 
measures ANOVA in SPSS without correcting for missing data.  
• The data appears grossly normal, but not completely adherent to the 
normal distribution line as discussed above. After discussion with a 
statistician, it was decided that I should perform parametric analysis. 
• There are multiple variables to be tested, which may be linked. 
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• There were several outliers in the raw data, some of which were 
physiologically impossible. 
 
I was advised to perform these statistical tests by a professional statistician, 
the data were reviewed by my supervisors, two intensive care consultants with 
prior experience of publishing their own work, and the data was subsequently 
published in a journal after peer-review. I had attended a University of 
Edinburgh course that taught basic statistics aimed at postgraduate students 
studying for masters and doctoral degrees. How to perform a two-way repeat 
measures ANOVA with multiple imputation for missing data was not covered 
in this course and so the practical aspects of running these tests was self-
taught. The most difficult aspect of statistical analysis for me was not 
identifying the correct tests to perform, but learning how to practically apply 
them in the software packages. There are so many options available that it is 
very easy to make the wrong choice. Furthermore, some packages provide so 
much information after running a test that it can be difficult to establish which 
piece of information is actually useful.  
 
My advice to other PhD students would be to make the most of the University 
courses available, because they are very good, but also to acknowledge that 
a professional statistician is likely to be needed for complex statistics. A 
learning point, and suggestion to others writing a thesis, is to clearly defend 
the use of statistical methods in the thesis to avoid having to do so in the viva. 
Or to at least have a defence in your thesis that may aid your viva discussion. 
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Alpha Calcitonin Gene-Related Peptide Study 
 
Kokkorris et al., in their review of αCGRP and aSAH, noted that there has been 
a lack of further research after the intravenous administration of αCGRP in 
patients with SAH by the European CGRP in Subarachnoid Haemorrhage 
Study Group in 1992 (see chapters 3 and 4) (599, 640). As the authors of that 
paper suggested, the next logical step appears to be to investigate the effect 
of αCGRP after intrathecal administration. I completed a study protocol for the 
intrathecal administration of αCGRP in humans and an application to submit 
to the First in Human committee in Edinburgh (Appendix 4). Initially, we had 
attempted to investigate intrathecal αCGRP as a Phase I trial in patients 
receiving spinal anaesthesia for urological procedures. We planned to 
administer αCGRP via spinal and sample CSF via spinal catheter in patients 
undergoing day case urological procedures who would have otherwise 
received spinal anaesthesia. The First in Human committee in Edinburgh 
decided that because αCGRP had previously been administered to humans 
(albeit as an intravenous administration, never intrathecal), they were not the 
correct regulatory body to approve such a study. I decided to re-write the 
protocol and change our study population from healthy volunteers to patients 
with poor-grade aSAH requiring an IVD or EVD that could be used for αCGRP 
administration and CSF sampling. In this way, patients would be on the ICU 
and would have continuous monitoring and the ability to receive CT scans and 
frequent Doppler imaging of their MCA. Although this study was, to my mind, 
a dose-testing and tolerability study, we had aimed to collect some evidence 
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of efficacy to facilitate progression to the next phase. After re-writing the 
protocol, aspects of it were reviewed by Professor Andrews, Dr Harris 
(research nurse), Cat Graham (statistician), Dr Downer (interventional 
radiology) and Ioannis Fouyas (neurosurgery). This took us into the second 
year of the PhD.  
 
The design of our proposed CGRP study has been discussed fully in Chapter 
4, along with my thoughts on why the study did not receive funding at the 
beginning of Chapter 5, so I have not repeated this here. Evidence of study 
design can be seen both in appendices 3 and 4 and in the above chapter. The 
main difficulties that I experienced whilst writing the protocol were in explaining 
it clearly to others. Aspects of the protocol that seemed obvious to me were 
causing confusion for others. For example, there was confusion regarding the 
3x3 escalation rule, which appeared simple to many people but had to go 
through different iterations before it was clear to everyone. There was also 
some concern regarding the predicted sample size and duration of the study. 
The difficult here is identifying a duration that will enable enough recruitment 
without being prohibitively expensive. To help facilitate this I discussed the 
study with patients and the relatives of patients who were seen in follow-up 
clinics after having had SAH. This was done in coordination with a specialist 
nurse (Karen Briggs) involved with the coiling service in Edinburgh. Patient 
and relative information leaflets were included in the trial protocol appendices. 
We determined three-quarters of patients would have consented/been 
consented to be part of the study. This, together with the number of patients 
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admitted with poor-grade SAH, gave us an estimate of how many patients we 
expected to be able to recruit. I projected a conservative study duration (see 
Appendix 5 for Gantt Chart of proposed study milestones).  
 
In March 2015 I submitted a grant application to the MRC, which was rejected 
based upon insufficient supporting evidence being available. In addition to this, 
the MRC thought that commercial exploitation could be difficult and that 
potential industry collaborations were vague. I subsequently submitted a 
further grant application to the MRC in July 2016. Since the first application I 
had, with the help of named colleagues, completed a systematic review and 
meta-analysis of animal studies investigating intrathecal αCGRP as a 
treatment for ‘vasospasm’ after SAH and looked at CSF concentrations of 
αCGRP in patients with SAH. The second application was accepted to the full 
application stage. After the first application it became apparent that it would be 
useful to have some evidence of CSF concentrations of αCGRP to help de-
risk the study. I had performed a PubMed search of studies that had 
investigated αCGRP in animal studies as part of the meta-analysis. This 
search was duplicated by Dr Begg, a co-author of the meta-analysis but did 
not identify the publication by Schebesch et al. (727). 
 
The learning point from this experience for me was to acknowledge that 
research is fundamentally a financial endeavour. Having acknowledged this, I 
should try to identify what the weaknesses of the proposed study are and 
combat these. For example, with αCGRP the scientific uncertainty is that some 
Physiological responses to brain tissue hypoxia and blood flow after acute brain injury 
 
Conclusion and Reflection 220 
authors no longer think that vasospasm plays a large role in DCI. Other authors 
have provided evidence to suggest that DCI does not actually contribute to 
mortality in a significant way (see chapters 3 and 4 for referenced discussion). 
There is little evidence that αCGRP can improve neurological function in 
animal studies (our meta-analysis suggests a potential benefit). Finally, 
previous studies have demonstrated an intervention that is able to dilate 
arteries without improving outcomes (see Clazosentan discussion in Chater 
3). The financial weakness was that our application was based solely upon 
obtaining orphan status.  
 
Personal Learning Points 
 
I have been approached by a number of postgraduate medical doctors wanting 
advice regarding research. Some have been specifically asking about the 
MMedSci programme and some have been asking about undertaking a PhD. 
My first question tends to be “Why do you want to do research?” Sometimes it 
is because of a specific area of interest and sometimes because the medical 
specialty they are employed in has an expectation of research. On an 
individual level I think both of these are acceptable reasons, but perhaps they 
should be tackled differently. One dour surgical colleague, when I asked why 
he undertook a PhD, replied “nobody in Edinburgh takes you seriously unless 
you’ve tortured some mice for three years”. Unfortunately, I think there is some 
truth to his comment. If conducting a research degree purely for progression 
and to make the acquisition of a consultant post less arduous, I would suggest 
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trying to find a supervisor who has a background of high-profile publications in 
journals with a high impact factor. More important than this is to find one with 
funding available and ideally someone who has already submitted for ethical 
approval. Alternatively, some of my colleagues have become PIs for research 
led by pharmaceutical companies, who are able to provide funding and employ 
staff to tackle ethical applications. If undertaking research because of a 
specific interest or because of a desire to further understanding, ones’ 
approach might be different. It may be more difficult because the barriers to 
research appear to be money and regulatory approval. Both of these barriers 
can lead to compromises on study design and quality. An example of this is 
sample size: an adequate sample size can be limited both ethically and 
financially. Before starting my PhD, I had thought that hard work and 
organisation would mitigate most problems. However, ultimately money seems 
to be the most important thing in research. Some may argue that good 
research is the most important thing. I would argue that it is impossible to 
conduct ‘good’ research without enough money. High impact factor 
publications lead to a higher chance of getting more acclaim and subsequently 
a higher chance of a successful grant. The learning point here is: be organised. 
Look for a study that has funding and ethical approval. If a good idea has 
neither of these things consider looking for something else, and if adamant that 
this is what you want to do, immediately start applying for a research grant. 
Nine out of twenty of the MRC’s outline application questions and 30% of the 
allocated words are dedicated to funding. The full application includes 
expanded sections on ‘Downstread Project Support’ and ‘Intellectual Property’. 
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The RCT I proposed at the end of Chapter 5, to investigate the effect of 
induced hypertension in patients with DCI, is worthwhile. I think this not only 
because we currently do not know whether we are causing harm, or whether 
we may be able to provide better care with more specific targets, but because 
I think we are currently applying a blind intervention based upon unproven 
theory. The problem is that it will be difficult for me to argue a financial case 
for such a study. The potential financial benefits are:  
• Decreased patient hospital stay (reduced direct costs and indirect from 
decreased risk of infection etc.); 
• Reduced time off work and therefore increased gross domestic 
productivity (GDP); 
• Reduced cost of current ineffective interventions. 
The first two can apply to any successful intervention for any disease. The 
difficulty is quantifying and justifying any proposed benefit. If I propose that we 
are causing harm with induced hypertension in patients with DCI, how could I 
quantify that harm? I have little evidence to suggest that it is causing more 
harm than benefit. In terms of cost of the current intervention, the cost of 
noradrenaline and an associated arterial line is low. Similarly, with my 
recommendation to repeat a nimodipine trial that I suspect would show no 
benefit. What is the financial incentive to perform such a trial? The cost of 
nimodipine is minimal, and as the Cochrane review states, the potential harm 
is also minimal (see chapter 3 for full discussion) (544). The important point 
here is to try and be pragmatic and think about how the research one proposes 
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to do will benefit society and how that can be argued in a grant application. 
With an intervention such as CGRP, if it was suggested to significantly reduce 
morbidity or mortality then it is potentially financially viable.   
Timing of Research in a Career 
 
I suspect that most UK clinicians who have not undertaken a PhD prior to 
studying medicine do so during their registrar years. I have no reference to 
support this, it is speculation and from my experience of speaking to 
colleagues who have completed postgraduate degrees. Many colleagues have 
finished a masters degree or diploma after their first two years of postgraduate 
clinical work, but few seem to have done an MD or PhD. Certainly, the 
Edinburgh Clinical Academic Track (ECAT) targets clinicians at the registrar 
level (a requirement for acceptance is to hold a national training number, which 
is typically awarded at Specialist Training year 3). The ECAT programme 
appears ideal for those with an interest in clinical academia. It offers two 
routes: 
1. A clinical lectureship: successful applicants are employed until six 
months after completion of clinical training. The first year offers the 
opportunity to plan for a PhD and is thus called a 1+3 year model to 
obtain a PhD. After this time, trainees return as clinical lecturers with 
protected academic time until completion of training (CCT). 
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2.  ECAT PhD fellowships: candidates do not have to hold national 
training numbers, although it is strongly encouraged. The degree is 3 
months + 3 years, with the first 3 months used to facilitate the 
development of a PhD proposal. After this time, trainees may take up 
the opportunity to become clinical lecturers.  
With regards to the knowledge or intellectual capability required, stage of 
training should not be a barrier to research. There is no greater intellectual 
complexity involved than was required at medical school, and I believe this is 
true throughout medical training. There is a great breadth of knowledge 
required which may have been acquired in some specialties with prior 
knowledge. However, many colleagues undertaking laboratory research have 
stated that they were required to learn a great deal of basic science knowledge, 
which their non-medical peers had learnt as undergraduates and which they 
did not learn, and would not need to learn as senior clinical trainees or 
consultants. The greatest challenge I have faced doing a PhD during my stage 
of training has occurred since returning to full time training. Returning to 
training has been much more difficult than I had anticipated. This is chiefly 
because my level of training is not congruent with the number of years that I 
have been practicing as a doctor. This is perhaps another reason I would 
encourage anyone considering a PhD to go through the ECAT programme if 
wanting to do so in Edinburgh. I suspect that undertaking a PhD after finishing 
postgraduate exams would fit more easily into a training schedule. I have had 
the opportunity since finishing this work to investigate other research proposals 
but have declined because of training commitments. Therefore, I think in 
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retrospect I would encourage others to undertake a PhD at a later stage, if only 
for these practical reasons.  
Conclusion  
 
I have learnt a great deal from undertaking this PhD separate from the 
academic work presented in the first four chapters. I have learnt about study 
design and statistical analysis. I have learnt about the practical aspects of 
undertaking research and the huge amount of work that must be performed in 
setting up a trial. I have come to appreciate that even small trials, such as my 
investigation of CSF samples, involve a larger number of people than I had 
previously thought. Perhaps one of the best skills I have gained is to readily 
question interventions and our reasons for implementing them. I not only refer 
to data from recent publications promoting a new intervention, or repurposed 
interventions, but also the treatments that we currently administer as part of 
routine care. The examples I give are nimodipine and induced hypertension 
but I could equally include many of the drugs that are routinely given in ICUs 
and theatres.
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Appendix 1: Raw Data for Chapter 2 
 
Table 12: Raw Core Temperature Data. Missing data highlighted in grey. 
Hour = time from randomisation. First group = normothermia group. Second 
Group = hypothermia group.  
 
Table 13: Raw PbtO2 Data. Missing data highlighted in grey. Hour = time from 
randomisation. First group = normothermia group. Second Group = 
hypothermia group.  
 
Table 14: Raw ICP Data. Missing data highlighted in grey. Hour = time from 
randomisation. First group = normothermia group. Second Group = 
hypothermia group.  
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